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High-grade serous ovarian cancer (HGSOC) has the highest incidence rate of the 
various subtypes of ovarian cancer. HGSOC patients usually respond to initial 
platinum therapy, however approximately 70% of patients relapse, or worse, become 
resistant to therapy. Members of the Human Epidermal growth factor Receptor (HER) 
family, especially EGFR and HER2, are frequently involved in disease progression, 
hence strategies to inhibit their action could prove advantageous as treatment for 
selected ovarian cancer patients. Monoclonal antibodies (mAbs) and tyrosine kinase 
inhibitors (TKIs) targeted against the HER family have demonstrated valuable anti-
tumour activity in multiple other cancer types, and their possible use in ovarian cancer 
merits further study.  
This study sought to evaluate the effectiveness of HER-targeted therapy in platinum-
resistant and platinum-sensitive HGSOC, and the implications of HER family 
expression and other biomarkers in response to treatment. The effects of five TKIs 
(afatinib, canertinib, lapatinib, neratinib and sapitinib) targeted against multiple HER 
family members on cellular functionality were studied in three pairs of HGSOC cell 
lines, wherein each pair was derived from the same patient before and after clinical 
resistance to platinum-based chemotherapy. The effects of the TKIs were compared 
with the anti-HER2 mAbs trastuzumab and pertuzumab. The outcomes of modulation 
of EGFR, HER2 and HER3 expression on treatment sensitivity were also investigated, 
along with gene expression differences upon treatment.  
The TKIs were found to be effective in inhibiting proliferation, migration and invasion, 
even in the presence of epidermal growth factor (EGF) and heregulin (HRG). The 
mAbs investigated were not as effective as the TKIs. Combination strategies of TKI 
with cytotoxic agents (cisplatin, carboplatin and paclitaxel) and TKI with mAbs were 
compared for their anti-proliferative behaviour. Combinations involving neratinib with 
pertuzumab or cisplatin demonstrated a degree of synergy. Knock-down of EGFR 
expression affected the anti-migratory effects of neratinib, but did not influence its 
anti-proliferative activity.  Overexpression of HER2 or HER3 in the platinum-sensitive 




happened when HER2 or HER3 were overexpressed in the platinum-resistant cell 
lines. 
The MAPK pathway was stimulated by EGF and HRG, as was the PI3K pathway. 
Protein expression through western blot analysis showed that neratinib decreased 
phosphorylation of ERK and Akt in the cell lines. Neratinib was the most potent TKI 
of those tested in growth inhibition studies, and was used to investigate the effects of 
TKI treatment on gene expression. Neratinib down-regulated the MAPK and PI3K 
pathways in most cell lines, even in the presence of HRG, whilst reducing proliferation 
and migration processes. Based on gene expression data, CCAAT Enhancer Binding 
Protein Gamma (CEBPG), DNA Damage Inducible Transcript 4 Like (DDIT4L), Ral 
guanine nucleotide dissociation stimulator (RALGDS), and Sprouty homolog 2 
(SPRY2) were identified as possible HER-targeted therapy-induced biomarkers, 
whose expression changed upon neratinib-treatment from this data set, and mAb-
treatment based in another data set. Assessment of these proteins in tissue microarrays 
consisting of ovarian cancer xenografts treated with mAbs over a period of days, 
identified higher expression in the mAb-treatment group than the controls for all 
proteins except SPRY2, which had lower expression.  
In conclusion, treatment with HER-targeted TKIs could be a useful approach even in 
the treatment of platinum-resistant HGSOC, where the expression of EGFR, HER2 







Imagine your garden with plants and trees, and then unwanted weeds start to grow. 
Ovarian cancer is the weed, and is the 8th most deadly cancer type in women 
worldwide. Current treatments for ovarian cancer, which include removing as much as 
possible of the cancer and administering platinum-based chemotherapy is effective in 
about 70% patients, but as with using herbicides in a garden, some cancers/weeds 
become resistant and continue to grow. Therefore, this project aimed to study the 
effects of other therapies (herbicides) that target ovarian cancer (weed) more 
specifically. The novel treatments act upon one or more of a family of four molecules, 
known as HER1, HER2, HER3 and HER4. 
This study found that the targeted therapies evaluated (called afatinib, canertinib, 
lapatinib, neratinib and sapitinib), were more able to inhibit growth, migration and 
invasion in the ovarian cancer cells that were resistant to initial therapy, than in the 
ovarian cancer cells that were sensitive to initial therapy. This was all achieved at drug 
concentrations that humans can safely tolerate. The combination of one of the above 
targeted therapies (neratinib or lapatinib) with platinum-based drugs or pertuzumab 
(another targeted therapy), produced results that were much more effective than single 
therapy alone. Altering the level of the target molecules (HER1, HER2 and HER3) 
changed the response to treatment. 
A large data-driven experiment to examine changes induced by one of these drugs, 
neratinib, identified a number of key genes, which like the characteristics of weeds 
responding to a new herbicide could be used to identify how and which patients will 
respond to new treatments.  
In conclusion, these new drugs were effective in ovarian cancer cells, and therefore 
could be a promising treatment option to patients who stop responding to first-line 
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1  Introduction 
Cancer is characterised as a group of diseases that proliferate abnormally and have the 
ability to invade or metastasise from their origin to other parts of the body. There were 
approximately 18 million new cancer cases worldwide and around nine million 
fatalities due to cancer in 2018, of which almost nine million new incidences and 
around four million deaths occurred in women [1]. These incidence rates are predicted 
to be reducible by about 40% in high-income countries, by decreasing exposure to 
environmental risks and changing lifestyle [2]. In males, lung cancer followed by 
prostate cancer are the most common types of cancer. In women, breast cancer, 
followed by colorectal cancer and lung cancer are the most frequently occurring [1]. 
Ovarian cancer is the 8th most common cancer type in females, bearing 3.4% of the 
total female cancer incidence rate (Figure 1.1) [1]. Although worldwide cervical 
cancer still kills more women than ovarian cancer, in most Western countries, ovarian 
cancer has become the most lethal gynaecological malignancy. This is because cervical 
cancer is frequently detected at an earlier stage through screening and is also prevented 





Figure 1.1: Incidence and mortality rates of cancer types in women in 2018  
Pie charts represent the most common cancer types in women worldwide versus in the Western 
world. Adapted from [1]. 
1.1 Hallmarks of cancer 
The hallmarks of cancer encompass six biological traits that cancer cells, including 
ovarian cancer cells, acquire during the development of tumours. This notion was 
developed by Hanahan and Weinberg in 2000 [4], and revised in 2011 [5]. These 
hallmarks include the following: 
Sustained proliferative signalling: Whilst normal cells regulate the activity of 
growth-promoting signals, cancer cells are frequently unable to control these signals 
[5]. This leads to the over-activity of molecules such as tyrosine kinases and 
downstream signalling pathways, notably the MAPK and PI3K pathways in ovarian 
cancer [6] (discussed in detail in section 1.4). Therefore, in ovarian cancer, targeted 
inhibitors that target tyrosine kinases and other molecules up-stream of the MAPK and 
PI3K pathways would be beneficial in blocking the initiation of these signals, leading 




Activation of invasion and metastasis: Cancers migrate from the primary site to other 
body sites due to their ability to invade neighbouring tissue and metastasise in a multi-
step process. In ovarian cancer, cells which detach from the primary tumour are carried 
by the physiological movement of the peritoneal fluid and adhere to the mesothelial 
cells mediated by integrins [7]. Once bound to the mesothelial cells, the tumour cells 
can invade the peritoneum and omentum [8]. 
Evasion of growth suppressors: Cancer cells are able to circumvent the natural 
negative regulation of cell proliferation, through tumour suppressors such as RB 
(retinoblastoma-associated) protein and TP53 protein [5]. In ovarian cancer, some 
patients present with alterations to the RB pathway and mutations in TP53 [9] 
(discussed further in section 1.3.1). 
Induction of angiogenesis: Cancers have the ability to generate neovasculature in 
order to sustain the tumour with nutrients and oxygen, and eliminate waste 
components. Key proteins that sustain angiogenesis are vascular endothelial growth 
factor-A (VEGF-A) and thrombospondin-1 (TSP-1) [5]. In ovarian cancer, 
bevacizumab, which inhibits VEGF-A, was the first anti-angiogenic agent to be 
approved for the management of recurrent ovarian cancer [10]. 
Resistance to cell death: Programmed cell death serves as a natural process to stop 
cancer initiation. However, abnormalities in regulators such as TP53 trigger resistance 
to cell death. In ovarian cancer the Bcl-2 family plays an important role in pro-
apoptotic and anti-apoptotic mechanisms [11].  
Other factors which are associated with cancer survival and development include 
tumour-promoting inflammation, which also helps with the formation of new blood 
vessels. Their genome instability and ability to mutate, even to treatment, makes 
tumours harder to treat, along with replicative immortality, meaning that they are 
capable of indefinite growth. Emerging hallmarks include capability to avoid immune 
interaction to circumvent destruction as well as deregulating cellular energetics, 




1.2 Ovarian cancer overview 
1.2.1 Aetiology 
The most common form of ovarian cancer are carcinomas (malignant epithelial 
tumours) representing over 90% of cases [12]. Other types of ovarian cancer include 
the sex cord-stromal tumour (eg granulosa cell tumours), which occurs in 5-6% of 
tumours and germ cell tumours (eg yolk sac tumours and dysgerminomas), which 
occur in 2-3% of cases [12] (Figure 1.2). Recent understanding of the pathology of 
ovarian cancer has revealed that ovarian cancer cells frequently originate from sites 
other than the ovaries, such as the fallopian tubes and involve the ovaries secondarily 
[13, 14]. Although this is a speculative hypothesis, it is supported by the fact that the 
histology of serous ovarian cancer is similar to the morphology and TP53 signatures 
of the fallopian tube [15], suggesting that the neoplastic process could initiate at the 
tubal lesions and migrate to the ovaries where they progress aggressively. Ovarian 
endometriosis, occurring through retrograde menstruation, is also thought to give rise 
to other subtypes (endometrioid and clear cell) of ovarian cancer [16, 17]. 
 
Figure 1.2: Aetiology of ovarian cancer 
The common forms of ovarian cancer and their frequency detailed in this diagram 1 [18]. 
                                               
1 Krafts K. Presentation: Female Reproductive System. 




1.2.2 Risk factors and epidemiology 
The incidence rate of ovarian cancer is highest in North America and Europe [19], and 
the lifetime risk of having ovarian cancer stands at around 1.5% [20]. Risk factors for 
developing ovarian cancer include both genetic and hormonal elements. The risk 
increases by three to seven-fold if a woman has first-degree family members who 
developed ovarian cancer [21]. Germline mutations in BRCA1 or BRCA2 increase the 
lifetime risk of developing ovarian cancer by 44% and 27% respectively [22-24], 
whilst Lynch syndrome, which is characterised by mutations in the mismatch repair 
system, increases the risk of ovarian cancer by fourteen-fold [25, 26]. Other 
predisposing risk factors include increasing age, infertility, endometriosis, hormonal 
factors (such as late age at menopause, hormone replacement therapy and early age at 
menarche) and obesity [27-29]. On the other hand, factors that decrease the risk of 
ovarian cancer include pregnancies, breast feeding, oral contraceptive pill and 
hysterectomy [28-32].  
1.2.3 Screening, diagnosis and staging 
Ovarian cancer patients usually present with non-specific symptoms, which 
contributes to the low percentage (approximately 20%) of patients being diagnosed 
when at early stages of the disease. Symptoms include abdominal discomfort, pelvic 
pain, loss of appetite, weight loss, frequency in urination, changes in bowel habits and 
ascites [33]. A palpable pelvic mass can sometimes be found on clinical examination. 
Women are not offered routine screening, however when there is a suspicion of ovarian 
cancer, the National Institute for Health and Care Excellence (NICE) recommends 
initial investigations using ultrasonography and/or sequential blood tests for the 
biomarker Cancer Antigen 125 (CA125) [34]. The drawback of CA125 is that it is a 
non-specific marker in premenopausal females and can be increased during 
menstruation, fibroids, pelvic inflammatory disease or pregnancy. Additionally, about 
20% of ovarian cancers do not express this antigen, while this test is less sensitive in 
patients presenting at early stages of ovarian cancer [35]. However, a recent study- UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)- assessing the effect of 




algorithm) or transvaginal ultrasound screening found that multimodal screening 
helped reduce mortality when prevalent cases were excluded [36]. 
Recent studies have tried to look at other potential biomarkers for early ovarian cancer 
diagnosis. One of the biomarkers was HE4, which appears specific to ovarian 
carcinoma, and is expressed in about 34% of ovarian cancers which do not express 
CA125 [35]. However, when a Risk of Ovarian Malignancy Algorithm together with 
HE4 serum levels were assessed against CA125 performance alone, it emerged that 
CA125 was a better predictive marker of ovarian carcinoma [37]. Another potential 
biomarker is HK10, which was absent in normal cells, but was expressed in ovarian 
carcinoma, as well as in CA125-deficient cancers [35]. 
Staging of ovarian cancer is necessary for comparative terminology between oncology 
centres as well as to help develop the optimal clinical plan for each individual patient 
[12]. The FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) staging 
of ovarian cancer is depicted in Figure 1.3. Imaging modalities, such as ultrasound, 
computerised tomography (CT), magnetic resonance imaging (MRI) and Positron 
emission tomography–computed tomography (PET-CT) scanning technologies are 
used to help stage ovarian cancer [38].  
The approximate five-year survival rate stands at 47% [39, 40]. This survival rate 
depends on the stage at diagnosis. The five-year survival rate for patients diagnosed at 
early stages of ovarian cancer is 93%, while patients diagnosed in stage III or IV have 





Figure 1.3: Pictorial depiction of FIGO staging  
The four stages of ovarian cancer and what is clinically defined by each stage, based on [12]. 




1.2.4 Management and treatment  
Ovarian cancer management is largely based on the stage at which the patient presents. 
The current first-line treatment regimen for patients with advanced ovarian cancer 
consists of tumour surgical debulking, combined with adjuvant therapy consisting of 
carboplatin with or without paclitaxel for six cycles (Figure 1.4) [41]. The response 
rate to first line management of advanced ovarian cancer is at 70-80% [42]. Some late 
stage ovarian cancer patients are also offered neo-adjuvant therapy, to improve 
chances of successful tumour debulking.  
Combination of platinum-based therapy with paclitaxel has not been without some 
controversy, as clinical studies have shown differing results. A GOG-123 
(Gynaecologic Ovarian Group #123) clinical trial assessing the overall benefit from 
the combination versus monotherapy showed that cisplatin alone or in combination 
with paclitaxel produced better progression free survival (PFS) than paclitaxel alone 
[43]. In fact the PFS was 16.4, 10.8 and 14.1 months for cisplatin alone, paclitaxel 
alone and the combination respectively [43]. However, the cisplatin dose when used 
as monotherapy was higher than the dose used in combination with paclitaxel, which 
led to more side effects [43]. Other earlier clinical studies, the GOG-111 and OV10 
(European-Canadian Intergroup trial) which compared cisplatin and paclitaxel versus 
cisplatin and cyclophosphamide, have shown that the PFS was over 15.5 months 
versus 11.5 months respectively, while overall survival (OS) was over 10-14 months 
longer in patients receiving paclitaxel [44, 45]. Clinical studies evaluating the role of 
carboplatin in combination with paclitaxel, showed that this combination was better 
tolerated than cisplatin plus paclitaxel. However, both treatment arms had similar PFS 
and OS of around 18 months and 44 months respectively [46].  
Bevacizumab, which is an anti-VEGF agent, is currently marketed for the management 
of advanced ovarian cancer in combination with carboplatin and paclitaxel [47].  It is 
also used in combination with carboplatin plus gemcitabine or paclitaxel in primary 
recurrent platinum-sensitive ovarian cancer. In platinum-resistant recurrent ovarian 
cancer, it is used in addition to paclitaxel, topotecan or pegylated liposomal 




patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer (HGSOC) are 
the poly-ADP ribose polymerase (PARP) inhibitors, olaparib and niraparib [48, 49].  
 
Figure 1.4: Summary of management and treatment of ovarian cancer 
Information is based on NICE guidelines for ovarian cancer, updated in February 20192. 
PLDH refers to Pegylated liposomal doxorubicin hydrochloride, and the asterisk (*) refers to 
treatments which although are within the indications of the product’s marketing authorisation, 
they are not recommended to be used in the clinical setting by NICE. 
                                               
2 NICE. Ovarian Cancer Overview. First published in Feb 2012. Updated in Feb 2019. 





1.2.4.1 Platinum-based chemotherapy 
Platinum-based chemotherapy was discovered by serendipity in the 1960s, with an 
experiment to investigate electromagnetic fields on bacterial growth. When voltage 
was applied to these bacteria, they were observed to grow in filaments, over 300 times 
their normal length. This cell division interference was due to cis-
diamminetetrachloroplatinum (cisplatin; CDDP) [50]. The first platinum-based agent 
used in ovarian cancer was cisplatin, which showed significantly longer survival rates 
in contrast to the alkylating agent used at the time, cyclophosphamide [51]. Later 
studies led to a safer second-generation agent, carboplatin which was approved as 
standard of care for the treatment of ovarian cancer in 1989 [52]. Carboplatin offers 
less nephrotoxicity, less toxicity in the gastrointestinal tract and is less neurotoxic than 
cisplatin [53].  
Platinum-based chemotherapy is toxic to dividing cells, including cancer cells, as it 
forms interstrand and intrastrand DNA cross-links. While intrastrand cross-links occur 
in 90% of DNA cross-linking, interstrand cross-links are stronger [54]. Following this 
DNA-induced damage, DNA repair pathways decide the fate of the cells. These cross-
links can lead to single-strand or double-strand DNA breaks [41]. In response to the 
severity of DNA breaks, the cells can either initiate DNA repair, or induce apoptosis. 
Normally, single-strand DNA breaks are repaired through nucleotide excision repair, 
whereas double-strand DNA breaks are repaired through non-homologous end joining 
and homologous recombination. Nucleotide-excision repair refers to a process 
whereby large DNA adducts are removed as they would be distorting the double DNA 
helix. Non-homologous end joining is the process joining and resealing the two ends 
of a DNA double strand. On the other hand, homologous recombination is the copying 
of DNA sequence from an intact DNA molecule to fix replication deformities [55].  
In platinum-treated cells, the primary process of intrastrand DNA repair pathway 
following platinum-based chemotherapy is nucleotide excision repair. This process 
identifies and removes large DNA adducts as they distort the double DNA helix. Cells 
lacking nucleotide excision repair proteins such as XPC, XPA and ERCC1 exhibit no 




shown to be altered in about 8% of epithelial ovarian cancer and these alterations are 
associated with improved overall survival and progression-free survival compared 
with patients without nucleotide excision repair alterations [56]. Conversely, high 
levels of the ERCC1 protein, involved in the nucleotide excision repair process, have 
been linked with poor response to chemotherapy in ovarian cancer, and its mRNA 
levels increased in response to cisplatin-induced DNA damage [57].  
Double-strand DNA breaks are repaired through non-homologous end joining and 
homologous recombination. Non-homologous end joining is a repair process that joins 
and reseals the two ends of a DNA double strand in a Ku70/Ku86-dependent process 
which can result in error-prone repair, due to addition or loss of bases, or to ligation of 
the wrong ends [57]. Homologous recombination is an alternative mechanism dealing 
with double-strand break repair. It is an error-free mechanism that uses the sister 
chromatid as a template to repair the double strand break during the S and G2 phases 
of the cell cycle [56]. On recognition of the double strand break, BRCA1 facilitates 
recruitment of a complex (the MRN complex) which in conjunction with other key 
molecules resect the DNA ends. When end resection occurs, double strand breaks can 
be further repaired through error-free homologous recombination DNA repair by the 
recruitment of BRCA2 and the effector RAD51 to construct nucleoprotein filaments 
that catalyse the recombination between the broken strand and its undamaged 
homologue  [56, 58]. 
The Cancer Genome Atlas (TCGA) consortium has estimated that about 50% of 
HGSOC cases have homologous recombination-based repair defects [59]. 
Approximately 20% of these defects are related to germline or somatic BRCA1 or 
BRCA2 mutations [60, 61]. BRCA1 methylation also occurs in another 11% HGSOC 
while EMSY methylation and changes in other homologous recombination repair 
genes (e.g. Fanconi Anaemia genes) can account for another 10% of cases [62].  
Cells deficient in homologous repair (e.g. by BRCA1 and BRCA2 mutations or other 
components of the homologous recombination repair pathway) are unable to repair 
DNA strand breaks efficiently. This defect permits sensitivity not only to the platinum 




cells rely on this for cellular repair [56].  Mutations in BRCA1 and BRCA2 (germline 
or somatic) are associated with better overall responses to standard of care platinum-
based chemotherapy and longer progression-free survival relative to non-mutated 
BRCA1/2 cases [63, 64]. Consistent with homologous recombination deficiency being 
associated with platinum sensitivity, restoration of homologous repair proficiency can 
be associated with platinum resistance. In both cell line models and in clinical cancers, 
reversion mutations in BRCA1 and BRCA2 have been demonstrated, resulting in the 
re-acquisition of homologous repair proficiency and development of resistance to both 
platinum drugs and PARP inhibitors [56]. 
1.2.4.2 Taxane chemotherapy 
The taxanes were originally derived in 1971 from the bark of a Pacific Yew tree, 
whereby paclitaxel was the main constituent [65]. Later on, docetaxel was developed, 
which is a semisynthetic derivative of T. baccata needles [66]. Paclitaxel was approved 
by the FDA in 1992 to treat women with epithelial ovarian cancer. This approval was 
based on positive clinical trials in ovarian cancer patients. A phase II paclitaxel clinical 
trial in ovarian cancer demonstrated a PFS of over 4 months, irrespective of platinum-
sensitivity [67]. In metastatic ovarian cancer patients, the median survival was 27 
months and 6 months for responders and non-responders respectively [68]. A similar 
phase II clinical trial resulted in 30% of metastatic patients responding to therapy for 
3-15 months [69]. 
Paclitaxel monotherapy has not been very favourable in ovarian cancer patients, 
however, using it in combination with platinum-based chemotherapy allowed for a 
reduction in platinum dose, thus decreasing the side effects [43]. Paclitaxel 
monotherapy has also shown prolongation of PFS when it was used as continuation 
therapy after platinum or paclitaxel therapy response. In fact, a 12-month cycle follow-
on treatment with paclitaxel resulted in PFS of 28 months [70]. 
Taxanes, are cytoskeletal targeting drugs, acting on tubulin. Microtubules are 
important in normal cells as they help maintain shape, with motility and signal 
transmission. Cancer cells have defects in mitotic spindle assembly, chromosome 




stabilises microtubule polymer and inhibits metaphase spindle configuration. The 
microtubules formed by paclitaxel are stable and dysfunctional. Thus, cells are unable 
to progress to mitosis, and undergo apoptosis [71]. Mechanisms of acquired resistance 
to taxanes include an impaired ability of tubulins to polymerise, which in turn would 
have a slow rate to assemble microtubules [72]. Another mechanism of resistance is 
amplification of drug efflux pumps [72]. 
Nanoparticle, albumin-bound paclitaxel (Nab-paclitaxel) has been developed after 
paclitaxel, and is currently being used in breast cancer, lung cancer and pancreatic 
cancer. The formulation of nab-paclitaxel is not solvent-based, and this reduces the 
toxicities associated with excipients in solvents [73]. Additionally, preclinical studies 
found that the uptake of nab-paclitaxel in tumours is higher than conventional 
paclitaxel [74]. A phase II clinical trial evaluating the use of nab-paclitaxel in 
platinum-resistant ovarian cancer resulted in an OS of 17.4 months [75]. 
1.2.4.3 Anti-VEGF therapy 
Bevacizumab (Avastin®) was the first anti-VEGF monoclonal antibody to be approved 
for the treatment of epithelial ovarian cancer, in combination with chemotherapy in 
advanced or recurrent cancer patients. It specifically targets VEGF-A, an isoform of 
VEGF, related to endothelial cell proliferation and migration. Bevacizumab is thought 
to cause regression in existing microvessels and inhibition of new vessel growth and 
neovascularisation (angiogenesis) [76]. 
Bevacizumab is a popular maintenance therapy, as a phase III clinical trial in newly 
diagnosed, late stage ovarian cancer patients (GOG-0218) has shown that patients who 
were administered bevacizumab throughout their therapy had their median PFS 
prolonged by four months over patients who received chemotherapy only [77]. 
Another similar phase III trial (ICON7) has shown a median OS of 34 and 39 months 
respectively in standard chemotherapy alone, versus addition of bevacizumab to 
standard chemotherapy, with beneficial results also observed in patients at high risk 
for disease progression [78]. More positive results were encountered when a phase III 
trial in platinum-resistant ovarian cancer patients, AURELIA, showed an improved 




cancer patients [79]. A phase II clinical trial assessing the use of bevacizumab in 
combination with nab-paclitaxel in platinum-resistant ovarian cancer patients, had 
positive outcomes, whereby the PFS was approximately 8 months, while the OS was 
17 months [80]. 
1.2.4.4 PARP inhibitors 
PARP inhibitors inhibit the PARP enzyme, which is involved in the detection and 
initiation of DNA repair in response to single-strand DNA breaks [81]. PARP 
inhibitors induce replication fork collapse, which is frequently more pronounced in 
cancer cells due to their constant replication stress. These inhibitors are useful in the 
treatment of ovarian cancer, given that many ovarian cancer cases present with 
homologous recombination defects; as such, platinum sensitivity might be a marker 
for the treatment response to PARP inhibitors. 
There are currently three PARP inhibitors approved for the maintenance treatment of 
platinum-sensitive relapsed ovarian cancer patients, with germline mutations in BRCA; 
olaparib (Lynparza®), niraparib (Zejula®) and rucaparib (Rubraca®). A phase III 
clinical trial in BRCA positive recurrent ovarian cancer patients, assessed the activity 
of olaparib versus current chemotherapy treatments (paclitaxel, gemcitabine topotecan 
or pegylated liposomal doxorubicin). It had positive results, whereby the olaparib 
treatment arm had a PFS of 13.4 months, versus 8.5 months in the current 
chemotherapy arm [82]. Pivotal clinical trials using of the PARP inhibitors include the 
olaparib SOLO-2 study, which was restricted to patients with BRCA mutations, and 
results showed that the quality adjusted PFS was over 6 months more in the olaparib-
treated cohort than the placebo [83].  
In the NOVA clinical trial assessing niraparib versus placebo in patients with or 
without BRCA mutations, the outcomes revealed that although in the mutated BRCA 
patients the PFS was greater, patients with wild type (WT) BRCA can also benefit 
from PARP inhibitors [84, 85]. Similarly, in the ARIEL-3 clinical trial assessing 
rucaparib’s efficacy in BRCA mutated or non-mutated patients, although the PFS in 




therapy. The PFS difference in patients receiving PARP inhibitor versus placebo was 
12 months in BRCA mutated patients, and 9 months in WT BRCA patients [86]. 
1.2.5 Platinum-refractory ovarian cancer 
The time taken to relapse after initial platinum-based therapy is a positive indicator of 
the response to secondary platinum treatment. If the time to relapse is more than 12 
months, there is a high chance for secondary platinum treatment sensitivity, while 
relapse within 6 months generally indicates platinum resistance [62]. Approximately 
50% of relapsed patients have platinum-sensitive disease, whereas about 30% have 
platinum-resistant disease. The remaining 20% of patients termed to have platinum-
refractory disease, are those who do not respond to platinum-therapy or progress whilst 
on treatment [87].  
There are several plausible mechanisms to explain recurrent platinum-sensitive 
ovarian cancer. One of the hypotheses is the role of putative cancer stem cells, whereby 
the bulk of the tumour responds to chemotherapy, and small populations of 
chemotherapy-sensitive cells remain dormant, which start replicating upon treatment 
completion [88]. In addition, cells may become dormant due to the unfavourable 
microenvironment, such as in hypoxia or nutrient stress [89], and revive after some 
time. Platinum-sensitive ovarian cancer patients are managed by tumour debulking, 
followed by platinum-based chemotherapy and paclitaxel, with or without 
bevacizumab and maintenance therapy using PARP inhibitors. Other common 
regimens include carboplatin with gemcitabine and carboplatin with pegylated 
liposomal doxorubicin. Primary recurrent patients are still able to respond to therapy, 
with an improvement in PFS (29 months) and OS (13 months) [90]. A second or further 
relapse, is associated with a PFS of 5-12 months, with an OS of around 9 months [91, 
92]. Optimal debulking plays an important role in the PFS and OS [92]. The PFS of 
patients having more relapses is similar to patients presenting with platinum-resistant 
disease, with response rates to therapy of only 10-20% [92]. There are no guidelines 
to platinum-sensitive ovarian cancer treatment beyond second recurrence, and therapy 




Resistance frequently develops in patients who are initially sensitive to platinum-based 
therapy. Resistance to platinum-based chemotherapy in ovarian cancers could be due 
to inadequate drug exposure in first line therapy, for example due to insufficient dosing 
or poor distribution of treatment at tumour site. Reduced uptake of cisplatin into the 
cell due to alterations in trans-membrane transport systems is also detrimental [41] and 
studies show that platinum-resistant cell lines had 23-55% less cisplatin intake than 
sensitive cell lines [93]. Increased drug efflux by the multidrug-resistance associated 
proteins encoded by ABC genes, also plays an important role in chemotherapy 
resistance [94]. Amplification of 19q12 involving CCNE1 (occurs in about 20% of 
ovarian cancer patients, and intervenes in cell cycle progression and proliferation) is 
also associated with acquired primary treatment failure [95]. Resistance to therapy can 
also be determined by homologous recombination and other DNA damage repair 
pathways, whereby BRCA mutations are reversed [96, 97]. Epigenetic mechanisms, 
(defined by heritable changes to the genetic expression through mRNA regulation, 
histone modification and DNA methylation), are thought to play a crucial role in 
platinum-resistant disease [98]. 
Patients presenting with recurrent platinum-resistant ovarian cancer are rarely treated 
with a curative intent, and treatment is usually focused on controlling the symptoms 
and improving the quality of life. Clinical studies have looked at the possible use of 
pegylated liposomal doxorubicin versus gemcitabine in platinum-resistant ovarian 
cancer patients. Both monotherapies have resulted in a PFS of approximately 3.4 
months, and an OS of 12.7 versus 13.5 months in gemcitabine and pegylated liposomal 
doxorubicin respectively [99]. Currently, there is no highly effective therapy for 
patients presenting with resistant disease, but anthracyclines (eg pegylated liposomal 
doxorubicin), docetaxel, and paclitaxel with or without bevacizumab are the most 
commonly administered therapies. These treatments generally have limited efficacy 
[100].  
1.3 Classification of ovarian cancer 
Traditional morphological description has classified epithelial ovarian cancer into five 




cancers. In 2004, molecular analysis of ovarian cancer led to their classification into 
Type I and Type II cancers [101]. Type I tumours comprise low-grade serous, low-
grade endometrioid, clear cell and mucinous types and often possess mutations in 
HER2, BRAF, PTEN, CTNNB1, KRAS, ARID1A and PIK3CA [17]. Low-grade 
tumours are more differentiated, tend to grow slowly and are less likely to metastasise. 
On the other hand, Type II carcinomas comprise high-grade serous and high-grade 
endometrioid types with high frequencies of TP53 mutations [17]. High-grade 
carcinomas are less differentiated with morphology very different from normal tissues. 
Type II patients respond well to initial platinum-based chemotherapy, unlike many 
patients with Type I disease [41]. Usually, the prognosis of Type I patients is better 
than that of Type II patients, as the latter patients are more likely to present with 
symptoms at advanced stages of the malignancy [97].  
A more recent approach to the classification of epithelial ovarian cancer has led to the 
latest grouping of ovarian carcinomas, whereby the different subtypes are classified 
under five histological groups, namely high-grade serous ovarian cancer (HGSOC), 
endometrioid, clear cell, mucinous and low-grade serous ovarian cancer (Table 1.1) 
[61, 102]. There is an increasing appreciation that these subtypes with different 
histological, clinical and molecular abnormalities, represent separate disease entities, 
indicating different treatment approaches [103]. Globally, the most common subtype 
is HGSOC with over 70% incidence rate, followed by endometrioid and clear cell with 
10% incidence rate each, and low-grade serous and mucinous carcinoma, with less 
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Table 1.1: Characteristics of epithelial ovarian cancer subtypes 
Adapted from [19], [61], [104], and [105]. Where HGS refers to High-Grade Serous, LGS 
refers to Low-Grade Serous, amp refers to amplification, OCP refers to oral contraceptive 
pill, BMI refers to body mass index, HT refers to hormone therapy. 
1.3.1 High-grade serous ovarian cancer 
HGSOC is the most common ovarian carcinoma, which is now thought to frequently 
arise from the fallopian tube. Patients generally present at late stages of the disease, 
hence the prognosis is often poor. Fortunately, more than 80% of patients respond well 
to the primary platinum ± taxane therapy [41]. Less than 20% of patients present with 
intrinsic resistance. Nevertheless, about 70% of cases relapse 6 months or more after 
initial treatment [106]. Patients are then given further chemotherapy, to which 30-60% 
respond, depending on how long it took until relapse [106]. Alas, approximately 80% 




with only 10% responding to second line therapy [106]. There are currently limited 
treatment options for these patients. 
A primary hallmark of HGSOC is the presence of TP53 mutations, which occur in 
almost 100% of HGSOC cases, and are often linked with its genesis [108]. TP53 
mutations are also found in the distal fallopian tube, which suggests either a 
pronounced exposure of this tissue or higher sensitivity of these cells to DNA damage, 
however, the cause of this DNA damage is unknown [109]. Other genetic anomalies 
that characterise HGSOC are BRCA1 and BRCA2 inactivation, occurring in 
approximately 5-10% [110-112] and 6% [111, 113] of ovarian cancer patients 
respectively. Women with germline BRCA mutations have a 30-70% chance of 
developing ovarian cancer [114]. These mutations can also arise sporadically [61]. A 
sequence of events proposed by Bowtell relates TP53 mutations and BRCA mutations 
as follows: an initial TP53 loss, followed by BRCA loss, leads to homologous 
recombination repair deficiency, which ultimately causes chromosomal instability and 
widespread copy number changes [109]. Other important mutations characterising 
HGSOC include PTEN loss, CCNE1 amplification and RB1 loss [61]. 
1.3.2 Endometrioid ovarian cancer 
Endometrioid ovarian cancer had traditionally been subdivided into low-grade and 
high-grade disease. However, as the histology and gene expression of high-grade 
endometrioid resembles more HGSOC, the term endometrioid nowadays is being 
restricted to low-grade endometrioid disease, which is thought to originate from 
endometriosis [105, 115]. Distinguishing factors between endometrioid and high-
grade serous include the absence of WT1 [116, 117], and TP53 [118] in ovarian 
endometrioid cancer cells. Patients presenting with endometrioid carcinoma have good 
prognosis, as they are often diagnosed at early to mid-stage of the disease, and its 
response to first line platinum therapy is frequently positive [115]. The most common 
mutations occur in CTNNB1 in 30-50% of patients, and these are linked to better 
outcome, squamous differentiation and low tumour grade [119]. PTEN is mutated in 
about 20% of endometrioid carcinomas, which leads to inhibition of apoptosis [120, 




associated with a worse prognosis [122]. Mutations in ARID1A, which is known to 
regulate transcription also occur in these cancers [123]. 
1.3.3 Clear cell ovarian cancer 
Clear cell cancer patients frequently present with advanced stages of the disease, do 
not respond to platinum therapy as well as HGSOC, and often have poor prognosis 
[124, 125]. Similar to endometrioid carcinoma, clear cell carcinoma is also associated 
with endometriosis, and when these patients present during early stages, their 
prognosis is better [125]. Genetic defects in this subgroup of cancers are also similar 
to those found in endometrioid carcinoma, with frequent mutations in ARID1A, 
PIK3CA and PTEN [126, 127]. 
1.3.4 Mucinous ovarian cancer 
Patients with mucinous carcinoma often present at earlier stages than HGSOC, and are 
not usually sensitive to first line platinum therapy. Mucinous carcinoma is thought to 
originate from transitional cell nests at the tubal-mesothelial junction, and are 
frequently borderline tumours [128]. Some mucinous tumours are thought to 
metastasise from the gastrointestinal tract [105]. Because of their possible 
gastrointestinal origin, KRAS genetic mutations are frequently found in mucinous 
cancers of intestinal differentiation [129]. They often also present with HER2 
amplification [130]. 
1.3.5 Low-grade serous ovarian cancer  
Low-grade serous ovarian cancer patients usually present at early stage and patients 
are frequently of young age, with the disease following a comparatively indolent 
course [105]. The progression from benign serous cystadenoma to borderline serous 
tumour leads to low-grade serous ovarian carcinoma. This disease does not normally 
progress to HGSOC. Genetic mutations in BRAF and KRAS characterise low-grade 




1.4 HER signalling pathway involved in ovarian cancer 
The human epidermal growth factor receptor (HER) family has been associated with 
progression in several types of cancer including breast, lung and colon cancers [132]. 
In ovarian cancer, amplification and/or high expression of epidermal growth factor 
receptor (EGFR), HER2 and HER3 receptors have been implicated in the progression 
and prognosis of the disease [133-136]. 
The HER family (also known as the erythroblastic leukaemia viral oncogene (erbB) 
family), exist on the cell surface as monomers in the absence of ligand activation. 
There are four members of this family, EGFR (HER1/erbB1), HER2 (neu/erbB2), 
HER3 (erbB3) and HER4 (erbB4) (Figure 1.5). The common structure of the HER 
family of receptors consist of an extracellular domain, a transmembrane domain and 
an intracellular tyrosine kinase domain with C-terminal domain [137]. With the 
exception of HER2, ligands bind to their extracellular domain and form homo- or 
heterodimers with other members of the family, preferentially with HER2 which has 
the most favourable kinase activity and exists in an activated form [138]. HER ligands 
are divided into three groups; those which bind specifically to EGFR (epidermal 
growth factor/EGF, amphiregulin and transforming growth factor-α/TGFα), others 
conferring dual specificity for EGFR and HER4 (betacellulin, heparin-binding EGF, 
and epiregulin), and those which bind to HER3 and HER4 (neuregulins/ heregulins  
(HRG)) [139]. HRG preferentially induces HER2-HER3 heterodimerisations [140], 
and its overexpression in breast cancer has been associated with poor prognosis [141]. 
The kinase domain and tyrosine residues which are phosphorylated will be dependent 
on the type of HER dimerization activated. The phosphorylated residues operate as 
docking sites which successively activate the downstream signalling response [137]. 
1.4.1 Downstream signalling pathways 
Upon receptor dimerization, multiple downstream pathways are activated which 
regulate cell proliferation, differentiation, angiogenesis, survival and cellular 
metabolism amongst other functions. Heterodimerisation allows for a myriad of 
phosphotyrosine residues to bind, which in turn increases the signalling pathway 




kinase (MAPK) / ERK pathway that regulates cellular proliferation and invasion; the 
phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of 
rapamycin (mTOR) pathway which regulates cell survival and metabolism; the 
phospholipase Cγ (PLCγ) pathway which controls calcium-dependent actions and the 
signal transducer and activation of transcription (STAT) pathway which governs cell 
proliferation and differentiation [138, 143, 144].  
In tumourigenesis, mutations within components of these pathways can cause cancer 
cells to acquire certain aptitudes, including impartiality of proliferation signals, 
circumvention of apoptosis, insensitivity to growth inhibitory signals, augmented 
replicative potential and the capability to metastasise [145]. 
The PI3K/Akt and MAPK pathways regulate migration through a variety of 
downstream signalling pathways, [146] including, rho-family GTPases, which control 
cytoskeletal regulators; integrins and associated matrix adhesion proteins; enzymes 
which degrade ECM proteins, facilitating cell invasion as they reduce adhesive 
contacts; cell-cell adhesion components; transcription factors which regulate proteins 





Figure 1.5: Cell proliferation pathways regulated by HER-family members 
The downstream pathways regulated by HERs are the MAPK, PI3K/Akt, STAT and PLCγ 
pathway. Where MEK= Mitogen-activated protein kinase, ERK= extracellular signal-
regulated kinases, PLCγ= phospholipase Cγ, DAG= diacylglycerol, IP3= inositol 
trisphosphate, PKC= protein kinase C, CaMK= calcium-calmodulin dependent kinase, JAK= 
Janus kinase, STAT= signal transducer and activator of transcription, PI3K= 
Phosphoinositide 3-kinase, PIP= Phosphatidylinositol (3,4,5)-trisphosphate, Akt= protein 
kinase B , mTOR= mechanistic target of rapamycin, S6K= Ribosomal protein S6 kinase beta. 
Adapted from [147]. 
The MAPK pathway is regarded as a paradigm for signal transduction in molecular 
biology. A signal is propagated along the pathway in response to stimuli via sequential 
phosphorylation of three kinases, specifically MAPKKK (e.g. B-Raf), MAPKK (e.g. 
MEK1/2) and MAPK (e.g. ERK1/2) [148]. There are six different groups of MAPKs 
in mammals, including ERK1/2, ERK3/4, ERK5, ERK7/8, JNK1/2/3 and p38/ERK6 
[145]. The location of ERK when it phosphorylates target molecules determines its 
effects within the cell. In the cytoplasm, it affects cellular movement, metabolism, cell 




phosphorylated ERK promotes cell cycle progression [151]. Sprouty and Spred, are 
cytoplasmic proteins which inhibit the MAPK pathway by decreasing phosphorylation 
[151, 152]. Additionally, ERK can promote tumour suppression through senescence 
[153] which acts through terminal cell cycle arrest [154]. 
Mutations in EGFR (eg del19EGFR), KRAS and BRAF can result in constitutive 
activation of the MAPK pathway, leading to induction and progression of 
tumourigenesis. There are some inhibitors acting on these oncogenes, such as 
vemurafenib, which inhibits BRAF and is currently being used in melanoma [155]. 
Selumetinib is another inhibitor of the MAPK pathway, which acts on the MEK protein 
[156]. A phase II clinical trial featuring selumetinib in recurrent low-grade serous 
ovarian cancer patients resulted in a 15% overall response rate (ORR) and median PFS 
of 11 months [157]. The response was not correlated with any mutations in BRAF or 
KRAS [157]. On the other hand, an investigational drug, CI-1040 was found to be 
effective in vitro in BRAF or KRAS mutated ovarian cancer cell lines [158]. 
In the PI3K/ Akt/ mTOR pathway, upstream stimulation of the HER receptors results 
in the eventual phosphorylation of Akt and PDK1 kinases. The binding of PI3K to its 
ligands causes allosteric activation, leading to the conversion of PIP2 to PIP3. The 
latter triggers PDK1 proteins and recruitment of Akt proteins in the plasma membrane. 
Active Akt controls downstream mediators such as mTOR. The latter in turn 
phosphorylates ribosomal S6 kinase-1, which is essential for translation of mRNA and 
crucial for cell cycle progression from G1 to S phase [159]. PTEN dephosphorylates 
PIP3 to PIP2, acting as a negative regulator of this pathway [160]. Recently, phase I 
and phase II clinical trials of mTOR inhibitors such as temsirolimus and everolimus, 
have demonstrated positive results in ovarian cancer [161-163]. However, none has 
yet been approved for the treatment of ovarian cancer, as the outcome to treatment was 
insufficient.  
This pathway is frequently driven by the genetic mutation and amplification of key 
pathway components, namely loss of PTEN, somatic activating mutations in PIK3CA, 
mutations in PIK3R1, EGFR, HER2 and AKT2 in ovarian cancer [148, 164, 165]. Most 




ovarian cancer [120, 121, 126, 127]. Perifosine, an Akt inhibitor demonstrated 
synergistic inhibition when combined with paclitaxel in ovarian cancer patients [166].  
The PLCγ pathway is associated with calcium dependent cellular functions such as 
cell proliferation, migration, inflammation and gene expression. PLC-catalysed 
hydrolysis of phosphatidylinositol 4,5-bisphosphate produces the messenger 
molecules inositol 1,4,5-trisphosphate (increases the intracellular free Ca2+) and 
diacylglycerol (activates protein kinase C), mediated by the PLC-γ isozymes [167]. 
Phospholipases transmit their signals via lipid mediators to produce calcium in the 
endoplasmic reticulum [168]. An in vitro ovarian cancer study linked PLCγ to 
migratory ability of the cells [169]. 
The STAT pathway consists of seven cytoplasmic transcription factors, which are 
activated by receptor tyrosine kinases to form dimers, which migrate to the nucleus to 
control gene expression of proteins whose up-regulation leads to uncontrolled cell 
proliferation and cell cycle progression [170]. The STATs are not only involved in 
carcinogenesis and progression, but also contribute to cancer cell survival. Inhibiting 
these STATs causes apoptosis of tumour cells [171]. Different STATs play various 
functions. This pathway is often linked with several cancer types, namely ovarian 
cancer, whereby STAT3 and STAT5 play an important role [172], and are involved in 
cell cycle progression, angiogenesis and inhibition of apoptosis. STAT proteins can be 
directly activated by HER through one of their domains, SH2 [173]. However, STAT 
activation could also occur indirectly by the activation of inflammatory cytokines, such 
as IL6 [174]. 
1.4.2 HER receptor significance in ovarian cancer 
1.4.2.1 EGFR 
The EGFR (HER1) is a protein-tyrosine kinase receptor comprising an extracellular 
ligand-binding domain with 622 residues, a 23-residue transmembrane segment, and a 
large, 522-residue intracellular domain [142]. EGFR plays an important role in 
epithelial cell development, as this process is often regulated by EGF [175]. EGFR has 




signalling cascade initiated by EGFR activation and these include Tyr1068, Tyr1148, 
Tyr1173, Tyr992 and Tyr1086 [177]. 
EGFR is normally only weakly expressed in the ovary, however multiple studies have 
demonstrated that EGFR can be highly expressed in ovarian cancer. 
Immunohistochemistry studies have indicated that 30-70% of ovarian cancers have 
EGFR expression [178-180]. High expression of EGFR is associated with poor PFS, 
advanced tumour grade, greater residual tumour mass and rapid proliferation [133, 
134, 136]. It has also been suggested that high EGFR expression in tumour stroma is 
associated with aggressive clinical conditions, and EGFR up-regulation in fibroblasts 
is associated with growth and migratory abilities of ovarian cancer cells [181]. Several 
studies have reported EGFR expression as being an independent prognostic factor of 
poor outcome in ovarian cancer [182, 183]. Additionally, recent studies indicate that 
activation of EGFR during platinum treatment leads to the development of platinum 
resistance [184, 185]. 
1.4.2.2 HER2 
The HER2 receptor consists of 1255 amino acids and is a 185 kD transmembrane 
glycoprotein [186]. It lacks a ligand-binding domain, thus it requires other HERs for 
dimerization. However, when HER2 is overexpressed, it is able to form homodimers 
which are able to elicit downstream signalling responses [187]. HER2 is thought to 
have the strongest catalytic kinase activity, thus HER2-containing heterodimers have 
the greatest signalling capacity, and HER2-HER3 heterodimers are considered to be 
the most potent when it comes to signalling [188]. HER2 has multiple phosphorylation 
residues including Tyr1139, Tyr1196, Tyr1221/1222 and Tyr1248 [189]. 
HER2 is overexpressed in approximately 6-30% of ovarian cancer patients [134, 190] 
and was initially associated by Slamon et al. with DNA amplification and poor 
prognosis [134, 191, 192]. Overexpression is often found in the mucinous (19%) [193] 
and clear cell (14%) [194] subtypes. A study by Mccaughan et al. found that some 
serous (3%) and endometrioid ovarian cancers (2%) have HER2 overexpression also 
[195]. These data were reanalysed recently to reflect the new ovarian cancer 




HER2 amplified (personal communication- S. Langdon, 2018), suggesting significant 
percentages of these more frequent subtypes possess HER2 amplification.  
1.4.2.3 HER3 
HER3 is expressed as a full-length receptor on the cell surface at a size of 180 kD, in 
parallel with truncated intracellular iso-forms. However, the activity of the latter is not 
well defined [196, 197]. HER3 has very weak protein tyrosine kinase activity, hence 
transphosphorylation by other HER members would result in stronger propagation of 
cell signals [142, 198].  
HER3 is more frequently expressed in ovarian cancer (30-80%) than EGFR and HER2 
[199] and is more common amongst borderline and early-stage lesions [200]. The most 
potent signalling complex among the dimerization possibilities is generated when 
HER3 heterodimerises with HER2 [201]. High HER3 expression has been associated 
with poor clinical outcome; average survival time for patients with low HER3 
expression was 3.3 years, in contrast to 1.8 years for patients with high HER3 
expression [135]. Studies in various cancer types show that when HER3 and MET are 
both highly activated, they are often associated with therapy resistance [202-204]. 
Other studies show that high expression of HER3 may lead to a HER3-PI3K-Akt 
signalling cascade in doxorubicin and cisplatin treated ovarian cancer, which often 
leads to therapy resistance [205, 206].  
1.4.2.4 HER4 
HER4 is the least understood receptor of the HER family. It occurs in spliced isoforms, 
often being further processed by enzymes into a soluble intracellular domain which 
can disperse to the cell cytoplasm or nucleus [207]. In breast cancer, the nuclear 
localization of the intracellular domain in combination with oestrogen expression, 
predicted for worse clinical outcomes compared to membrane HER4 and oestrogen 
[208].  
There are conflicting views about the presence of HER4 in ovarian cancer, with earlier 
reports finding decreased or absent presence of the receptor [209], while more recent 




[199, 210, 211]. Although the implication of HER4 expression in ovarian cancer is 
unclear, two studies found a possible correlation between HER4 expression and serous 
ovarian cancer resistance to chemotherapy [210, 212]. 
1.5 Monoclonal antibodies 
Conventional chemotherapy often does not discriminate normal cells from tumour 
cells, therefore can lead to multiple side effects. Conversely, targeted therapy is 
designed to affect molecular targets which have a role in irregularly dividing cells. 
Often, they are used in combination with radiotherapy or chemotherapy for an 
additional or synergistic effect [213].  
Monoclonal antibodies (mAbs) are immunoglobulins that recognise specific binding 
sites or epitopes on an antigen [214]. They consist of constant heavy chains and light 
chains, with the latter having a variable region, which is the antigen 
binding/recognition region. To overcome immunogenicity, “humanised” chimeric 
mouse-human antibodies have been developed [215]. HER-targeted mAbs are 
currently being used widely in the treatment of breast cancer [216, 217], and colorectal 
cancer [218, 219]. Recent in vitro and in vivo preclinical studies and clinical trials have 
been focusing on the role of mAbs targeted against HER2 in ovarian cancer, especially 
given that selected subtypes, particularly mucinous cancers, have HER2 amplification 
and overexpression [130, 220]. However, to date there are no HER-targeted mAbs 
approved for the treatment of ovarian cancer. 
1.5.1 Trastuzumab 
The first HER2-targeted mAb to be approved for use in oncology was Trastuzumab 
(Herceptin®) in 1998. Trastuzumab is indicated in metastatic breast cancer 
overexpressing HER2 as monotherapy or in combination with paclitaxel depending on 
whether the patient had received chemotherapy regimens for their metastatic disease 
[221]. It is a recombinant humanized mAb, which binds to the juxtamembrane region 
of the extracellular HER2 domain, inhibiting extracellular domain cleavage, 




mediated cytotoxicity [222, 223] (Figure 1.6). In breast cancer, trastuzumab requires 
HER2 overexpression for its effects [223, 224].  
A phase II trastuzumab clinical trial involving 41 eligible ovarian cancer patients with 
HER2 overexpression, demonstrated an ORR of 7.3%, which included one complete 
and two partial responses. The median PFS was two months [225].  
1.5.2 Pertuzumab 
Pertuzumab (Perjeta®) was approved in 2012 for the treatment of HER2 positive 
metastatic breast cancer patients who had not been previously exposed to anti-HER2 
therapy or chemotherapy for metastatic disease and for the neoadjuvant treatment of 
HER2 positive early stage breast cancer [226]. Pertuzumab acts by blocking the 
dimerization domain on HER2, thus inhibiting HER2 hetero-dimerization [223] 
(Figure 1.6). Unlike trastuzumab, it still produces inhibitory effects in the absence of 
HER2 overexpression [227, 228].  
In a phase III breast cancer clinical trial (CLEOPATRA), the combination of 
trastuzumab and pertuzumab plus docletaxel showed additional benefit compared to 
monotherapy, which subsequently led to the approval of the combination for HER2 
positive metastatic breast cancer [229]. Pertuzumab was assessed in a phase III clinical 
trial (PENELOPE) in platinum-resistant ovarian cancer featuring low HER3 
expression, after a randomised phase II clinical trial with pertuzumab showed a better 
PFS (5.3 months vs 1.4 months with placebo) in patients with low HER3 expressing, 
platinum-resistant ovarian cancers [230, 231]. In the PENELOPE trial, the addition of 
pertuzumab to chemotherapy produced a PFS of 4.3 months and an ORR of 13.1%, 
when compared to the PFS of 2.6 months and ORR of 8.7% in placebo plus 
chemotherapy patients [231]. In the in vivo setting using ovarian cancer xenografts, 
our group has demonstrated that the combination of pertuzumab and trastuzumab 
produces more prolonged growth inhibition, when compared to either antibody used 
as single agent [232]. Furthermore, another preclinical study has also suggested that 
trastuzumab could augment sensitivity in ERα-positive ovarian cancer to endocrine 





Figure 1.6: Mode of action of HER2-targeted mAbs 
The HER-targeted mAbs act on homo or heterodimers that involve HER2 to prevent the 
downstream signalling pathways brought about by the HERs. 
1.5.3 Trastuzumab-emtansine 
Trastuzumab-emtansine, T-DM1 (Kadcyla®) is a HER2 targeted mAb conjugated to a 
microtubule inhibitor (emtansine). It was approved in 2013 for the treatment of 
recurrent advanced or metastatic breast cancer [234]. T-DM1 acts by binding to HER2, 
triggering the endocytosis of the HER2-T-DM1 complex. Once in the cytoplasm, DM1 
is released from the complex and inhibits microtubule assembly, leading to cell death 
[235]. In a phase III breast cancer clinical trial, the T-DM1 treated cohort showed a 
superior clinical outcome (PFS 9.6 months) compared to patients who received 
lapatinib plus capecitabine (6.4 months) [236].  It was later approved as monotherapy 
for HER2 positive metastatic breast cancer resistant to trastuzumab treatment [237]. 
In a recent in vivo study by Menderes et al., T-DM1 demonstrated superior tumour 
growth inhibitory activity against HER2 overexpressing ovarian cancer primary cell 
lines, than pertuzumab, trastuzumab and their combination [238]. It also improved 
survival in a xenograft model [238]. This agent was also shown to have similar 
antibody-dependent cell-mediated cytotoxicity as pertuzumab, trastuzumab and their 




subcutaneous and intraperitoneal growth of the SKOV3 ovarian cancer xenograft 
model [239]. 
1.5.4 Other HER-targeted antibodies 
Cetuximab (Erbitux®) is an EGFR-targeted mAb that is currently being used in the 
treatment of colorectal cancer [218]. It is active in patients who do not harbour a KRAS 
mutation and who possess EGFR amplification [240, 241]. In a phase II trial using 
cetuximab plus carboplatin in recurrent platinum-sensitive ovarian cancer patients, 
there was a response rate of almost 27% in EGFR-positive patients [242]. This 
contrasts to a 9% response rate in EGFR-positive patients when cetuximab was used 
as monotherapy [243]. 
Panitumumab (Vectibix®) is also an EGFR-targeted mAb which has been approved in 
2006 for the treatment of recurrent metastatic colorectal carcinoma [219]. 
Panitumumab requires a WT BRAF and KRAS phenotype for optimal therapeutic effect 
[244, 245]. Panitumumab with pegylated liposomal doxorubicin was effective in a 
phase II platinum-resistant ovarian cancer study, with an OS of 8.1 months [246]. A 
phase II clinical trial investigating the administration of panitumumab with platinum-
based chemotherapy in relapsed platinum-sensitive patients, revealed that this 
combination did not offer advantages over the standard treatment [247].  
Seribantumab is an anti-HER3 mAb which was previously in phase II clinical trials 
[248]. Interestingly, from a phase II clinical trial on platinum-resistant or refractory 
ovarian cancer patients, it emerged that detectible levels of HRG and low levels of 
HER2 were important for its therapeutic effects [249]. 
1.6 Tyrosine kinase inhibitors 
Tyrosine kinases are enzymes that catalyse the phosphate transfer from adenosine 
triphosphate (ATP) onto a tyrosine residue within a target protein. This transfer may 
then elicit a further response within a signalling pathway. Cellular molecules that 




derived growth factor receptors (PDGFR), and also non-receptor tyrosine kinases 
BCR-ABL and KIT among others [213, 250].  
The tyrosine kinase inhibitors (TKIs) are small molecular drugs which inhibit tyrosine 
kinases, and can be classified into three main types. Most small molecule TKIs are 
type I, which compete with ATP by binding to ATP binding sites within the active 
conformation of the receptors, thereby interfering with the phosphorylation of tyrosine 
residues and inhibiting activation of downstream pathways [250, 251]. Type II TKIs 
bind to the inactive conformation of the kinase, while type III allosteric inhibitors bind 
to sites distant from the active site [252]. First generation TKIs included the EGFR 
inhibitors, gefitinib and erlotinib, which have shown clinical efficacy against EGFR 
mutant lung cancer [253, 254]. Since a resistance mutation at T790M frequently 
develops on treatment [255], covalent irreversible 2nd generation TKIs were developed 
[256]. These include afatinib and neratinib, which are active against this mutation. 
Other HER inhibitors were developed with broader acting inhibitory activity across 
multiple HER family members (pan-inhibitors) and these include lapatinib and 
canertinib as early developed inhibitors, followed by neratinib, sapitinib and 
dacomitinib. Finally, multitargeted TKIs that target not only the HER family but also 
other targets (e.g. PDGFR, VEGFR etc) include vandetininib and leflunomide. 
The HER-targeted TKIs differ in their side effect profiles, however they are generally 
well tolerated. The main side effects include skin/ hair toxicity, facial hair growth and 
erythema, haematological side effects (eg anemia, thrombopenia), oedema, gastric 
effects and hypothyroidism. Cardiac toxicity is one of the major long term adverse 
effects [257]. 
1.6.1 First generation TKIs 
1.6.1.1 Erlotinib  
Erlotinib (Tarceva®; OSI-774) is a quinazoline derivative, reversibly inhibiting EGFR 
(Table 1.2). It is indicated as first line therapy in non-small cell lung cancer (NSCLC) 
and in combination with gemcitabine in pancreatic cancer [258]. Erlotinib has shown 




respectively) in chemotherapy-naïve NSCLC patients, harbouring EGFR mutations 
[259]. An in vivo study in EGFR high expressing ovarian cancer demonstrated that a 
combination of erlotinib plus olaparib, a PARP inhibitor, had a greater tumour 
suppressor effect than the monotherapy alone [260]. A phase II study combining 
erlotinib with carboplatin showed that the combination was more effective in ovarian 
cancer patients with platinum-sensitive disease rather than platinum-resistant disease, 
with 57% and 7% objective response rates respectively [261]. This finding could be 
attributed predominantly to the anti-tumour activity of carboplatin. An exploratory 
phase II clinical trial involving bevacizumab and erlotinib determined that high levels 
of VEGF-A caused bevacizumab resistance, while erlotinib did not seem to contribute 
to the efficacy of the combination [262]. A randomised phase III study evaluated the 
efficacy of administering erlotinib in patients after first line chemotherapy for ovarian 
cancer. The median PFS in patients receiving erlotinib and placebo was 12.7 and 12.4 
months respectively, concluding that erlotinib does not provide pre-treated ovarian 
cancer patients with additional benefits [263]. In an extension to this phase III clinical 
trial, a tissue biomarker study concluded that increased EGFR gene copy number led 
to worse OS and PFS [264].  
1.6.1.2 Gefitinib  
Gefitinib (Iressa®, ZD-1839) is a type I quinazoline derivative TKI, reversibly 
selective for EGFR (Table 1.2). Gefitinib is marketed for monotherapy of locally 
advanced or metastatic NSCLC and is most effective in cancers with mutation or 
increased EGFR copy number [265]. Preclinical studies demonstrated that combining 
gefitinib with cisplatin, increased the efficacy of cisplatin, mainly due to EGFR 
downstream inhibition and blockade of DNA repair mechanisms of ovarian cancer 
[266]. When evaluated in an ovarian cancer phase II trial, gefitinib showed a limited 
response rate in platinum pre-treated ovarian cancer patients, with only one of twenty-
seven patients indicating an ORR of 4% [267]. However, this patient was the one 
participant in this cohort harbouring a mutation in the catalytic region of the EGFR, 
consistent with data for NSCLC. Another phase II clinical trial combining gefitinib 




any advantageous tumour responses with median time-to-progression being 58 days 
[268].  







































Table 1.2: Main characteristics of first generation HER-targeted TKIs 
1.6.2 Second generation TKIs 
1.6.2.1 Afatinib  
Afatinib (Gilotrif®, Giotrif®; BIBW-2992) is a type I anilinoquinazoline derivative 
TKI inhibitor, which irreversibly binds to EGFR, HER2 and HER4 [271] (Table 1.3, 
Figure 1.7). It is currently approved for the treatment of EGFR-mutated NSCLC. In 
vitro studies using ovarian cancer cell line models showed that afatinib possessed anti-
migration and anti-proliferation properties [272]. In an ovarian cancer preclinical 
study, afatinib reversed ABC-mediated multidrug resistance to paclitaxel and 
adriamycin, as well as increased the apoptosis efficacy of paclitaxel in ABCB1 
overexpressing tumours [273]. In vivo, afatinib plus docetaxel showed enhanced 
tumour size reduction, than either drug as a single agent [274]. It was also found 
effective in inhibiting basal and HRG-induced EGFR, HER2, Akt and ERK 
phosphorylation [272]. Afatinib has not been extensively tested in ovarian cancer in 
clinical trials. However, a phase I dose escalation study which included four ovarian 
cancer patients showed clinical promise as indicated by stable disease [275, 276]. In 
breast cancer, afatinib treatment was effective as it overcomes HERT798I-mediated 




1.6.2.2 Canertinib  
Canertinib (CI-1033; PD-183805) is a 4-anilinoquinazoline, irreversible, pan-HER 
TKI, which reached phase II clinical trials, however it was recently withdrawn [280] 
(Table 1.3, Figure 1.7). In vitro, it enhances the intracellular accumulation of certain 
cytotoxic drugs, in cells overexpressing ATP-binding cassette subfamily G2 (ABCG2) 
transporter [281]. Canertinib showed potent inhibitory effects in ovarian cancer cell 
lines, especially when combined with a c-MET inhibitor (PHA665752), which further 
reduced phosphorylation and total expression of signalling pathway [272, 282, 283]. 
A randomised phase II clinical trial in platinum-resistant or refractory ovarian cancer 
patients, resulted in disease stability in about 30% of patients, with median PFS and 
OS of 2.2 months and 9.1 months respectively [284]. Studies suggest that high HER 
levels and low HER autocrine ligands lead to canertinib resistance [285]. 
1.6.2.3 Lapatinib  
Lapatinib (Tyverb®; GW-572016) is an oral competitive TKI inhibitor selective for 
EGFR and HER2 (Table 1.3, Figure 1.7). It is indicated in HER2 overexpressing breast 
cancer.  Preclinical data indicate that lapatinib works better when HER2 is 
overexpressed and most likely homodimerised [286]. In breast cancer clinical trials, 
lapatinib has shown better inhibition when HER2 is expressed rather than when there 
was EGFR expression [287]. In a phase I study assessing lapatinib in combination with 
carboplatin in ovarian cancer, whilst there were some non-dose limiting toxicities, half 
of the patients had partial response or stable disease [288]. The combination of 
lapatinib and topotecan was assessed in a one-arm phase II trial (LapTop), whereby 
20% of patients experienced benefit, however hematologic adverse effects were 
considerable [289, 290]. In another one-arm phase II study in recurrent ovarian cancer, 
the median PFS was 1.8 months, OS was 10.5 months, and 8% of patients had PFS at 
6 months. The low PFS could be due to low EGFR and HER2 expression [291].  
1.6.2.4 Neratinib  
Neratinib (Nerlynx®; HKI-272) is an oral irreversible pan-HER inhibitor (Table 1.3, 
Figure 1.7). It has been recently approved for the adjuvant treatment of early stage 
HER2-positive breast cancer [292], after a phase III study concluded a 2-year invasive 




trastuzumab adjuvant therapy versus 92% in the placebo arm [293]. Neratinib has 
demonstrated pre-clinical efficacy in ovarian cancer, especially in HER2-amplified 
carcinosarcoma, whereby it inhibits proliferation and tumour growth [294], as well as 
decreases phosphorylation of transcription factor S6, and causes cell cycle arrest in the 
G0/G1 phase [295]. There is currently a phase II clinical trial underway assessing 
neratinib efficacy in HER2-positive solid tumours (SUMMIT Trial) with mutations in 
EGFR, HER2 or HER3, including ovarian cancer (NCT01953926). This included four 
evaluable ovarian cancer patients of whom one had stable disease while three had 
disease progression [296]. In a phase II study assessing neratinib in advanced NSCLC, 
patients with T790M EGFR mutation did not respond to therapy, however partial 
responses or disease stabilisation were seen in G719X EGFR mutated patients [297]. 
In HER2-positive breast cancer, neratinib as a single agent was well tolerated and has 
shown substantial clinical activity in trastuzumab-naïve patients, with a 16-week PFS 
rate of 78%, and medial PFS of 39.6 weeks versus 16-week PFS rate of 59% and 
median PFS of 22.3 weeks in trastuzumab pre-treated patients [298]. The activity of 
neratinib was correlated with HER2 levels and not with EGFR levels in vitro [299]. 
Other clinical trials in breast cancer assessed neratinib in combination with 
temsirolimus, vinorelbine, paclitaxel ± trastuzumab and capecitabine, all of which 
were well tolerated by patients and had anti-tumour properties [300-304].  
1.6.2.5 Sapitinib  
Sapitinib (AZD 8931) is a type I, reversible, equipotent inhibitor of EGFR, HER2 and 
HER3 receptor signalling, especially when HER2 is not overexpressed while EGFR is 
highly expressed [286, 305] (Table 1.3, Figure 1.7). In fact, sapitinib has shown 
superior tumour growth inhibition against EGFR-driven xenograft tumours when 
compared to lapatinib [286]. Preclinical studies suggest that sapitinib favours HRG-
induced HER2/HER3 heterodimers [286].  It has also demonstrated its ability to inhibit 
proliferation through the p-ERK and p-Akt pathways, and induces apoptosis through 
M30 and cleaved caspase-3 [286]. In vitro studies suggest that sapitinib in combination 
with trastuzumab may be an effective therapy in HER2 breast cancer, and it showed 
efficacy in trastuzumab sensitive and resistant cells [306]. In xenograft inflammatory 




the combination of paclitaxel and sapitinib was more effective than either agent alone 
[305]. Sapitinib has been tested in eight ovarian cancer patients amongst others in a 
phase I clinical trial, to assess the maximum tolerated dose, established to be 240 mg 
twice daily [307].  
 
Figure 1.7: Main sites of action of second generation TKIs used in this study  
The relative potency is indicated as follows: +++ is very potent, ++ is potent, + is mildly 
potent and – is generally inactive. Adapted from [147]. 
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Table 1.3: Main characteristics of second generation of HER-targeted TKIs used in this 
study.  




1.6.3 Biomarkers of response to TKIs in ovarian cancer 
In breast and lung cancers, informative biomarkers of sensitivity to HER TKIs include 
overexpression of HER2 and mutation of EGFR. HER2 overexpression is an effective 
biomarker of sensitivity to HER2-targeted TKIs such as lapatinib in breast cancer. 
Preclinical studies of T-DM1 in ovarian cancer suggest that even low HER2 expression 
was important for the anti-tumour properties of T-DM1 in model systems [316]. 
Analysis of a series of ovarian cancer xenograft models demonstrated that curative 
activity with the trastuzumab/pertuzumab combination was obtained in cancers with 
amplification and overexpression of HER2. There is currently little information to 
indicate how expression levels of HER2 relate to TKIs in ovarian cancer [232, 233] 
and there is an interesting case report of a dramatic remission of a chemotherapy-
resistant ovarian cancer to trastuzumab which was HER2-negative, suggesting that the 
rules governing response in ovarian cancer may differ from those for breast cancer 
[317]. In a phase II platinum-resistant/refractory ovarian cancer trial, an anti-HER3 
monoclonal antibody, seribantumab in combination with paclitaxel, was effective in 
patients with detectable HRG and low HER2 expression [249]. For EGFR, the mutated 
form with deletions in exon 19 indicates sensitivity to TKIs such as erlotinib and 
gefitinib in NSCLC [318]. However, the importance of EGFR mutations in ovarian 
cancer is still not well researched since the incidence is much lower. As mentioned 
above, in a phase II trial of gefitinib in 27 ovarian cancer patients, the one responding 
cancer did contain an EGFR mutation (2235del15; E746-A750del) in the catalytic 
domain consistent with this molecular feature being an indicator of sensitivity [267]. 
This requires validation in future studies.  
1.6.4 Resistance to TKIs 
Tumours may become resistant to TKI therapy through various mechanisms. One of 
them is through EGFR mutation, whereby a mutation at position 790, enhances affinity 
for ATP rather than TKIs at the ATP binding pocket [319]. Other mutations in EGFR 
that are frequent include L747S, D761Y, T854A [320]. HER2 overexpression and 
mutations such as HER2L869R [277, 321] could also lead to TKI therapy resistance. 
Abnormal activity in pathways also link with resistance, such as the amplification of 




factor (ligand for c-Met), overexpression of VEGF receptor (which leads to invasion) 
and EGFRvIII mutation (activates PI3K/AKT/mTOR pathway and increases 
proliferation), K-RAS mutation (leads to uncontrolled proliferation) and loss of PTEN 
(which usually inhibits cell migration) [322-325]. Alternative pathways which can 
bypass control include aberrant activation of MET and HGF [326, 327], modifications 
in VEGF receptors which trigger vascular permeability, in PDGF which regulate 
angiogenesis and in interleukin-6 which controls inflammatory processes [328-330]. 
ATP binding cassette transporters overexpression is also a worrying mechanism of 
resistance as it reduces drug uptake while increasing drug efflux, resulting in a low 
drug concentration in the cytoplasm [322]. 
1.7 Ovarian cell line models 
Human ovarian cancer cell lines have provided valuable model systems to study a 
variety of ovarian cancer characteristics, including chemo-sensitivity, cellular biology 
and molecular response [41].  A large number of ovarian cancer cell lines have been 
established and many of these are in widespread use [331, 332]. These models can 
reflect the diverse characteristics found in clinical specimens, such as varying response 
to chemotherapy. 
A panel of three pairs of human HGSOC cell lines was used in this study. Each pair of 
cell lines (PEA1 – PEA2; PEO1 – PEO4; PEO14 – PEO23) were established in 
Edinburgh from the ascites of the same patients at points before and after clinical 
resistance had developed within the same patient [333] and are described in Table 1.4 
and Figure 1.8. These cell lines are an excellent model for investigating response of 
drugs in naturally-occurring platinum-sensitive and acquired platinum-resistant 
ovarian cancer. The PEA2 cell line has been shown to express low levels of tumour 
necrosis factor receptor-associated protein 1 (TRAP1). TRAP1 is a key regulatory in 
cell metabolism, and cisplatin resistance was linked with increased oxidative 
metabolism [334]. Recent studies have demonstrated that PEO1 cell line is BRCA2 
mutant, whilst its counterpart, PEO4 cell line has a restored BRCA2 status through a 
secondary mutation [335]. On the other hand, the PEO14-PEO23 cell line pair does 




duplicator phenotype [336]. In general, the platinum-resistant counterpart of these 
three pairs of cell lines did not experience lower accumulation of platinum agent [337].  











Table 1.4: Summary of the characteristics of the HGSOC cell lines used in this study 
All cell lines were of HGSOC origin, with mutations in TP53 [331]. 
 
Figure 1.8: An overview of the cell line pairs used in this study  
The grey boxes represent the platinum-resistant cell lines [97]. 
Additionally, the non-HGSOC SKOV3 ovarian cancer cell line was used, which is 
characterised by its HER2 overexpression [338]. It was established from the ascites of 






1.8 Aims and objectives 
Recent studies in ovarian cancer show that resistance to platinum therapy is often 
associated with EGFR activation [184, 185]. Additionally, a preclinical study by Sims 
et al., demonstrates that ovarian cancer xenografts which are normally resistant to 
platinum therapy were sensitive to mAbs, especially in high HER2 ovarian cancers 
[232]. A phase II clinical trial of the anti-HER2 antibody pertuzumab suggested that 
platinum-resistant ovarian cancer might be more sensitive to pertuzumab than 
platinum-sensitive ovarian cancer [340]. HER2 targeted therapy has demonstrated 
clear value in the treatment of HER2 positive breast cancer [341]. This approach has 
not been studied extensively in ovarian cancer, and the possibility of using HER-
targeted therapy in platinum-resistant ovarian cancer has only had limited testing.  
The hypothesis being explored within this project is whether broad spectrum inhibition 
of the HER pathway, which is often associated with DNA repair [342, 343], would 
inhibit key functionality of platinum-resistant HGSOC cells, and whether this 
sensitivity inhibition could be correlated with the level of expression of HER family 
members. These findings will be useful as they give an indication whether HER 
expression could be a possible biomarker to treatment response and if there are 
plausible alternative therapies to patients presenting with platinum-resistant disease. 
Broad-spectrum TKIs were investigated in this project as previous studies suggest that 
more specific TKIs, such as gefitinib and erlotinib, are not as effective in ovarian 
cancer patients pre-treated with platinum-based chemotherapy [261, 267]. 
The different subtypes of ovarian cancer are recognised to be different diseases, and 
merit different treatment approaches. HGSOC is the most common ovarian cancer 
type, affecting over 70% of epithelial ovarian cancer patients. Therefore, this project 
aims to evaluate the effectiveness of broad-spectrum HER-targeted TKIs in the 





1. To investigate the proliferative, migratory and invasive response of HGSOC 
platinum-resistant versus platinum-sensitive ovarian cancer cell lines to HER-
targeted mAb and TKI treatment.  
2. To evaluate the effect of the combination of TKIs with mAbs or cytotoxics on 
proliferation.  
3. To assess the signalling pathways through which TKIs work when activated by 
EGF or HRG.  
4. To investigate the role of EGFR, HER2 and HER3 on the functional effects of 
neratinib and other TKIs on cellular functionality by knockdown and 
transfection studies.  
5. To identify expression changes linked to treatment by undertaking gene 
expression analysis of cell lines in the absence and presence of TKI. 
6. To identify potential biomarkers which are HER-targeted therapy-induced and 
validate these markers in tissue microarrays (TMAs) containing untreated and 









2  Materials and methods 
2.1 Cell culture 
The cell line panel - PEA1, PEA2, PEO1, PEO4, PEO14, PEO23 and SKOV3 cell 
lines (discussed in Section 1.7) - were cultured in Roswell Park Memorial Institute 
1640 (RPMI 1640; 218750, Gibco®) medium supplemented with 10% heat inactivated 
foetal bovine serum (FBS; 10270106, Gibco®) and 10,000 U/mL (1%) penicillin-
streptomycin (P/S; 151401, Gibco®). Frozen stocks of these cell lines had previously 
been confirmed negative for mycoplasma and authenticated by Short Tandem Repeat 
profiling. The cell lines were grown in T-175 flasks (83.3912.002, Sarstedt), in a 
humidified incubator at 37°C, and 5% CO2.  Media were changed at least every two to 
three days or when required. When cells reached 80-90% confluence, they were 
washed twice with sterile phosphate buffer saline (PBS) and 0.05% trypsin-EDTA 
(1X) dissociation agent with phenol red (253000, Gibco®) was added and left for about 
5 min or until the cells detached.  Fresh medium with serum was added to stop the 
trypsinisation process and cells were either passaged into new culture vessels or 
centrifuged and used as required for further experiments.   
2.1.1 Cell counting and seeding 
Cells were detached by the use of trypsin as described above, and the cell suspension 
was centrifuged at 21°C, for 5 min at 1,000 g. The cells were re-suspended in fresh 
medium. To count the cells, 10 µL of the re-suspended medium was placed in the 
haemocytometer and an average cell number per mL was calculated. Cells were seeded 
into flat bottomed 96 well plates (Thermo Scientific) or 6 well plates at densities based 




2.1.2 Cell preservation and recovery 
To preserve frozen stocks of the cell lines, cells were frozen down in a freeze mixture 
containing 10% dimethylsulphoxide (DMSO) with heat inactivated FBS and stored at 
-80°C in cryovials. For recovery of cells, the frozen cell suspension was rapidly 
defrosted, placed in routine medium and the cells were allowed to adhere to a T-25 
flask. Medium was changed after 24 h to remove traces of DMSO and cells were 
allowed to grow. 
2.1.3 Generation of multicellular tumour spheroids 
When cells reached 70% confluence in T-175 flasks, they underwent tryspinisation 
and centrifugation at 21°C, for 5 min at 1,000 g. Cells were re-suspended using a 
syringe in fresh 10% FBS-containing medium. The solution was transferred to a 100 
mL or 250 mL spinner flask. The spinner flasks were kept on a magnetic stirrer 
platform, in an incubator at 37oC and 5% CO2, until spheroids reached a maximum 
size, typically after 5 days. 
2.2 Cellular assays 
2.2.1 Sulforhodamine B (SRB) assay 
To assess the drug sensitivity of the ovarian cancer cell lines, the sulforhodamine B 
(SRB) assay was used (Figure 2.1). This assay quantifies the cellular protein content 
[344], which acts as an indirect measure of cell number. Cells were seeded as per 
section 2.1.1 in 100 µL of media. After 48 h, TKIs, mAbs or cytotoxic agents diluted 
in 100 µL of media were added to the wells (Table 2.1). The effects of 1 ng/mL EGF 
(AF-100-15, PeproTech) and 1 ng/mL HRG (396-HB/CF, R&D Systems) were also 
analysed. Day 0, untreated controls and vehicle controls were also included in each 


































mAbs Pertuzumab Kindly provided by 
Roche 
50 µg/mL 
Trastuzumab Obtained from 
Pharmacy, WGH 
50 µg/mL 
Table 2.1: Drug inhibitors used and their concentration ranges 
All TKIs and cytotoxic agents were bought in powder form and dissolved in DMSO, except for 
carboplatin which was solubilised in sterile water. The mAbs were supplied in prepared stock 
solutions. 
Cells were fixed after they had been incubated for 24 h - 120 h, by the addition of 50 
µL per well of cold 25% Trichloroacetic acid (TCA), and left for 1 h at 4°C. 
Afterwards, the plates were washed ten times with cold water, and allowed to dry in 
the oven at 50oC. Once dry, cells were stained with 50 µL of SRB dye solution and 
incubated for 30 min at room temperature. The SRB dye was washed four times with 
1% acetic acid, and left to dry. The cell-bound SRB dye was solubilised in 150 µL of 
10 mM Tris solution, at pH 10.5, followed by the measurement of optical density (OD) 





After reading the plates in the Microplate reader, a mean of the values of wells with 
the same drug concentrations was calculated. The growth as a percentage of growth of 
control was determined through the following formula: % Growth = B−A/C−A × 100, 
where A = A540 nm before treatment, B = A540 nm after treatment with drugs, and C 
= A540 nm after medium control. 
 
Figure 2.1: Pictorial depiction of the SRB proliferation assay 
 
2.2.1.1 Combinatorial treatment 
To assess the effects of a combination of drugs on cell proliferation, combinatorial 
experiments were carried out. After 48 h cell incubation in 96 well plates, the IC20 and 
IC30 values of cytotoxic drugs were combined with eight times the IC50 value of 
neratinib or lapatinib, followed by up to eight doubling dilutions added to the wells, 
either simultaneously or 2 h pre-treatment with the TKIs. The cells were fixed after 
120 h and the SRB assay was followed as in section 2.2.1. 
The measurable quantity of drug combination effects, combination index (CI) was 
calculated using CompuSyn Software [345]. The growth effects of the single agents 




corresponding to the drug concentrations used. The CompuSyn Software analyses the 
median-drug effects, which was originally described by Chou and Talalay [346]. This 
calculation assumes that the drugs, alone or in combination, would result in a 
sigmoidal concentration-response curve, and considers the potency of each drug as 
well as the shape of the concentration-response curve. The values which did not cause 
any growth inhibition, and the concentrations which caused complete cell kill were 
disregarded, as they decrease the sensitivity of the calculation. The CI values for each 
combination concentration indicated Synergism (CI<0.9), Additive Effect (CI: 0.9-
1.1) and Antagonism (CI>1.1).  
2.2.1.2 IC50 
The half maximal inhibitory concentration (IC50) is the concentration of inhibitor 
which is capable of halving the cell number. The IC50 value for each drug in different 
cell lines was calculated from sigmoidal concentration response curves using 
GraphPad Prism version 8 to give an indication of the potency of a drug. 
2.2.2 Migration (scratch) assay 
Cells were seeded in 6-well plates at a density of 1x106 - 2x106 cells per well in routine 
medium. When the cells reached 100% confluence (generally after 24 h), a 
perpendicular line was scratched across each well using a 200 µL pipette tip. Plates 
were washed in PBS until free floating cells had been removed and a clean well-
defined scratch was produced. The routine medium was replaced by medium 
containing 0.1% FBS and 1% penicillin-streptomycin. Some wells were used for 
controls (DMSO or media only), while others contained drug treatments, with or 
without growth factors.  
Photomicrographs were taken at time 0 h, and at regular time intervals thereafter using 
the x2.5 lens objective (Figure 2.2a). Marks were drawn on the lids so the same area 
would be photographed at every time point. Results were analysed using ImageJ 




The percentage that the cell lines migrated was calculated by subtracting the scratch 





Figure 2.2: Migration (scratch) assay protocol 
(a) Pictorial depiction of the migration (scratch) assay protocol. (b) Example of how the 
percentage area migrated was calculated. The area remaining after migration was calculated 
as a percentage from the total area migrated relative to 0 h. 
2.2.3 Adhesion assay 
Cells were grown in 100 mm petri dishes, until they reached 70% confluence.  Cells 
were then serum starved for 2 h and treated with 0.1 µM neratinib for 15 min. Cells 
were then re-suspended in serum free media containing the respective treatments. Cells 
were seeded in large numbers in uncoated, collagen coated (C7661, Sigma Aldrich), 
fibronectin coated (F1141, Sigma Aldrich) or laminin coated (L2020, Sigma Aldrich) 




then added to the wells with minimal volume of solution and was left overnight at 4°C. 
For fibronectin coated plates, 1 µg/cm2 of fibronectin was diluted in sterile PBS, then 
added to the wells with minimal volume of solution, and allowed to air dry for 45 min 
at room temperature. For laminin coated plates, 1 µg/cm2 of laminin was diluted in 
sterile PBS, added to the wells with minimal volume of solution, left for 2 h at 37°C 
and washed once with sterile PBS.  
The medium in the wells was changed after 1 h to normal medium and cells were fixed, 
and underwent the SRB assay protocol as per section 2.2.1. Results of the coated plates 
were then normalised to uncoated plates at each time point.  
2.2.4 Collagen invasion assay 
Cells were grown in 3D spheroids as described in section 2.1.3. When spheroids 
reached a maximum size, they were removed from spinner flasks and gently 
transferred to a petri-dish using a 25 mL serological pipette.  
A collagen mix was prepared as per Table 2.2, with or without treatment, and all 
contents were kept on ice before and after preparation. A single spheroid was taken up 
in 500 µL collagen mix solution, and placed centrally into a well in a 24-well plate 
(Figure 2.3a). The spheroids were incubated at 37oC, 5% CO2 for 1 h to allow the 
collagen solution to polymerise. Then, the polymerised gel solution was released from 
the edges and 500 µL media solution with or without treatment was added to each well 
respectively.  
Content Specifications Volume (mL) 
Collagen Ready-bought Cellmatrix type I-A 
(Alphalabs) 
2.5 
Acetic Acid (0.1%) 50µL of 100% acetic acid to 50 mL dH2O 4.5 
FBS Cell culture FBS 1 
NaOH (0.22M) 0.87993g NaOH (Sigma) into 100 mL dH2O 1 
10x DMEM One vial DMEM (Sigma) into 100mL dH2O 1 
Table 2.2: Contents of the collagen mix, required to make 10mL of solution  
The materials were made up outside the cell culture hood and were then passed through an 




Photomicrographs were taken using the x2.5 objective lens at time 0 h, 24 h and every 
24 h thereafter, for up to 120 h. Results were analysed using ImageJ software, based 





Figure 2.3: Invasion assay protocol 
(a) Pictorial depiction of the invasion assay protocol. (b) Example of how the percentage area 
invaded was calculated. The area invaded was calculated by subtracting the 0 h area from the 
area at each time point and presented as a percentage. 
2.3 Protein expression studies 
Protein expression in the cell lines was measured using the western blot technique 
following protein acquisition (Figure 2.4). Western blotting separates specific proteins 
in a sample based on molecular weight. The process allows for detection and 





Figure 2.4: Pictorial depiction of the western blot protocol 
2.3.1 Protein lysate collection 
Cells were grown in 100 mm petri dishes (Scientific Laboratory Supplies) or 6 well 
plates, in an incubator at the previously described conditions. Once they reached 80% 
confluence, they were washed twice with ice cold PBS and left on ice to preserve the 
proteins. 200 µL or 100 µL of the lysis buffer (Table 2.3) was pipetted onto 100 mm 
petri dish or 6 well plates respectively, and cells were scraped. After 10 min, the lysate 
was collected and placed in pre-labelled eppendorfs, and centrifuged at 13,000 g for 6 
min at 4°C. The supernatant was aliquoted by placing 10 µL in one eppendorf (for 
protein quantification) and the remaining supernatant into a 1.5 mL eppendorf for 
storage. Samples were stored at -70°C. 
Lysis buffer additives Catalogue No, Supplier 
1 complete protease inhibitor tablet 11836153001, Roche 
100 µL phosphatase inhibitor cocktail 2 P5726, Sigma Aldrich 
100 µL phosphatase inhibitor cocktail 3 P0044, Sigma Aldrich 
50 µL Aprotinin A6279, Sigma Aldrich 
100 µL TritonX-100 X100, Sigma Aldrich 
Table 2.3: Components of the lysis buffer 
The lysis buffer was made up of 50 mM Tris, 5 mM EGTA, 150 mM NaCl. The additives in the 
table were added to 10 mL of lysis buffer immediately before use. 
2.3.2 Bicinchoninic acid (BCA) assay 
This assay was used to determine the protein concentration in each sample. Lysates 
were placed on ice and a standard curve was prepared using eight known 




from each protein sample was added to 45 μL of distilled water in borosilicate tubes. 
One mL of BCA solution (1 mL of copper sulphate solution (C2284, Sigma Aldrich), 
and 49 mL BCA solution (B9643, Sigma Aldrich)) were added to all protein samples 
and standards. These were incubated at 60°C for 15 min. In a 96 well plate, 200 μL of 
each solution was pipetted in duplicate, and absorbance was measured at 540nm using 
a BP800 Biohit Microplate Reader. Sample protein concentration was determined 
from the protein concentration plot. 
Tube Final Concentration 
(µg/mL) 
Volume of 1 mg/mL 
Protein Standard (µL) 
Volume of Distilled 
H2O (µL) 
A 0 0 50 
B 50 2.5 47.5 
C 75 3.75 46.25 
D 100 5 45 
E 250 12.5 37.5 
F 500 25 25 
G 750 37.5 12.5 
H 1000 50 0 
Table 2.4: Dilutions of the protein standard for the protein standard plot 
2.3.3 Gel electrophoresis and transfer onto PVDF membrane  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to separate proteins according to their molecular weight. SDS 
polyacrylamide gels were set up using the Bio-Rad mini-Protean equipment using 
resolving and stacking gels (Table 2.5).  
 7.5% Resolving gel (mL) 3.6% Stacking gel (mL) 
30% Acrylamide  10 3.6 
1M Tris, pH 8.85 15 - 
0.375M Tris, pH 6.8 - 10 
10% SDS 0.4 0.3 
dH2O 14.6 16 
TEMED  0.1 0.1 
10% APS  0.1 0.1 
Table 2.5: Volumes of solutions required to produce 4 mini-gels  





Forty μg protein samples (containing the predetermined amount of protein lysate from 
BCA, lysis buffer and 5X loading buffer), were denatured at 95oC for 5 min, and 
loaded into the gels. Pre-stained protein marker (13953, Cell Signaling) was also 
loaded to aid identification of protein bands. Gels were electrophoresed through a 
stacking gel at 80 V for 15 min, and through the resolving gel at 150 V for about 90 
min with the aid of a running buffer (Table 2.6). 
Afterwards, proteins were transferred onto a methanol-activated Immobilon-P 
polyvinylidene fluoride (PVDF) Transfer Membrane (Immobilon). Transfer was 
performed at 100 V for 90 min in ice-cold transfer buffer (Table 2.6) at 4oC. 
 Running buffer Transfer buffer 
Tris base 6.06 g 6.06 g 
Glycine 28.84 g 28.84 g 
dH2O 2000 mL 2000 mL 
10% SDS 20 mL - 
Table 2.6: Contents of running buffer and transfer buffer enough for 4 mini-gels 
2.3.4 Probing and visualisation 
The transfer membrane was blocked for 1 h at room temperature with 1:1 PBS/ 
Odyssey blocking buffer (Odyssey) to prevent non-specific binding. Afterwards, the 
membrane was left overnight in primary antibody solution (Table 2.7) at 4oC. Then it 
was washed three times in PBS-0.1% Tween 20 to remove excess antibody. The 
membrane was subsequently incubated for 45 min, in the dark, and at room 
temperature with secondary fluorescent antibodies IRDye 680LT and IRDye 800CW. 
The membrane was then washed with PBS-0.1% Tween 20 three times then again with 






















(Tyr1221/1222) 2243 1:1000 
185 
p-Akt (Ser473) 9271 1:1000 60 
ERK 9102 1:1000 42, 44 
p-HER3 (Tyr1289) 2842 1:1000 185 
HER3 12708 1:1000 185 
HER4 4795 1:500 180 






HER2 2248 1:1000 185 
Akt 2920 1:1000 60 
p-ERK 
(Thr202/Tyr204) 9106 1:1000 
42, 44 
Beta-actin 8227 1:8000 42 
Table 2.7: The concentrations of the antibodies used were according to the manufacturer’s 
product usage information 
All primary antibodies were from Cell Signaling Technology, except for p-EGFR and beta-
actin which were from Abcam. The secondary antibodies are from Licor Odyssey. The primary 
antibodies were diluted in 1:1 PBS/ Odyssey blocking buffer solution, while the secondary 
antibodies were in 1:1 PBS/Odyssey Blocking Buffer containing 0.001% SDS. The antibodies 
selected for western blotting had all been previously validated for use within the laboratory 
and demonstrated banding at the expected molecular weight. Where MW means molecular 
weight. 
Proteins were visualized using the Odyssey Infrared Imaging System (Licor). Odyssey 
is equipped with two infrared channels for direct fluorescence detection at 680LT and 
800CW. The images were viewed and intensity of signal quantified using Image 
Studio Lite software (Licor). 
2.4 Effects of TKIs on signalling pathways 
Cells were seeded in 6-well plates at a density of 2x106 cells per well, in routine media. 
After 24 h, cells were washed twice with warm PBS, and media containing 0.1% FBS 
and TKIs was added to each well. The concentrations of TKIs were as follows: 0.08 
µM afatinib, 1 µM canertinib, 0.1 µM neratinib, 1.5 µM lapatinib and 1 µM sapitinib, 




cells were incubated with drugs for 24 h. Cells were treated with 1 ng/mL EGF or 1 
ng/mL HRG 30 min prior to lysate collection as described in section 2.3.1. 
2.4.1 Time course 
Cells were seeded in 6-well plates at a density of 2x106 cells, in routine media. After 
24 h cells were washed twice with warm PBS. Medium with 0.1% FBS and without 
any other added growth factor was aliquoted into the wells and incubated for 2 h. The 
media was then replaced with RPMI 1640 media containing 0.1 µM neratinib and/or 
1 ng/mL EGF and/or 1 ng/mL HRG. Controls were seeded on separate plates. Cells 
then underwent lysis as described in section 2.3.1 at 0, 5, 10, 15, 30 and 60 min time 
points. 
2.5 Immunostaining 
Immunostaining encompasses a set of techniques used to visualise the precise location 
of proteins or antigens within the cell. 
2.5.1 Immunohistochemistry of tissue microarrays 
The TMAs used in this study were obtained from mouse xenografts, which were 
treated with pertuzumab, trastuzumab or the combination over a period of time [232]. 
Tissues were formalin-fixed and paraffin-embedded, with triplicate cores cut and 
mounted onto TMA slides. Sections of the TMAs were cut and placed onto slides 
(Histology Laboratory, University of Edinburgh). 
The TMAs were initially deparaffinised by placing them twice in xylene for 5 min 
each time, then rehydrated by placing them for 2 min each time in decreasing 
concentrations of ethanol (99%, 99%, 80% and 50%) and afterwards, washed in 
running tap water. The sections were antigen retrieved by heating sodium citrate buffer 
at pH6 (18 mL 0.1 M citric acid, 82 mL 0.1 M sodium citrate, 900 µL dH2O) for 10 
min in a pressure cooker and then, placing the slides in the heated buffer and cooking 
for 5 min in a microwave. The slides were then allowed to cool. Afterwards, they were 




3% H2O2 onto each coverslip and incubation at room temperature for 10 min. After 
washing with PBST, 300 µL of blocking buffer (DAKO) was pipetted onto each 
coverslip and incubated for 10 min at room temperature in a humid environment. 
Following this incubation, 200 µL of primary antibody diluted in DAKO antibody 
dilution solution was pipetted onto the coverslips and incubated overnight at 4oC. 
Negative controls consisted of adding 200 µl DAKO antibody dilution solution 
without adding any primary antibodies to the coverslips. Coverslips were then washed 
twice with PBST and 6 drops of Envision labelled polymer (secondary antibody) were 
added and incubated for 30 min at room temperature. A 1:50 chromophore and 
substrate solution (DAKO) was prepared and 250 µL was added to each coverslip and 
left for 10 min. Coverslips were then assembled in a rack, counterstained in 
haematoxylin for 1 min and gently washed in water. Then, they were placed in Scott’s 
tap water substitute (STWS) for 30 s, washed gently with water and placed in DE-
HYD 50%, DE-HYD 80% solutions consecutively for 30 s. Later, they were placed 
twice in DE-HYD 100% solution for 2 min each time, and dehydrated in Xylene for 
10 min. DXP mountant was used to fix coverslips onto slides, and the slides were left 


















Table 2.8: Details of the primary antibodies used on the TMAs 
2.5.2 Analysis of TMA 
The TMAs were analysed using QuPath Software [347], a digital pathology image 
analysis programme, which recognises the areas of staining and outputs a percentage 
of positively stained cells from the total number of cells. To analyse, the area was 




“Positive %” was used as a measure of protein presence within the sample (Figure 
2.5b). This “positive %” score was multiplied by manually analysing the intensity of 
staining from 1 to 3, where 1 represented weak staining, 2 represented moderate 





Figure 2.5: QuPath software screenshots 




2.6 RNA interference 
2.6.1 Preparation of SiRNA 
Individual ON-TARGETplus SiRNA oligonucleotides targeting human EGFR were 
used (Table 2.9) as well as a non-targeting scrambled SiRNA (D-01810-01-20, 
Dharmacon) control. ON-TARGETplus SiRNA was chosen as off-target effects are 
reduced by up to 90%. SiRNA solutions were prepared at 20 µM stock solution, by 
adding 1x SiRNA buffer solution (dilution of 5x SiRNA buffer (Dharmacon) into 
RNase-free water (Dharmacon)). The solution was left for 30 min on an orbital shaker 
at room temperature. A NanoDrop Spectrophotometer ND1000 was used to identify 
the concentration of the reconstituted SiRNA solution. The individual oligonucleotides 
specified before were used as they produced the best knock-downs upon optimisation 
experiments. 
Target Target Sequence Catalogue No 
EGFR (individual) GUAACAAGCUCACGCAGUU J-003114-12 
EGFR (individual) CAGAGGAUGUUCAAUAACU J-003114-13 
Table 2.9: A list of SiRNA oligonucleotides used in this study 
The sequence they target and catalogue number are detailed. All SiRNAs used in this study 
were purchased from Dharmacon. 
2.6.2 SiRNA transfection 
Cells were seeded in 96 well plates or 6 well plates to assess the effects of EGFR 
knockdown on proliferation and migration respectively. RPMI 1640 media containing 
10% FBS and no P/S was used to seed the cells and these were seeded at densities that 
would achieve 60% confluence the following day. Cells were transfected 24 h after 
seeding, following manufacturer’s protocol, as illustrated in Figure 2.6a for 
proliferation assays, and Figure 2.6b for migration assays. Briefly, SiRNA solution or 
transfection reagent were incubated with serum-free and P/S free media for 5 min at 




at room temperature. The solutions were then pipetted into their respective wells. Each 





Figure 2.6: Figure illustrating the protocol for SiRNA transfection  




2.7 Generation of stable cell lines overexpressing HER 
2.7.1 Antibiotic optimisation 
To generate stable cell lines that would express the gene of interest, the minimum 
concentration of selection antibiotic, in this case GeneticinÒ (G418; 11811031, 
Thermo Fisher Scientific) that would kill untransfected cells was determined. Cells 
were seeded in 96 well plates at 2,000 cells per well, in P/S free media. After 24 h, the 
medium was changed to medium containing G418 at concentrations ranging from 100 
– 900 µg/mL. A control consisted of routine medium with P/S. The medium was 
changed every 3-4 days with the same concentrations of G418. The cells were 
observed daily under the microscope. After 2 weeks of culturing, the minimum 
concentration that killed all the cells in each cell line was established. 
2.7.2 DNA plasmid extraction 
HER2 WT (Addgene Plasmid #16257) and pcDNA3-HER3-DMVF-181-R (Addgene 
Plasmid #87621) were bought from Addgene as agar stabs. A 200 µL pipette was used 
to transfer a small amount of bacteria from the stabs and this was transferred to 3 mL 
Lysogeny broth (LB) with ampicillin in falcon tubes (Figure 2.7). These were left to 
incubate at 37°C on a shaker for 6 h. Later the bacteria growing in falcon tubes were 
transferred to 200 mL of LB without ampicillin in conical flasks and were allowed to 
grow at 37°C on a shaker overnight. 
The following day, the media suspension was centrifuged for 10 min at 6,000 g. The 
supernatant was discarded and the bacterial pellet was re-suspended in 10 mL of R1 
buffer (12162, QIAGEN MaxiPrep). Ten mL of R2 was added and mixed vigorously 
until the solution was blue and left to stand for 5 min. Then 10 mL of pre-chilled R3 
was added and mixed until the solution turned colourless. The solution was centrifuged 
at 4°C for 1 h at 14,000 g. In the meantime, QIAGEN tip 500 was equilibrated by 
adding 10 mL of Buffer QBT, and allowing it to flow through by gravity. The 
centrifuged supernatant was added to the QIAGEN-tip and allowed to enter the resin 




allowed to flow through by gravity.  Afterwards, the DNA was eluted using 15 mL 
Buffer QF into a fresh 50 mL tube. The DNA was then precipitated by adding and 
mixing 10.5mL isopropanol to the eluted DNA. The solution was centrifuged for 1 h 
at 4°C and 15,000 g. The DNA pellet was washed with 5mL 70% ethanol at room 
temperature and centrifuged for 10 min at 15,000 g. The supernatant was discarded 
and the DNA pellet was left to air dry for 1 h. The dry DNA was re-suspended in 500 
µL RNA-free water. 
The quality and quantity of the DNA was assessed using Nanodrop™ 
Spectrophotometer (Thermo Scientific). The spectrophotometer was firstly blanked, 
then 1 µL of the sample solution was measured for the concentration (ng/µL) and 
purity using the A260:A280 and A260:A230 ratios. An A260:A280 ratio of around 2.0 is 
considered pure. 
 
Figure 2.7: Pictorial depiction of the protocol followed to extract DNA from plasmids 
2.7.3 Transfection of plasmids into cells 
Over 1x105 cells were seeded in 500 µL of antibiotic-containing medium in 24 well 




solution to Lipofectamine 2000 transfection agent (116680, Thermo Fisher Scientific), 
as illustrated in Figure 2.8. This was done by separately diluting 1 µg of plasmid 
solution and 2 µL Lipofectamine 2000 transfection agent into 50 µL antibiotic free 
Opti-MEM medium. These two solutions were left to incubate at room temperature for 
5 min. They were then combined and left to further incubate at room temperature for 
20 min. The final transfection solution was gently added into the well. After 6 h, the 
medium of the cells was changed to fresh medium without antibiotics. After 24 h, the 
cells were trypsinised and transferred to 6 well plates, and G418 antibiotic was added 
to the cells at concentrations specified in Table 2.10, determined from antibiotic 
optimisation, detailed in section 2.7.1. The G418-containing medium was changed 
twice weekly. When cells reached 70% confluence, they were transferred to 24 well 
plates in very low cell dilutions. When colonies formed, they were transferred to 6 
wells plates, and finally to T-175 flasks for routine tissue culture. Cells were always 
supplemented with G418 to maintain selectivity.  
 
Figure 2.8: Figure illustrating the protocol for plasmid transfection in a 24 well plate 
The values represent the volumes required per well. 
Cell line PEA1 PEA2 PEO1 PEO4 PEO14 PEO23 
[G418] (µg/mL) 500 200 300 400 200 400 
Table 2.10: Concentrations of G418 used for each cell line 
The G418 antibiotic was purchased in powder form and dissolved in sterile distilled water 




2.8 Gene expression analysis 
2.8.1 Sample collection and RNA extraction 
Cells were seeded in 60 mm plates at a density of 2.5x106 and incubated for 24 h. Cells 
were incubated in decreased serum conditions (0.1% FBS) for 6 h, with or without 0.1 
µM neratinib. 10 ng/mL HRG was added to HRG control and HRG + 0.1 µM neratinib 
treatment for 90 min. Cells were then washed twice and trypsinised. The samples were 
centrifuged at 3,000 g for 5 min at 21°C. The cell pellets were re-suspended in 500 µL 
PBS, transferred to RNA-free microcentrifuge tubes and centrifuged for another 5 min 
at maximum speed. The supernatant was removed and cell pellet was stored at -80°C 
for RNA extraction.  
The QIAshredder (79654, Qiagen) and RNeasy Plus Mini kit (74134, Qiagen) were 
used for the extraction. The manufacturer’s protocol was followed, as illustrated in 
Figure 2.9. Briefly, the defrosted cell pellet was lysed and homogenised in 600 µL of 
RLT Buffer Plus. This was transferred to a QIAshredder assembled tube and 
centrifuged for 2 min at high speed. The flow-through was transferred to an assembled 
genomic DNA (gDNA) eliminator tube and centrifuged for 30 s. A volume of 600 µL 
of 70% ethanol was added to the flow-through, transferred and centrifuged for 15 s in 
two lots. The flow-through was discarded, and the column was washed with 700 µL 
Buffer RW1 (centrifuged for 15 s), and twice with Buffer RPE containing 80% ethanol 
(centrifuged for 15 s and then 2 min). The column was transferred to a new 2 mL 
collection tube and centrifuged for an additional 1 min to dry the spin column’s 
membrane. The column was then transferred to a 1.5 mL collection tube and 40 µL 






Figure 2.9: Pictorial depiction of the protocol for RNA extraction using QIAshredder and 
RNeasy Plus Mini kits (by Qiagen)  
Centrifugation was carried out at high speed. All buffers were supplemented with the kit. 
The quality and quantity of the RNA nucleic acid was assessed using a Nanodrop™ 
Spectrophotometer (Thermo Scientific). The spectrophotometer was firstly blanked, 
then 1 µL of the sample solution was measured for the concentration (ng/µL) and 
purity using the A260:A280 and A260:A230 ratios. An A260:280 ratio of around 2.0 is 
considered pure. 
2.8.2 mRNA sequencing and gene expression analysis 
Targeted whole transcriptome mRNA sequencing was performed using QuantSeq 
Lexogen (Edinburgh Clinical Research Facility, University of Edinburgh). The raw 
data obtained were Log2 transformed and quantile normalised. 
Differential gene expression analysis by Rank Product was conducted using TM4 MeV 
(multiple experiment viewer) software [348]. Rank product was used because it is a 
strong tool to analyse the differently expressed genes in small data sets, with reliable 
statistical power, and robustness against inconsistent changes, such as single outliers 
[349]. Gene enrichment of the differently expressed genes was performed online using 
DAVID3 and Gene Ontology (GO) was used to determine pathways and molecular 
function of the differently expressed genes [350]. Gene data were mean centred, 
                                               




average linked and clustered on Cluster 3.0 [351] and viewed in the form of heatmaps 
on Java Treeview software [352]. 
Publicly available gene expression datasets were mined to compare and contrast with 
the gene expression results obtained from this study. To do this, GEO datasets from 
the US National Library of Medicine National Institutes of Health website4 were 
accessed, and data sets containing gene expression of several cancer types treated with 
TKIs, mAbs or growth factors were downloaded.  
2.9 Statistical analysis 
Statistical tests were performed using GraphPad Prism version 8. Graphical data 
expressed as mean ± standard error were also generated using GraphPad Prism. The 
one-way or two-way ANOVA multiple comparison test was used to compare more 
than two groups, while the unpaired-sample t-test was used to compare data between 
two groups. Correlations between two variables were assessed using Spearman’s 
correlation. 
  
                                               








3  Effect of HER-targeted therapy 
on ovarian cancer cell 
functionality 
Initial investigations sought to assess the effectiveness of HER-targeted inhibitors on 
HGSOC cellular functionality. The HER-targeted inhibitors examined were five TKIs 
and two mAbs, which allowed comparisons between inhibitors with different modes 
of actions. The TKIs investigated were pan-HER inhibitors, which, unlike the first 
generation TKIs gefitinib and erlotinib, do not require specific HER family mutations 
to elicit their effects [259, 353]. The TKIs studied were afatinib, canertinib, lapatinib, 
neratinib and sapitinib, which differentially target HER family members and offer 
varied pharmacokinetic profiles [147]. Trastuzumab and pertuzumab were the mAbs 
investigated in this study, which are both currently used for the treatment of breast 
cancer [354]. A panel of HGSOC platinum-resistant and platinum-sensitive pairs of 
cell lines was used to investigate the effects of these inhibitors on cellular proliferation, 
adhesion, migration and invasion. This is a novel approach to the functional 
investigations of these TKIs, as to our knowledge, no other study to date has 
investigated their use in platinum-sensitive and resistant pairs of ovarian cancer cell 
lines. 
HER family protein expression levels across the cell line panel were first investigated 
in order to assess whether the potency of the inhibitors was related to HER expression 
levels. The anti-proliferative effects of the TKI and mAb panel of drugs were studied 
to assess the sensitivity of the cell lines to these agents, and in order to potentially link 




In the clinical scenario, most patients will receive combination therapy as it is unlikely 
that a patient would fully benefit from monotherapy only. In ovarian cancer for 
instance, carboplatin and paclitaxel are used in combination. To date, there are no 
approved drug combinations involving HER-targeted TKIs in HGSOC. The intentions 
of these experiments was to assess whether combining cytotoxic agents with TKIs 
would lead to lower concentrations being required for a sufficient anti-proliferative 
effect and explore novel combinations that could be considered for use in HGSOC. 
Cancer is characterised by its ability to invade, metastasise and adhere to organs distant 
from the primary tumour. Downstream components of the HER pathway have been 
implicated with increased progression potential in ovarian cancer  [355]. Hence, the 
objective was to evaluate the role of TKIs and mAbs for their ability to inhibit the 
progression of cancer, and to assess which HGSOC phenotypes were responsive to 
these agents.  
3.1 HER expression in the panel of cell lines 
The panel of six cell lines investigated in this study were initially characterised for 
their expression of the four HER receptors, as these receptors are the targets for the 
drugs under investigation. The cells were grown in 10% FBS media, without other 
additives, and lysates were collected once they reached 70% confluence and proteins 
detected by western blot. 
EGFR was expressed by all cell lines to different extents (Figure 3.1). The PEO1 cell 
line expressed the highest level of EGFR, while PEO14 had the least EGFR 
expression. HER2 was expressed in five of the six cell lines, with PEA2 expressing 
the greatest level, while HER2 expression in PEA1 was not detectable. The platinum-
resistant cell lines expressed over double the amount of HER2 than their respective 
platinum-sensitive cell lines. HER3 was expressed in all cell lines, with highest 
expression in PEO1, whereas there was minimal expression in PEA1. HER4 was only 















Figure 3.1: HER family expression across three pairs of HGSOC cell lines  
(a) Protein expression of the 4 HER receptors was detected by western blot. The intensity of 
the band was measured using Image Studio Lite software, and each HER intensity band was 
normalised to the b-actin control. The relative intensities for each cell line are presented in 
bar graphs (b) EGFR, (c) HER2, (d) HER3 and (e) HER4. This experiment was repeated once 
and the loading control is a representative to the other membranes. 
3.2 Effects of the agents on cell growth 
The effect of the drugs on proliferation was investigated in all six cell lines; PEA1, 
PEA2, PEO1, PEO4, PEO14 and PEO23 using the SRB assay, following a 120 h 
incubation with the cells. A range of concentrations was employed, based on initial 





























































































































3.2.1 Cell proliferation of the cell line panel 
This experiment was undertaken to assess the growth differences of the cell line panel 
over a 120 h period. The cells were seeded to achieve 30% confluence after 24 h. They 
were supplemented with routine media, containing 10% FBS and P/S, and fixed at 24 
h intervals. To quantify the cells, the SRB proliferation assay was used. The OD value 
at 0 h of the respective cell line was subtracted at every time point to obtain the increase 
in OD over time and results are presented as percentage growth increase. Figure 3.2 
shows that the PEA1-PEA2 pair have the highest proliferation rate amongst the cell 
lines, whilst PEO14-PEO23 pair have the lowest proliferation rate. The platinum-
resistant cell line PEO4 grew more rapidly than its platinum-sensitive counterpart 
PEO1, while PEO14 and PEO23 have similar proliferation rates.  
 
Figure 3.2: Comparison of the growth of the three pairs of HGSOC cell lines  
The graph represents the percentage proliferation rate over 120 h for the 6 cell lines. Each 
point is based on an average of 6 technical replicates and 3 biological replicates ± SEM. 
3.2.2 HER-targeted TKI effects on growth 
The anti-proliferative effects of the TKI panel were assessed and compared in the three 
pairs of HGSOC cell lines. All TKIs inhibited the growth of all cell lines under 
investigation in a concentration-dependent manner, as shown in Figure 3.3. The PEA1-
PEA2 cell line pair was the most sensitive pair overall to all TKIs, the PE01-PE04 pair 
had similar sensitivity, while the least sensitive pair was the PEO14-PEO23 cell line 
pair. The PE014 cell line, in particular, was markedly more resistant to the inhibitors, 
than the other cell lines.  Neratinib was the most potent inhibitor overall, with IC50 
values less than 1.05 µM across all cell lines, whereas lapatinib had IC50 values ranging 






























(a) afatinib concentration-response curves, (b) afatinib IC50 values, (c) canertinib 
concentration-response curves, (d) canertinib IC50 values, (e) lapatinib concentration-
response curves, (f) lapatinib IC50 values, (g) neratinib concentration-response curves, (h) 
neratinib IC50 values, (i) sapitinib concentration-response curves, and (j) sapitinib IC50 values. 
The TKIs at concentrations ranging between 0.003-6 µM were incubated for 120 h. Data are 
represented as average of 6 technical replicates and least 5 biological replicates ± SEM. The 
day 0 value is subtracted from the timed value and normalised to the vehicle control. 
3.2.3 Pertuzumab and trastuzumab effects on cell line growth 
The effects of the HER2-targeted mAbs were investigated after a 120 h incubation 
with all cell lines to compare with the effects of HER-targeted TKIs. Both mAbs had 
only modest effects on growth inhibition. The combination treatment of both mAbs 







Figure 3.4: Effect of the mAbs on cellular growth of the cell line panel  
Bar graphs shows treatment after 120 h with (a) 50 µg/mL pertuzumab, (b) 50 µg/mL 
trastuzumab and (c) 25 µg/mL pertuzumab + 25 µg/mL trastuzumab. Data are represented as 
average of 6 technical replicates and 3 biological replicates ± SEM. The day 0 value is 
subtracted from the timed value and normalised to the vehicle control. Statistical analysis was 



























































































3.2.4 Cytotoxic agent effects on cell growth 
Cisplatin has been the standard treatment in patients presenting with ovarian cancer in 
the past before being superseded by carboplatin. Response to the drug served as an 
indicator of prognosis, whereby patients who did not respond initially to this agent 
generally had an overall poor prognosis [356]. The cell lines were derived from 
patients who were exposed to cisplatin therapy and had become resistant to this 
platinum-agent. Hence, an SRB proliferation assay was conducted to confirm the 
cisplatin sensitivity and resistance in the cell lines being investigated. The platinum-
sensitive counterparts were, as expected, more sensitive to this agent than their 
resistant counterparts, with 2.1-fold, 3.5-fold and 2.5-fold difference in IC50 
concentrations between the PEA1-PEA2, PEO1-PEO4 and PEO14-PEO23 cell line 
pairs respectively (Figure 3.5 a, b).  
As carboplatin would be the current treatment of choice for patients with ovarian 
cancer, its effects were investigated to compare with those of cisplatin. The cisplatin-
sensitive cell lines were more sensitive than the cisplatin-resistant cell lines to 
carboplatin, but not to the same extent as for cisplatin treatment. Specifically, PEA1-
PEA2 pair had a 1.2-fold difference, PEO1-PEO4 cell lines had a 3.4-fold difference, 
while the PEO14-PEO23 pair had a 1.4-fold change (Figure 3.5 c, d). 
The taxane, paclitaxel, was also investigated for its cytotoxic effects on the three cell 
line pairs as it is often combined with platinum-based agents for the treatment of 
ovarian cancer. In contrast to results with the carboplatin and cisplatin- treated PEO1-
PEO4 cell line pair, paclitaxel caused only a 0.9-fold change between cisplatin-
sensitive and resistance cell lines, whereas with platinum treatment, this pair had a 
more than 3.5-fold variation (Figure 3.5 e, f). The PEA1-PEA2 cell line pair had the 
greatest fold change, with a 2.3-fold difference between the platinum-sensitive and 


















Figure 3.5: Effect of cytotoxic agents on cellular growth of the cell line panel  
(a) cisplatin concentration-response curves, (b) cisplatin IC50 values, (c) carboplatin 
concentration-response curves, (d) carboplatin IC50 values, (e) paclitaxel concentration-
response curves, and (f) paclitaxel IC50 values. The cytotoxic agents were incubated for 120 h 
and concentrations ranged between 0.05-12 µM for cisplatin, 0.1-24 µM for carboplatin and 
0.01-100 nM for paclitaxel. Data are represented as average of 6 technical replicates and at 
least 5 biological replicates ± SEM. The day 0 value is subtracted from the timed value and 





3.3 Effects of combinatorial agents on cell growth 
The response of a series of two-drug combinations on the growth of ovarian cancer 
cell lines was next investigated, using the PEA1 and PEA2 cell line pair. The cytotoxic 
agents carboplatin, cisplatin and paclitaxel were used at a constant concentration based 
on their IC20 and IC30 in each cell line. Trastuzumab and pertuzumab were used at 25 
µg/mL or 50 µg/mL. Each cytotoxic agent and mAb was combined with lapatinib or 
neratinib. These TKIs were chosen as lapatinib is more established and is a widely 
used TKI in cancer treatment, whereas neratinib has been recently approved in breast 
cancer treatment and shows good clinical potential. Additionally, lapatinib is a 
reversible TKI, whilst neratinib is the most potent TKI and has irreversible 
characteristics. The concentrations of these agents tested were calculated based on 
eight times their IC50, followed by up to eight doubling dilutions. The two agents were 
either administered simultaneously or the TKIs were administered for 2 h before the 
cytotoxic agents or mAbs were added. The cell lines were pre-exposed for a short 
period because the TKIs have been shown to work within a short period in these cell 
lines. One rationale behind pre-exposing the cells to the TKIs was because previous 
studies suggest that the HER pathway is involved with the DNA-repair process [343]. 
In fact, previous studies whereby ovarian cancer cell lines were treated with a MAPK 
inhibitor 30 min before the addition of cisplatin exhibited better anti-proliferative 
effects [357]. The CI method would indicate whether the addition of another drug 
would sensitise the cell lines to the cytotoxic agents and mAbs. The CI was calculated 
using CompuSyn Software as explained in section 2.2.1.1.  
Cisplatin or carboplatin (± paclitaxel) are first line treatment for ovarian cancer 
patients. Although HGSOC patients are normally sensitive to this combination, some 
patients do not achieve the full benefit from monotherapy while others become 
resistant to this platinum-based agent. The combination of the cytotoxic agents and the 
TKIs was sought to evaluate whether the TKIs would be able to sensitize the cell lines. 
Some combinations were previously assessed in vivo using lapatinib, but not neratinib, 
and outcomes were promising [358]. HER-targeted mAbs are not currently used in 




have been carried out. However, breast cancer patients who were administered 
trastuzumab in combination with lapatinib have achieved favourable outcomes [359]. 
3.3.1 TKIs + cisplatin 
The combination of multiple concentrations of lapatinib with cisplatin in PEA1 and 
PEA2 cell lines mostly produced additive effects, as most CI values ranged from 0.9-
1.3 (Figure 3.6 a, b). On the other hand, pre-treatment with neratinib produced 
synergistic effects in PEA1 and PEA2 cell lines at selected concentrations (Figure 3.6 
c-e), especially with the higher cisplatin concentrations. Simultaneous administration 










Figure 3.6: Combination index for TKIs + cisplatin  
(a) CI values for lapatinib + cisplatin in PEA1, (b) CI values for lapatinib + cisplatin in PEA2, 
(c) CI values for neratinib + cisplatin in PEA1 (d) CI values for neratinib + cisplatin in PEA2.  
The CI values were calculated using CompuSyn software. The data used were a mean of 3 
technical replicates and 3 biological replicates. The abbreviations “Sim.” and “Pre.” refer 
to simultaneous treatment and pre-treatment with TKIs respectively. (e) bar graph of 
inhibitory effect in PEA1 with neratinib 0.051 µM + cisplatin 2.43 µM combination, (f) bar 
graph of inhibitory effect in PEA2 with neratinib 0.0093 µM + cisplatin 5.6 µM combination. 
The bar graphs represent mean ± SEM, and statistical analysis was conducted using two-way 














































3.3.2 TKIs + carboplatin 
The combination of lapatinib and carboplatin was next compared and this typically 
resulted in additive or antagonistic effects in PEA1 and PEA2 cell lines, especially 
when pre-treating cells with lapatinib (Figure 3.7 a, b). Combining neratinib and 
carboplatin produced predominantly additive effects in PEA1 and PEA2 cell lines 
(Figure 3.7 c, d). 
  
Figure 3.7: Combination index for TKIs + carboplatin  
(a) CI values for lapatinib + carboplatin in PEA1, (b) CI values for lapatinib + carboplatin 
in PEA2, (c) CI values for neratinib + carboplatin in PEA1 (d) CI values for neratinib + 
carboplatin in PEA2.  The CI values were calculated using CompuSyn software. The data used 
were a mean of 3 technical replicates and 3 biological replicates. The abbreviations “Sim.” 




3.3.3 TKIs + paclitaxel 
The combination of lapatinib with paclitaxel produced mainly synergistic effects in 
PEA1 cells (Figure 3.8 a). On the other hand, lapatinib with paclitaxel had additive 
effects in PEA2 cells (Figure 3.8 b). When neratinib was combined with paclitaxel, it 
mainly resulted in additive effects in PEA1 cells. In the PEA2 cell line, pre-treatment 
with neratinib and the addition of low concentration paclitaxel produced synergistic 
effects, while the higher concentration of paclitaxel resulted in antagonistic effects 
(Figure 3.8 c, d). 
  
Figure 3.8: Combination index for TKIs + paclitaxel  
(a) CI values for lapatinib + paclitaxel in PEA1, (b) CI values for lapatinib + paclitaxel in 
PEA2, (c) CI values for neratinib + paclitaxel in PEA1 (d) CI values for neratinib + paclitaxel 
in PEA2.  The CI values were calculated using CompuSyn software. The data used were a 
mean of 3 technical replicates and 3 biological replicates. The abbreviations “Sim.” and 




3.3.4 TKIs + pertuzumab 
When pre-treatment of lapatinib or neratinib was combined with pertuzumab, it 
generally resulted in synergistic effects in the PEA1 cell line. The simultaneous 
administration of the TKI and mAb had an additive effect (Figure 3.9 a, c). Similarly, 
the simultaneous administration of lapatinib or neratinib and pertuzumab in PEA2 cell 
line produced mainly additive effects. However, the pre-treatment of neratinib or 
lapatinib with pertuzumab had antagonistic outcomes in PEA2 cell line (Figure 3.9 b, 
d). 
  
Figure 3.9: Combination index for TKIs + pertuzumab  
(a) CI values for lapatinib + pertuzumab in PEA1, (b) CI values for lapatinib + pertuzumab 
in PEA2, (c) CI values for neratinib + pertuzumab in PEA1 (d) CI values for neratinib + 
pertuzumab in PEA2.  The CI values were calculated using CompuSyn software. The data used 
were a mean of 3 technical replicates and 3 biological replicates. The abbreviations “Sim.” 
and “Pre.” refer to simultaneous treatment and pre-treatment with TKIs respectively, while 




3.3.5 TKIs + trastuzumab 
The combination of trastuzumab with lapatinib or neratinib mainly produced additive 
or antagonistic effects. In PEA2 cells, the combination generally resulted in 
antagonistic results, especially for pre-treatment with TKIs. On the other hand, 
simultaneous treatment of the TKIs and trastuzumab produced additive effects in 
PEA1 (Figure 3.10). 
 
 
Figure 3.10: Combination index for TKIs + trastuzumab  
(a) CI values for lapatinib + trastuzumab in PEA1, (b) CI values for lapatinib + trastuzumab 
in PEA2, (c) CI values for neratinib + trastuzumab in PEA1 (d) CI values for neratinib + 
trastuzumab in PEA2.  The CI values were calculated using CompuSyn software. The data 
used were a mean of 3 technical replicates and 3 biological replicates. The abbreviations 
“Sim.” and “Pre.” refer to simultaneous treatment and pre-treatment with TKIs respectively, 




3.4 Effects on cellular migration 
To assess the migratory ability of the cell lines under investigation, the scratch assay 
was undertaken, whereby a scratch was made across a cellular monolayer and the 
percentage migration into the created gap at specific time points was measured. The 
medium in the cells was changed to 0.1% FBS containing medium to limit the effects 
of proliferation. The cell lines under investigation had differing migratory rates as 
indicated in Figure 3.11. The PEA1-PEA2 pair of cell lines were the most migratory, 
migrating over 35% in 24 h. On the other hand, the least migratory pair was the PEO1-
PEO4 pair, which only migrated about 14% in 24 h. 
 
Figure 3.11: Migration of the panel of cell lines over 24 h  
The graph shows the migration properties of all cell lines in a 24 h period, with no added 
inhibitors or growth factors. Data are represented as average of 6 technical replicates and at 
least 4 biological replicates ± SEM. The data are normalised to 0 h. 
3.4.1 Effect of TKIs on migration 
Migration may be driven by downstream pathways that are shared with HER pathways 
[360].  The abilities of the five TKIs to inhibit migration in the panel of cell lines was 
next evaluated. The TKIs were added to the wells at concentrations which are 
achievable in patient sera at the maximum tolerated dose of treatment [307, 310, 312, 
314, 361], thus in accordance with the concentrations potentially available within in 
vivo tumours. 
The TKIs reduced migration to different extents, as can be seen in Figure 3.12. In the 
PEA1-PEA2 pair of cell lines, the most effective TKI was sapitinib, which inhibited 
migration by 56% and 68% respectively (Table 3.1). On the other hand, lapatinib was 
























the least effective inhibitor especially in the PEA1 cell line, where it only inhibited 
migration by 18%. In general, the PEA2 cell line was more sensitive to the anti-
migratory properties of the TKIs. 
For the PEO1 cell line, neratinib was the most effective TKI, while sapitinib produced 
better inhibitory outcomes in the PEO4 cell line.  The least effective TKI effects were 
with afatinib in the PEO1 and neratinib in the PEO4 cell lines. Similar to the PEA1-
PEA2 cell line pair, the platinum-resistant counterpart was more sensitive to the TKI 
anti-migratory effects. 
Comparable to the PEA1-PEA2 cell line pair, sapitinib was the most effective inhibitor 
in the PEO14-PEO23 cell line pair inhibiting migration by 70% and 28% respectively. 





























Figure 3.12: TKIs inhibit migration of all cell lines 
The graphs show the migration properties of all cell lines in a 24 h period, when TKIs were 
added. (a) PEA1 cell line, (b) PEA2 cell line, (c) PEO1 cell line, (d) PEO4 cell line, (e) PEO14 
cell line and (f) PEO23 cell line. Data are represented as average of 6 technical replicates 
and at least 4 biological replicates ± SEM. The data are normalised to 0 h. Statistical analysis 
was performed by two-way ANOVA. 



















































































 PEA1 PEA2 PEO1 PEO4 PEO14 PEO23 
Afatinib (0.08 µM) 34% 52% -1% 45% 33% 24% 
Canertinib (1 µM) 38% 61% 33% 45% 65% 17% 
Lapatinib (1.5 µM) 18% 56% 35% 48% 33% 20% 
Neratinib (0.1 µM) 27% 62% 48% 32% 47% 21% 
Sapitinib (1 µM) 56% 68% 40% 53% 70% 28% 
Table 3.1: Percentage relative inhibition on migration compared to control at 24 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control, b= % migrated by TKI, as 
explained in section 2.2.2. Migration inhibition greater than 35% (median migration 
inhibition) is shown in green, whilst migration inhibition less than 35% is shown in red.  
3.4.2 Effect of mAbs on migration 
The PEA1-PEA2 pair of cell lines was chosen to assess the inhibitory role of HER2-
targeted mAbs on ovarian cell line migration, as these cell lines were the most 
migratory of the panel investigated. The platinum-resistant cell line, PEA2, was 
markedly more sensitive to the mAb effect on migration than its PEA1 partner, which 
expressed less HER2 than PEA2 cell line. The combination of pertuzumab and 
trastuzumab (25+25 µg/mL) had the greatest effect on migration in both cell lines 
compared to monotherapy, especially in PEA2 cells with almost 58% migration 
inhibition, as seen in Figure 3.13 and presented in Table 3.2. As monotherapy, 






Figure 3.13: mAbs inhibit PEA2 cell line migration 
The graphs show the migration properties of PEA1-PEA2 cell lines in a 24 h period, when 
mAbs were added. (a) PEA1 cell line, (b) PEA2 cell line. Data are represented as average of 
6 technical replicates and 3 biological replicates ± SEM. The data are normalised to 0 h. 





























 PEA1 PEA2 
Pertuzumab (50 µg/mL) 5% 26% 
Trastuzumab (50 µg/mL) 6% 47% 
Combination (25+25 µg/mL) 9% 58% 
Table 3.2: Percentage relative inhibition on migration compared to control at 24 h  
Calculation: ((a-b)/a)*100; where a=% migrated by control, b= % migrated by mAb. 
3.5 Effects on cellular adhesion 
The adherence properties of the cell lines to different ECMs was next investigated 
(Figure 3.14). The 96-well plates were coated with either collagen, fibronectin or 
laminin and the cells were seeded into the coated or non-coated plates and left to 
incubate for 1 h before they were fixed. It is evident that the cells were able to adhere 
more to collagen, and least to laminin. The platinum-resistant cell lines adhered more 
to collagen and fibronectin than their corresponding platinum-sensitive cell line. 
 
Figure 3.14: Cell line adherence to ECM components 
The graph indicates the extent of cell line adherence to each ECM on the 6 cell lines after 1 
h. The values show the percentage of cells that adhered to each of the ECM-coated wells 
normalised to the cells adhered to the non-coated wells, seeded in normal media. Data are 
presented as mean of 3 technical replicates and 5 biological replicates ± SEM. Statistical 
analysis was performed by unpaired t-test between each cell line pair within specific ECMs, 
and by one-way ANOVA to analyse the statistical significance of the different ECMs within 
each cell line (where *P≤0.05, **P≤0.01, *** P≤0.001, and ****P<0.0001). 
Neratinib was chosen to test the effect of TKIs on adhesion, as it had good inhibitory 
effects on growth and migration at or less than its therapeutic concentration. 




adhesion in all fibronectin-exposed cell lines, but not as well in the PEA1 and PEA2 
cell lines (Figure 3.15). However, it did not inhibit the adhesion of collagen- and 
laminin- exposed PEO14 cells. The inhibition was greater in the PEO1-PEO4 cell line 
pair. In the PEA1-PEA2 and PEO14-PEO23 cell line pairs, neratinib had a more potent 
effect on the platinum-resistant cell lines.  
 
Figure 3.15: Neratinib reduces adhesion after 1 h 
The graph represents the effect of neratinib on adhesion of cells to each ECM after 1 h. The 
values shown were calculated as follows: ((a-b)/(c-d))*100; where a= ECM control, b= 
uncoated control, c= ECM + neratinib and d= neratinib control. Data are presented as mean 
of 3 technical replicates and 5 biological replicates ± SEM. Statistical analysis was performed 
by unpaired t-test between each cell line pair within specific ECMs, and by one-way ANOVA 
to analyse the statistical significance of the different ECMs within each cell line (where 
**P≤0.01). 
3.6 Effects on invasion 
Invasion is one of the defining hallmarks of cancer [5]. To investigate this, cell lines 
were grown in spinner flasks to form 3D spheroids. All cell lines, except PEA1, formed 
spheroids in sufficient sizes that could be used for the invasion assay. Spheroids were 
implanted into a collagen matrix and invasion was monitored by microscopy over a 96 
h period. Percentage invasion was calculated by normalising the area at each time point 
and comparing this with the area at 0 h.  
The relative invasion capacity of all cell lines is presented in Figure 3.16. The PEO1-
PEO4 pair of cell lines invaded more than the other cell lines, with over 6-fold increase 




























Figure 3.16: Comparison of the invasion properties across the three HGSOC cell lines  
The graph shows the invasion properties of all cell lines over a 96 h period, in collagen mix 
with no added inhibitors or growth factors. Data are represented as average of 4 technical 
replicates and at least 2 biological replicates ± SEM. The data are normalised to 0 h. 
3.6.1 Neratinib effects on invasion 
Spheroids were also treated with neratinib at a concentration of 0.1 µM to investigate 
its anti-invasive action. Neratinib was again chosen as the representative TKI due to 
the novelty of assessing its use in in vitro invasion assays. 
Neratinib reduced invasion in ovarian cancer cell lines, as illustrated in Figure 3.17. It 






















Figure 3.17: Neratinib inhibits invasion of the cell lines 
The graphs represent the effects of neratinib on invasion in (a) PEA2, (b) PEO1, (c) PEO4, 
(d) PEO14 and (e) PEO23. Each point is normalised to 0 h and data represent mean of 4 
technical replicate and at least 2 biological replicates. Statistical analyses were performed 
using two-way ANOVA (where **P≤0.01, and ****P<0.0001). 
 
PEA2 PEO1 PEO4 PEO14 PEO23 
Neratinib 45% 65% 56% 71% 71% 
Table 3.3: Percentage inhibition on invasion relative to control at 96 h 
Calculation: ((a-b)/a)*100; where a=% invaded by control, b= % invaded by neratinib, as 
explained in section 2.2.4. 
























































































3.7.1 TKIs inhibit growth in HGSOC cell lines  
One of the main aims of this study was to investigate the effect of different HER-
targeted therapies on the growth of platinum-resistant and platinum-sensitive HGSOC 
cell line pairs. To do this, HER-targeted TKIs and mAbs were compared. The cell lines 
under investigation had different levels of expressions of the HER receptors, which 
allowed determination of whether a particular profile of HER expression conferred 
more sensitivity than another. Generally, higher expression of HER3 was associated 
with a lower proliferation rate. 
All the TKIs investigated in this study caused a reduction in cellular proliferation, in a 
concentration-dependent manner. The most potent TKI amongst the ones studied was 
neratinib, as tabulated in Table 3.4, which targets EGFR, HER2 and HER4 receptors 
[298]. The IC50 values in PEA2 were all under the serum concentrations achieved in 
vivo after maximum tolerated dose administration [307, 312, 314, 361], except for 
afatinib, which was considerably higher, taking into account its serum concentration 
in vivo is about 0.1 µM [310]. The most sensitive cell line pair was the PEA1-PEA2 
cell line pair, while the least sensitive pair was the PEO14-PEO23 cell line pair. 
Interestingly, the PEA1-PEA2 cell lines had the greatest proliferation rates, while 
PEO14-PEO23 had the slowest. The PE014 cell line was most resistant to the TKI 
inhibitors and also to Pertuzumab and the antibody combination. This may be 
associated with the lower levels of EGFR and HER2 expression found in this cell line 
relative to the other cell lines leading to a reduced level of dependency on these 
receptors. 
The reversible EGFR- and HER2-targeting TKI lapatinib [251] was the least potent 
agent. Lapatinib had the highest IC50 values amongst all the TKIs in all the cell lines. 
The IC50 values are higher than the therapeutic concentration usually achieved by 
lapatinib in vivo [361], except in PEA2. Thus, the cell lines were generally resistant to 
lapatinib. The PEO14 and PEO23 cell lines were both resistant to sapitinib therapy as 




platinum-resistant cell lines PEA2 and PEO23 were more sensitive to the TKI therapy 
than their platinum-sensitive counterpart. With regard to the other platinum-resistant 
cell line, PEO4, this only responded better than PEO1 to sapitinib and lapatinib 
treatment. Although canertinib usually acts more effectively in the presence of low 
HERs [285], it was not the case in these cell lines, as the most resistant cell line was 
PEO14 cell line, which did not express high levels of HERs. 











 PEA2 Neratinib Sapitinib Canertinib Afatinib Lapatinib 
PEA1 Neratinib Sapitinib Afatinib Canertinib Lapatinib 
PEO1 Neratinib Sapitinib Afatinib Canertinib Lapatinib 
PEO4 Neratinib Sapitinib Afatinib Canertinib Lapatinib 
PEO23 Neratinib Afatinib Canertinib Sapitinib Lapatinib 
PEO14 Neratinib Afatinib Canertinib Sapitinib Lapatinib 
Table 3.4: Compilation of IC50 values ordered in accordance to potency of TKI and 
sensitivity of cell line to TKIs 
 
There were no statistically significant correlations between the level of HER 
expression and the potency of each TKI, which was also noted in other studies [272, 
362]. However, there is an increased tendency that higher levels of the HERs, increase 
TKI potency. With regards to HER3, the relationship mostly existed with sapitinib, 
which relates to the fact that sapitinib targets HER3. 
The two mAbs investigated in this project were not capable of reducing growth under 
70% of the control value, which could be because the ovarian cancer cell lines used in 
this study did not overexpress HER2. Pertuzumab had better inhibitory effects than the 
combination of pertuzumab and trastuzumab. The concentration used (50 µg/mL) for 
both mAbs was based on the clinical target concentration to saturate the HER2 receptor 
(20 µg/mL [363]), and the usual serum concentration achieved by these mAbs 
(pertuzumab ~70 µg/mL [227, 364], trastuzumab 35-148 µg/mL [365]). Increased 
EGFR expression was associated with reduced potency of trastuzumab. This is similar 
to previous breast cancer studies, which concluded that overexpression of EGFR in 




significant correlation between the HER2 expression and the cell line response to 
pertuzumab (P<0.05; Spearman rank test), as seen in Figure 3.18.  
 
Figure 3.18: Correlation between HER2 protein expression and anti-proliferative response 
to mAbs 
The results were correlated using Spearman correlation method and the Spearman r values 
are shown in the graph (where *P≤0.05).  
Three cytotoxic agents (cisplatin, carboplatin and paclitaxel) were also investigated 
for their effects on proliferation. All three cytotoxic agents were able to decrease the 
growth of the cell lines, however, the platinum-sensitive cell lines were more sensitive 
to all three cytotoxic agents. The cisplatin-sensitive cell lines were still sensitive to the 
agent as their IC50 were normally below the usual cisplatin average serum 
concentration of about 3.3 µM [367, 368]. On the other hand, all the cell lines had 
IC50s below the usual plasma concentrations of paclitaxel (>5 µM [369, 370]). This 
suggests that there is no cross-resistance between cisplatin and paclitaxel, which was 
also noticed in vivo [337, 371]. There was no association between the sensitivity to the 
cytotoxic agents and sensitivity to TKIs or HER expression. However, there seems to 
be an inverse correlation between the sensitivity to trastuzumab and sensitivity to 
cisplatin. Previous studies in breast cancer also failed to correlate HER2 expression 
with response to the cytotoxic agents [372-375], while others attribute high expression 




3.7.2 Combining neratinib with cisplatin and pertuzumab potentiates 
cytotoxicity 
For optimal patient treatment, drugs are often combined as combination treatment can 
offer several advantages. These advantages include use of lower drug doses as a lower 
drug dose is frequently still effective which leads to lesser adverse effects and better 
tolerability. The targeting of multiple cell signalling pathways also reduces the chances 
of developing drug resistance and can increase sensitivity. However, not all drug 
combinations are effective, as some drugs might interact with each other and cause 
antagonistic effects, thus reducing their actual anti-proliferative effect. In this section, 
the drug combinations that produced additive effects, or better still, synergistic effects 
are discussed. 
Previous studies show that EGFR activation due to cisplatin treatment, reduces the 
efficacy of cisplatin [184, 185]. Additionally, matuzumab, an anti-EGFR mAb 
inhibited cisplatin-induced EGFR activation, and resulted in reduced tumour growth 
[377]. Hence, this study looked at the effects of combining cisplatin with an EGFR 
inhibitor. The combination of cisplatin and lapatinib tested resulted in additive or 
antagonistic effects in the two ovarian cancer cell lines in this study. This contradicts 
other reports demonstrating synergistic results obtained from the cisplatin and 
lapatinib combination in gastric cancer cell lines [378]. However, the pre-treatment of 
neratinib with cisplatin produced synergistic effects in the ovarian cancer cell lines. 
One possible explanation as to why prior TKI administration had synergistic effects 
but not with simultaneous administration could be that HER receptors may have a role 
in DNA-repair processes [379]. Thus when neratinib was pre-administered, it 
produced HER receptor blockade, which might enhance cisplatin-stimulated 
cytotoxicity [342].  
When the TKIs were combined with carboplatin, they did not show any clear 
favourable results. This was also seen before in a platinum-sensitive recurrent ovarian 
cancer clinical trial, whereby lapatinib plus carboplatin showed no encouraging 
effects, and patients suffered from increased toxicity [288]. However, another ovarian 




stage III or IV relapsed patients, had positive results and toxicity was not a limitation 
[358, 380]. The estimated OS of relapsed ovarian cancer patients receiving the 
combination treatment was 16 months in the platinum-sensitive patients, as opposed 
to 39 months in the platinum-resistant patients [380]. 
The co-administration of paclitaxel and lapatinib in PEA1 cells gave very promising 
synergistic results, as opposed to the additive effects obtained when lapatinib was 
administered in PEA2 cells. This might suggest that paclitaxel sensitizes cells to 
lapatinib treatment, as was also noticed in a clinical trial whereby lapatinib was 
combined with paclitaxel and carboplatin [380]. Previous studies in HER2-positive 
gastric cancer revealed that this combination gave better efficacy in IHC3+ patients, 
with median OS of 11 months [381]. Combining neratinib with paclitaxel resulted 
predominantly in additive effects in the PEA1 and PEA2 ovarian cancer cell lines. Pre-
clinical and clinical trial breast cancer studies show that co-administration of neratinib 
and paclitaxel have a favourable clinical efficacy, despite the side effects [304, 382, 
383]. 
Lapatinib and neratinib were able to sensitize the ovarian cancer cell lines to 
pertuzumab. PEA1 cells were not very sensitive to lapatinib treatment, however the 
addition of pertuzumab increased the anti-proliferative effect of lapatinib, supported 
by results gathered from lapatinib-resistant breast cancer cell lines [384]. Neratinib has 
previously been investigated in combination with trastuzumab in breast cancer, and it 
produced better inhibitory effects than either agent alone, even in trastuzumab-
resistant tumours [299]. Similarly, lapatinib combined with trastuzumab had enhanced 
inhibitory effects in breast cancer [385] and trastuzumab/pertuzumab-resistant 
colorectal cancer [386]. In this experiment, neratinib was able to produce an additive 
inhibitory effect with trastuzumab in the PEA1 cell line, a cell line which is not very 
responsive to trastuzumab. However, unlike previous studies, lapatinib did not give 
additive or synergistic effects when combined with trastuzumab in the ovarian cancer 





Although these combinations show promise, further experiments with different 
concentration, schedules and in vivo testing are required. It is imperative to make sure 
that the combination treatment doses are safe in vivo and that the benefits from 
prolongation of life out-way the risks. 
3.7.3 TKIs reduce adhesion, migration and invasion in all ovarian 
cancer cell lines 
Metastasis forms one of the hallmarks of cancer [5]. This process involves the 
shedding of cells from the primary tumour, invasion to surrounding tissue, migration 
to other sites, and finally adhesion to new sites, which is often the peritoneal cavity in 
the case of ovarian cancer. This process is very frequent in HGSOC [387]. Metastasis 
can be driven by the HER pathway, thus inhibiting this signalling by use of TKIs or 
mAbs should diminish this process. Therefore, to test this hypothesis, the TKIs and 
mAbs were used in experiments to assess their activity against migration, adhesion 
and invasion in the ovarian cancer cell lines. 
The cell lines were first grown as spheroids to mimic the in vitro hypoxic and cell-cell 
interaction environment. The only cell line which did not grow spheroids was the 
PEA1 cell line. Generally, the higher the EGFR, HER2 and HER3 expression, the 
better the invasion ability of the cells, which was also found in other studies [388-391]. 
When neratinib was added to the spheroids, these reduced their invading abilities, 
supporting neratinib as an anti-invasive agent. 
Overexpression of EGFR and HER2 have been found to promote breast cancer cellular 
migration [392, 393]. However, in this study the higher the EGFR expression level, 
the lower the rate of migration. With respect to HER2, there was no obvious 
relationship between HER2 expression and migration.  
Previous studies have shown how TKIs inhibit migration of cancer cells [272, 394], 
however this notion has not been studied with all the TKIs investigated in this study. 
Therefore, a scratch assay was performed on all cell lines when they were 100% 




were able to inhibit migration, however, sapitinib performed better than the others 
overall, followed by canertinib; both are reversible TKIs (Figure 3.19). The platinum-
resistant cell lines, PEA2 and PEO23, were more sensitive to the anti-migratory effects 
of the TKIs. However, the other platinum-resistant cell line PEO4 was not as sensitive 
to the TKIs, similar to the results obtained from proliferation experiments. Overall, 
PEO4 was the least sensitive cell line, which interestingly ties with its lower migratory 
rates. Additionally, the cell lines which had higher migratory rates from each pair, 
were more sensitive to the TKI anti-migratory effects than their counterpart cell line. 
This suggests that TKIs are more effective against more rapidly migrating cells. 
 
Figure 3.19: Illustration of the percentage migration inhibitory effect of the 5 TKIs on each 
cell line 
 
The mAbs were also assessed for their inhibitory effects on the ovarian cancer cell 
lines. Only the PEA1-PEA2 pair was studied as it was the most migratory. Here, the 
mAbs had an anti-migratory effect on the PEA2 cell line, and a minimal effect on the 
PEA1 cell line. This could be attributed to the fact that PEA2 cell line had more HER2 
expression than the PEA1 cell line. The combination of mAbs, (which consisted of 25 



































especially in PEA2 cell line. This contrasts with the mAb effect on proliferation, where 
pertuzumab showed more beneficial effects. 
Following adhesion, tumour cells often release proteolytic enzymes which start 
degrading ECM molecules to give way to invasion into proteolytic tissue [395]. In 
vitro studies indicate that collagen has better adhesive effects for ovarian cancer cell 
lines than other ECM proteins [396, 397]. This was also noticed in this study, whereby 
cells adhered better to collagen than fibronectin or laminin. The effect of neratinib on 
adhesion was assessed by pre-incubating cells with neratinib and adding neratinib in 
the wells. Neratinib was able to reduce adhesion of almost all the cell lines, except for 
collagen and laminin in PEO14. Intriguingly, PEO14 was also resistant to neratinib 
anti-proliferative treatment. Studies suggest a link between integrins and activation of 
the MAPK pathway [398], which could suggest that the PEO14 cell line’s lack of 
sensitivity towards neratinib could be because it is unable to inhibit the MAPK 
pathway. 
In conclusion, the TKIs inhibit proliferation, migration, adhesion and invasion of these 
cell lines, irrespective of their platinum sensitivity. Although mAbs have a role in the 
reduction of proliferation and migration, they are not as effective in these ovarian 
cancer cell lines as the TKIs under investigation, even though their clinical target 
concentration has been met. Furthermore, the functional assays revealed a trend that 
suggested that the higher the HER receptor expression, the better the response to the 
HER-targeted therapies. Selected combinations of inhibitors were able to increase 
potency and these combinations included neratinib with cisplatin, lapatinib with 








4  The response of HER-targeted 
therapy to EGF and HRG 
modulation in ovarian cancer 
cell lines 
EGF and HRG are ligands found in varying concentrations within ovarian cancers and 
act on the HER pathway receptors, causing receptor dimerisation [139].  The dimerised 
receptors elicit signalling transduction, which leads to cellular proliferation and 
resistance to apoptosis [147]. These two ligands were chosen for further investigation 
as they differentially stimulate the HER family receptors, with EGF activating EGFR, 
whilst HRG activates the HER3 and HER4 receptors. From the previous chapter, the 
HER family expression was shown to play an important role in the efficacy of the TKIs 
and mAbs, and this chapter seeks to determine whether ligand activation is as 
important in the efficacy of inhibitors. 
This chapter describes studies that explored how the platinum-sensitive and platinum-
resistant HGSOC cell lines respond to EGF and HRG. The effects of the growth factors 
on cell signalling and functionality were investigated in the absence and presence of 
TKIs and mAbs.  
Additionally, the effect of TKIs and mAbs on the suppression of the response that 
these ligands bring about in the ovarian cancer cell lines was investigated. This may 




4.1 Time course effects of EGF and HRG modulation on HER 
receptors 
The effects of EGF and HRG on cell signalling in the cell lines over a period of 48 h 
were first investigated. Cells were exposed to 1 ng/mL EGF or 1 ng/mL HRG for 24 
h or 48 h before collecting lysates. These concentrations of EGF and HRG are typical 
concentrations found in cancer patients [399-403] and have been widely used in 
previous in vitro studies [404, 405]. Neratinib (0.1 µM) was also added for the same 
time period to assess its effect on ligand activation. Neratinib was the TKI chosen since 
the cell lines responded well in terms of proliferation and within therapeutic 
concentrations. Cells were maintained in 0.1% FBS, since FBS might contain these 
growth factors in unknown amounts. The cells were not completely serum starved so 
they would not struggle to grow. Figure 4.1 represents western blots obtained for 
PEA1-PEA2 cell lines, Figure 4.2 for PEO1-PEO4 cell lines, and Figure 4.3 for 
PEO14-PEO23 cell lines. The effects of EGF and HRG on the downstream signalling 
pathways PI3K/Akt/mTOR and Ras-Raf-MEK-ERK were indicated by increased 
expression of p-Akt (Ser473) and p-ERK (Thr202/Tyr204) respectively. 
Addition of EGF increased the expression of HER2 and HER3 in PEA1 and PEA2 
cells and HER4 in only PEA2 cells after 24 h and 48 h, whilst expression of EGFR 
decreased (Figure 4.1). Similarly, addition of HRG increased expression of HER2, at 
48 h in both cell lines, while the expression of EGFR, HER3 and HER4 remained 
relatively unchanged. The addition of neratinib reduced HER2 expression at both time 
points in both cell lines, and HER4 expression at all time points and with EGF and 
HRG in PEA2. p-Akt was stimulated in PEA2 upon addition of EGF after 48 h and 
upon addition of HRG at 24 h and 48 h. Similarly, p-ERK was stimulated in both cell 
lines, at both time points with EGF as well as HRG. Neratinib reduced the Akt and 






Figure 4.1: HER protein expression and downstream signalling proteins for PEA1-PEA2 




(a and b) western blots of the HER receptors and downstream signalling effects of EGF/HRG 
± neratinib for (a) PEA1 cell line, or (b) PEA2 cell line, (c-j) Bar graphs of HER expression 
normalised to loading control in PEA1 for (c) EGFR, (d) HER2, (e) HER3 and (f) HER4 and 
in PEA2 for (g) EGFR, (h) HER2, (i) HER3 and (j) HER4. EGF or HRG with or without 0.1µM 
neratinib were added to the cells for 24 h or 48 h. The experiment was repeated twice and the 
results are presented as mean of the relative intensity and error bars show standard deviation. 
The western blots are a representative of the repeated results, and the loading controls are 
representative of the other membranes. N/A means not applicable. 
In PEO1 and PEO4 cells, addition of EGF or HRG had little effect on EGFR, HER2, 
HER3 expression (Figure 4.2). However, 48 h following EGF addition, HER4 
expression increased in both cell lines. When neratinib was added to the cells, it 
decreased HER4 expression in EGF-stimulated PEO1 cells and HER2 and HER4 
expression in EGF and HRG-induced PEO4 cells. The addition of EGF and HRG for 
24 h and 48 h did not affect Akt phosphorylation, whereas addition of EGF increased 
ERK phosphorylation after 24 h and further stimulated phosphorylation after 48 h in 
both cell lines. HRG only stimulated p-ERK in PEO4 cells after 48 h. Neratinib 
inhibited the phosphorylation of ERK, except when HRG was added for 48 h in the 





Figure 4.2: HER protein expression and downstream signalling proteins for PEO1-PEO4 




(a and b) western blots of the HER receptors and downstream signalling effects of EGF/HRG 
± neratinib for (a) PEO1 cell line, or (b) PEO4 cell line, (c-j) Bar graphs of HER expression 
normalised to loading control in PEO1 for (c) EGFR, (d) HER2, (e) HER3 and (f) HER4 and 
in PEO4 for (g) EGFR, (h) HER2, (i) HER3 and (j) HER4. EGF or HRG with or without 
0.1µM neratinib were added to the cells for 24 h or 48 h. The experiment was repeated twice 
and the results are presented as mean of the relative intensity and error bars show standard 
deviation. The western blots are a representative of the repeated results, and the loading 
controls are representative of the other membranes. N/A means not applicable. 
For the PEO14 cell line, EGFR, HER2, and HER4 expression remained unchanged 
after EGF and HRG addition, while HER3 expression decreased for the PEO23 cell 
line (Figure 4.3). HER2 expression increased 48 h after addition of EGF and after 24 
h and 48 h addition of HRG. Neratinib reversed these HER2 stimulations. P-Akt in 
both cell lines remained unaffected upon the different treatments. The addition of EGF 
and HRG did not increase the baseline phosphorylation of ERK in PEO14 cells, 
however neratinib inhibited baseline phosphorylation. In PEO23 cells EGF and HRG 





Figure 4.3: HER protein expression and downstream signalling proteins for PEO14-PEO23 




(a and b) western blots of the HER receptors and downstream signalling effects of EGF/HRG 
± neratinib for (a) PEO14 cell line, or (b) PEO23 cell line, (c-j) Bar graphs of HER expression 
normalised to loading control in PEO14 for (c) EGFR, (d) HER2, (e) HER3 and (f) HER4 and 
in PEO23 for (g) EGFR, (h) HER2, (i) HER3 and (j) HER4. EGF or HRG with or without 
0.1µM neratinib were added to the cells for 24 h or 48 h. The experiment was repeated twice 
and the results are presented as mean of the relative intensity and error bars show standard 
deviation. The western blots are a representative of the repeated results, and the loading 
controls are representative of the other membranes. N/A means not applicable. 
4.2 Downstream pathway response to HER-targeted therapy 
with EGF and HRG modulation 
The cell lines were treated with TKIs or mAbs, and subsequently EGF or HRG were 
added to investigate whether the HER-targeted therapy would be able to suppress 
pathway stimulation in the presence of EGF/HRG modulation. p-EGFR (Tyr1289) and 
p-HER2 (Tyr1221/1222) expression were evaluated as indicators of EGFR and HER2 
activation respectively. Similar to experiments described in section 4.1, 
phosphorylation of the downstream products Akt and ERK were monitored to evaluate 
the response of these pathways to HER-targeted therapy. 
4.2.1 TKIs with EGF and HRG modulation 
The cell lines were first treated with pharmacologically achievable concentrations of 
the TKIs (afatinib 0.08 µM, canertinib 1 µM, lapatinib 1.5 µM, neratinib 0.1 µM, 
sapitinib 1 µM) [307, 310, 312, 314, 361] for 24 h in media containing 0.1% FBS. 
Subsequently, 1 ng/mL EGF or 1 ng/mL HRG were added 30 min before lysate 
collection. Figure 4.4 represents the western blots obtained for PEA1-PEA2 cell lines, 
Figure 4.5 for PEO1-PEO4 cell lines, while Figure 4.6 represents PEO14-PEO23 cell 
lines. 
EGF and HRG stimulation in the PEA2 cell line increased EGFR phosphorylation 
(Figure 4.4). All TKIs tested reduced this growth factor stimulated phosphorylation. 
Total EGFR expression remained unchanged at this time point. Phosphorylated HER2 
did not increase with the addition of EGF or HRG but all TKIs inhibited p-HER2 in 
the PEA2 cell line, and all except for lapatinib in EGF and HRG stimulated PEA1 




HRG, and was reduced by the TKIs. Afatinib, canertinib, and neratinib caused a 
modest decrease in total HER2 in PEA2 cells. 
In PEA1 cells, HRG stimulated a small increase in p-Akt, which was reduced by the 
TKIs. In contrast, there were no changes to p-Akt expression in PEA2 cells. 
Phosphorylation of ERK was stimulated by EGF and HRG in both cell lines. The TKIs 
reversed the phosphorylation in EGF-stimulated PEA1. In HRG-stimulated PEA1 
cells, this p-ERK increase was partially reversed. In EGF-stimulated PEA2 cells, the 
phosphorylation was unaffected by TKIs, while the HRG-stimulated cells had their 
phosphorylation decreased by the TKIs.  
 
Figure 4.4: HER pathway signalling proteins for PEA1 and PEA2 cell lines when 
EGF/HRG with or without TKIs were added 
TKIs were added at clinically achievable concentrations for 24 h, and 30 min before lysate 
collection, 1 ng/mL EGF or HRG were added to the cells. The experiment was repeated twice 
and the results show a representative of the results obtained for the western blots, and the 
loading controls are representative of the other membranes. 
Addition of EGF and HRG to the PEO4 cell line, caused phosphorylation of EGFR 
(Figure 4.5). Afatinib, canertinib and neratinib (but not lapatinib or sapitinib) inhibited 
EGF-driven EGFR phosphorylation, while all TKIs apart from sapitinib reduced HRG-
stimulated EGFR phosphorylation. Although PEO1 cells expressed low levels of total 
HER2, p-HER2 expression was present in the unstimulated cells. This basal level of 
phosphorylation was inhibited by all TKIs. In PEO4 cells, addition of EGF and HRG 




expression was reduced in afatinib and neratinib treated EGF and HRG stimulated 
PEO4 cells. 
In PEO1 cells, phosphorylated Akt increased when EGF and HRG were added. All the 
TKIs, except canertinib in EGF-stimulated cells, were able to reduce the 
phosphorylation. Conversely, there was no detectable active p-Akt in PEO4 cells. In 
PEO1 cells, p-ERK increased with EGF and HRG stimulation, which was decreased 
in the presence of the TKIs. PEO4 demonstrated an increase in p-ERK with the 
addition of HRG, which was only partially inhibited by the TKIs.  
 
Figure 4.5: HER pathway signalling proteins for PEO1 and PEO4 cell lines when 
EGF/HRG with or without TKIs were added 
TKIs were added at clinically achievable concentrations for 24 h, and 30 min before lysate 
collection, 1 ng/mL EGF or HRG were added to the cells. The experiment was repeated twice 
and the results show a representative of the results obtained for the western blots, and the 
loading controls are representative of the other membranes. 
PEO14 cells have basal EGFR phosphorylation, which was not affected by the addition 
of EGF and HRG (Figure 4.6). This phosphorylation, was reduced by afatinib, 
neratinib and sapitinib. In the PEO23 cell line, EGF and HRG stimulated p-EGFR. All 
TKIs reduced this phosphorylation, especially afatinib, canertinib and neratinib. All 
TKIs except lapatinib reduced p-HER2 in EGF-stimulated PEO14 cells, while all TKIs 
reduced p-HER2 in HRG-stimulated PEO14 cells. In PEO23 cells, all TKIs apart from 
canertinib reduced p-HER2. Total HER2 remained the same in PEO14 cells, however 




In PEO23 cells, p-Akt was stimulated on addition of EGF and HRG. All TKIs were 
able to reduce the phosphorylation, apart from canertinib in EGF-stimulated PEO23 
cells. Phosphorylated ERK was stimulated on addition of HRG to PEO14 cells. 
Afatinib and sapitinib were the TKIs best able to reduce this phosphorylation. In 
PEO23 cells, ERK was phosphorylated upon the addition of EGF and HRG, which 
was inhibited in the presence of all the TKIs.  
 
Figure 4.6: HER pathway signalling proteins for PEO14 and PEO23 cell lines when 
EGF/HRG with or without TKIs were added 
TKIs were added at clinically achievable concentrations for 24 h, and 30 min before lysate 
collection, 1 ng/mL EGF or HRG were added to the cells. The experiment was repeated twice 
and the results show a representative of the results obtained for the western blots, and the 
loading controls are representative of the other membranes. 
4.2.2 The effects of mAbs on EGF and HRG modulation 
The six cell lines were treated with 50 µg/mL pertuzumab, 50 µg/mL trastuzumab or 
25 µg/mL + 25 µg/mL of the combination for 24 h in 0.1% FBS media. Following this 
incubation, 1 ng/mL EGF or 1 ng/mL HRG were added 30 min before lysate collection. 
The western blots for all the cell lines are illustrated in Figure 4.7. 
With prior addition of the mAbs, p-Akt expression in the EGF-stimulated cell lines 
was not reduced, while in all cell lines apart from PEO4, p-Akt increased. Similarly, 
p-ERK was increased in all cell lines, except PEO4 upon the addition of EGF. The 




Both PE04 and PE023 cells had enhancement of p-Akt when HRG was added to the 
cells. All mAbs were able to reduce this phosphorylation in PE023 cells and 
pertuzumab and the combination in PE04 cells.  HRG produced a marked increase in 
ERK phosphorylation in all cell lines, which was reversed by the mAbs under 







Figure 4.7: HER pathway signalling proteins for the cell lines when EGF/HRG with or 
without mAbs were added 
Western blots for (a) PEA1-PEA2 cell lines, (b) PEO1-PEO4 cell lines, and (c) PEO14-
PEO23 cell lines. mAbs were added at clinically achievable concentrations for 24 h, and 30 
min before lysate collection, 1 ng/mL EGF or HRG were added to the cells. P means 
pertuzumab; T means trastuzumab. The experiment was repeated twice and the results show 
a representative of the results obtained for the western blots. 
4.2.3 Time course effect of neratinib with EGF and HRG 
The downstream signalling changes after addition of EGF and HRG over a period of 
60 min were analysed by western blot. This was investigated by adding 0.1 µM 




time points chosen were 5 min, 10 min, 15 min, 30 min and 60 min. The cells were 
serum deprived (0.1% FBS in medium) for 2 h prior to the addition of growth factors 
at each time point. 
For PEA1 cells, the addition of EGF or HRG individually had no effect on p-Akt 
expression (Figure 4.8). Combination of EGF and HRG caused a stimulation in p-Akt 
as early as 5 min with a subsequent reduction of expression. Neratinib inhibited this 
stimulation to some degree. P-ERK stimulation occurred with EGF addition at 5 min, 
and was sustained up to 30 min. Neratinib inhibited the amplitude of this 
phosphorylation as early as 5 min. The addition of HRG caused a modest increase in 
phosphorylation of ERK, which peaked at 30 min. Addition of neratinib inhibited this 
phosphorylation, especially at 30 min. When EGF and HRG were added 
simultaneously, the phosphorylation increased gradually from 5 min to 15 min and 
started decreasing by 30 min. When neratinib was added to the combination, it was 
ineffective at decreasing ERK phosphorylation. 
 
Figure 4.8: HER pathway signalling proteins for PEA1 cell line when EGF/HRG with or 
without neratinib was added 
Western blots for (a) PEA1 with 1 ng/mL EGF stimulation ± neratinib, (b) PEA1 with 1 ng/mL 
HRG stimulation ± neratinib (c) PEA1 with EGF and HRG stimulation ± neratinib. Graphs 




Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control p-ERK (0 
min). The experiment was repeated twice and the results show a representative of the results 
obtained for the western blots. Error bars represent standard deviation. 
In the PEA2 cell line (Figure 4.9), the addition of EGF and HRG separately caused 
initial modest phosphorylation of Akt at 5 min which, decreased by 15 min. When 
EGF and HRG were added simultaneously, p-Akt peaked at 10 min, and gradually 
started to decrease. Neratinib had no effect on this. Phosphorylated ERK expression 
was increased by both ligands, alone and simultaneously. Expression of p-ERK peaked 
at 5 min and afterwards the phosphorylation gradually decreased, until 60 min. As for 
p-Akt, neratinib had no effect on these expression changes in this cell line. 
 
Figure 4.9: HER pathway signalling proteins for PEA2 cell line when EGF/HRG with or 
without neratinib was added 
Western blots for (a) PEA2 with 1 ng/mL EGF stimulation ± neratinib, (b) PEA2 with 1 ng/mL 
HRG stimulation ± neratinib (c) PEA2 with EGF and HRG stimulation ± neratinib. Graphs 
representing the normalised (d) p-Akt expression with Akt from the induction of the control p-
Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control p-ERK (0 
min). The experiment was repeated twice and the results show a representative of the results 
obtained for the western blots. Error bars represent standard deviation. 
Upon the addition of EGF, HRG and their combination to the PEO1 cell line, p-Akt 




when EGF and HRG were administered concurrently When neratinib was 
administered simultaneously, it reversed the effects of the HRG and the combination 
of ligands. The ligands caused phosphorylation of ERK, as early as 5 min, which 
peaked at 10-15 min and gradually decreased until the 60th min. The combination 
peaked at 10 min, after which it steadily decreased. EGF and the combination of EGF 
and HRG caused the greatest stimulation of p-ERK. When neratinib was added to 
either EGF or HRG alone, it decreased the amplitude of the phosphorylation at all time 
points. However, when neratinib was added to the combination of ligands, p-ERK 
expression was not reduced. 
 
Figure 4.10: HER pathway signalling proteins for PEO1 cell line when EGF/HRG with or 
without neratinib was added  
Western blots for (a) PEO1 with 1 ng/mL EGF stimulation ± neratinib, (b) PEO1 with 1 ng/mL 
HRG stimulation ± neratinib (c) PEO1 with EGF and HRG stimulation ± neratinib. Graphs 
representing the normalised (d) p-Akt expression with Akt from the induction of the control p-
Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control p-ERK (0 
min). The experiment was repeated twice and the results show a representative of the results 
obtained for the western blots. Error bars represent standard deviation. 
In PEO4 cells, ligands increased p-Akt to different extents (Figure 4.11). Increased 
phosphorylation occurred by 5 min, and in EGF-stimulated cells, this peaked at 15 




added to the PEO4 cell line, they caused increased phosphorylation of p-ERK, even at 
5 min. With EGF, the phosphorylation peaked at 10 min. In all cases, the 
phosphorylation decreased rapidly by 15 min. The addition of neratinib did not 
diminish this activation. 
 
Figure 4.11: HER pathway signalling proteins for PEO4 cell line when EGF/HRG with or 
without neratinib was added 
Western blots for (a) PEO4 with 1 ng/mL EGF stimulation ± neratinib, (b) PEO4 with 1 ng/mL 
HRG stimulation ± neratinib (c) PEO4 with EGF and HRG stimulation ± neratinib. Graphs 
representing the normalised (d) p-Akt expression with Akt from the induction of the control p-
Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control p-ERK (0 
min). The experiment was repeated twice and the results show a representative of the results 
obtained for the western blots. Error bars represent standard deviation. 
In the PEO14 cell line (Figure 4.12), addition of EGF and the combination of EGF and 
HRG increased phosphorylation of Akt to similar extents, while the presence of HRG 
alone produced limited stimulation. The addition of neratinib to all three scenarios 
fully inhibited the ligand-activated phosphorylation of Akt, as early as from the first 5 
min. ERK phosphorylation was increased by all three growth factor additions. Increase 
in phosphorylation was observed at 5 min, and continued to increase up to 15 min. 
After that, the p-ERK remained steady for the remaining 45 min. When neratinib was 





Figure 4.12: HER pathway signalling proteins for PEO14 cell line when EGF/HRG with 
or without neratinib was added 
Western blots for (a) PEO14 with 1 ng/mL EGF stimulation ± neratinib, (b) PEO14 with 1 
ng/mL HRG stimulation ± neratinib (c) PEO14 with EGF and HRG stimulation ± neratinib. 
Graphs representing the normalised (d) p-Akt expression with Akt from the induction of the 
control p-Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control 
p-ERK (0 min). The experiment was repeated twice and the results show a representative of 
the results obtained for the western blots. Error bars represent standard deviation. 
Akt was phosphorylated in PEO23 cells when EGF, HRG and their combination was 
added to the cells, which peaked at 15 min (Figure 4.13). Expression gradually reduced 
during the following 45 min. Upon the addition of neratinib, p-Akt phosphorylation 
was completely inhibited at all time points. Addition of EGF with HRG to PEO23 cells 
caused the greatest ERK phosphorylation, which peaked at 10 min. The addition of 
EGF and HRG separately, also stimulated ERK phosphorylation, which reached its 
climax at 15 min and gradually decreased during the subsequent 45 min. Neratinib 





Figure 4.13: HER pathway signalling proteins for PEO23 cell line when EGF/HRG with 
or without neratinib was added 
Western blots for (a) PEO23 with 1 ng/mL EGF stimulation ± neratinib, (b) PEO23 with 1 
ng/mL HRG stimulation ± neratinib (c) PEO23 with EGF and HRG stimulation ± neratinib. 
Graphs representing the normalised (d) p-Akt expression with Akt from the induction of the 
control p-Akt (0 min), and (e) p-ERK expression with ERK from the induction of the control 
p-ERK (0 min). The experiment was repeated twice and the results show a representative of 
the results obtained for the western blots. Error bars represent standard deviation. 
4.3 Effect of EGF and HRG modulation on proliferation 
The effects of 1 ng/mL EGF and 1 ng/mL HRG on proliferation were assessed over a 
period of 120 h on all cell lines (Figure 4.14). EGF-stimulated cells grew more than 
the control in PEA2 and PEO1. On the other hand, HRG-stimulated cells proliferated 





Figure 4.14: Effect of EGF and HRG on proliferation of the cell lines  
The cells were grown in charcoal stripped serum medium for 120 h, and incubated with 1 
ng/mL EGF or 1 ng/mL HRG. Results are expressed as mean ± SEM of 3 technical replicates 
and 3 biological replicates. Statistical analysis was performed by two-way ANOVA (where 
*P≤0.05 and **P≤0.01). 
4.3.1 TKI influence on modulated cells 
The effects of lapatinib and neratinib on the proliferation of all the cell lines in the 
presence of EGF and HRG was assessed using the SRB assay after 120 h simultaneous 
incubation. The cells were treated with a range of lapatinib and neratinib 
concentrations (0.003 µM – 6 µM), in the presence of 1 ng/mL EGF or 1 ng/mL HRG 
in charcoal stripped media. Lapatinib was chosen as a reversible inhibitor and specific 
to EGFR and HER2 receptors. In contrast, neratinib is an irreversible inhibitor and 
targets pan-HER. Additionally, neratinib was the most potent TKI of the compounds 
tested. 
The results show that both lapatinib as well as neratinib were able to inhibit 
proliferation, even in the presence of EGF and HRG (Table 4.1). The cells 
concomitantly treated with lapatinib and EGF caused the lapatinib to be less potent 
against the cell lines. On the other hand, when neratinib and EGF were administered 
in combination, only in PEO14 did this combination cause the neratinib to be more 
potent within the cell line. Conversely, when lapatinib and HRG were used, PEA1, 
PEO1 and PEO23 cell lines were more sensitive to lapatinib treatment. PEA2, PEO1, 




 Lapatinib (µM) Neratinib (µM) 
 Control EGF HRG Control EGF HRG 
PEA1 2.82 5.06**** 2.03*** 0.07 0.11** 0.08 
PEA2 1.10 1.64** 1.31 0.06 0.09*** 0.07 
PEO1 0.29 0.73** 0.19 0.01 0.02 0.002 
PEO4 0.54 0.98 0.63 0.05 0.10 0.07 
PEO14 5.46 5.78 6.06* 0.56 0.32** 0.42**** 
PEO23 0.32 0.84*** 0.21 0.01 0.02 0.002 
Table 4.1: IC50 values of the cell lines treated with lapatinib and neratinib in the presence 
of EGF or HRG 
The green values are the ones where the IC50 values were below the IC50 value of their 
respective control, while the red values are the ones whose IC50 value was higher than the IC50 
value of their respective control. The experiment was repeated 3 times with 3 technical 
replicates each time. Statistical analysis was performed by two-way ANOVA followed by 
Tukey’s multiple comparisons test (where *P≤0.05, **P≤0.01, ***P≤0.001, and 
****P≤0.0001). 
4.3.2 mAb influence on modulated cells 
The cells were treated with 50 µg/mL pertuzumab, trastuzumab or the mAb 
combination (25 µg/mL + 25 µg/mL) for 120 h and incubated simultaneously with 
either 1 ng/mL EGF or 1 ng/mL HRG. The SRB assay was used to assess the anti-
proliferative effects of these mAbs when combined with EGF and HRG. 
Figure 4.15 shows the anti-proliferative effects of the mAbs when combined with EGF. 
The mAbs demonstrated their anti-proliferative effects even in the presence of EGF. 
In the PEA1, PEA2, PEO4 and PEO23 cell lines, combining EGF with all of the mAbs 
resulted in decreased anti-proliferative effects, especially with pertuzumab. On the 
other hand, in PEO1 cells, the mAbs were more potent when EGF was added. In the 
case of PEO14, pertuzumab had similar effects with or without EGF, trastuzumab 
displayed less potency with EGF and the combination of mAbs were more potent in 










Figure 4.15: Anti-proliferative effects of mAbs when administered with EGF 
(a)50 µg/mL pertuzumab in combination with 1 ng/mL EGF, (b) 50 µg/mL trastuzumab in 
combination with 1 ng/mL EGF, (c) 50 µg/mL pertuzumab + trastuzumab in combination with 
1 ng/mL EGF. The results show the mean percentage control growth ± SEM of 6 technical 
replicates and 3 biological replicates. Statistical analysis was performed by One-way ANOVA 
(where *P≤0.05). 
Figure 4.16 presents the graphs of anti-proliferative effects when mAbs were 
combined with HRG. The mAbs exhibited their anti-proliferative effects even in the 
presence of HRG. PEA2, PEO1, PEO4 and PEO23 cells were inhibited more 
effectively by the mAbs when they were combined with HRG. PEA1 and PEO14 cell 
lines also demonstrated improved response when HRG was added to the combination 











Figure 4.16: Anti-proliferative effects of mAbs when administered with HRG 
(a)50 µg/mL pertuzumab in combination with 1 ng/mL HRG, (b) 50 µg/mL trastuzumab in 
combination with 1 ng/mL HRG, (c) 50 µg/mL pertuzumab + trastuzumab in combination with 
1 ng/mL HRG. The results show the mean percentage control growth ± SEM of 6 technical 
replicates and 3 biological replicates. Statistical analysis was performed by One-way ANOVA 
(where *P≤0.05). 
4.4 Effect of EGF and HRG modulation on migration 
The PEA1-PEA2 pair of cell lines was chosen for these experiments, as the cell lines 
were the most migratory of those tested. Cells were seeded in 6 well plates to achieve 
100% confluence the following day. A scratch was made, media changed to 0.1% FBS 
and 1 ng/mL EGF or 1 ng/mL HRG added to the media. Cells were allowed to migrate 
over 24 h. When EGF and HRG were added to the PEA1 cell line, the cells migrated 
more rapidly than the control (Figure 4.17). With the PEA2 cell line, the EGF-
stimulated cells migrated faster than the control while the HRG-stimulated cells 









Figure 4.17: Effect of EGF and HRG on cellular migration 
(a) PEA1 cell line, (b) PEA2 cell line. Results are presented as mean ± SEM of 4 technical 
replicates and 3 biological replicates. Each time point is normalised to 0 h.  Statistical analysis 
was performed by two-way ANOVA followed by Holm–Šidák test (where *P≤0.05, **P≤0.01, 
and ***P≤0.001). 
4.4.1 TKI influence on migration in growth factor modulated cells 
To assess the anti-migratory activity of the TKIs in the presence of EGF and HRG, the 
scratch assay was carried out by adding each TKI (0.08 µM afatinib, 1 µM canertinib, 
1.5 µM lapatinib, 0.1 µM neratinib and 1 µM sapitinib) with 1 ng/mL EGF or HRG 
simultaneously. The assay was performed over 24 h, and migration was assessed in 
relation to the 0 h scratch area. 
All TKIs investigated were able to inhibit the migration of PEA1 and PEA2 cell lines 
even in the presence of EGF or HRG (Figure 4.18). The effects of the TKIs on EGF 
or HRG stimulated cells was similar to the final anti-migratory effect achieved in the 
absence of the growth factors. The presence of the growth factors enhanced the anti-






























(a) afatinib 0.08 µM on PEA1 cell line, (b) afatinib 0.08 µM on PEA2 cell line, (c) canertinib 
1 µM on PEA1 cell line, (d) canertinib 1 µM on PEA2 cell line, (e) lapatinib 1.5 µM on PEA1 
cell line, (f) lapatinib 1.5 µM on PEA2 cell line, (g) neratinib 0.1 µM on PEA1 cell line, (h) 
neratinib 0.1 µM on PEA2 cell line, (i) sapitinib 1 µM on PEA1 cell line, and (j) sapitinib 1 
µM on PEA2 cell line. Results are presented as mean ± SEM of 4 technical replicates and 3 
biological replicates. Each time point is normalised to 0 h.  Statistical analysis was performed 
by two-way ANOVA followed by Holm–Šidák test (where **P≤0.01, and ****P≤0.0001). 
 PEA1 PEA2 
 TKI only + EGF + HRG TKI only + EGF + HRG 
Afatinib (0.08 µM) 34% 58% 47% 52% 50% 28% 
Canertinib (1 µM) 38% 64% 57% 61% 59% 33% 
Lapatinib (1.5 µM) 18% 40% 40% 56% 48% 33% 
Neratinib (0.1 µM) 27% 47% 42% 62% 49% 34% 
Sapitinib (1 µM) 56% 76% 69% 68% 77% 45% 
Table 4.2: Percentage relative inhibition on migration compared to each condition’s 
respective control at 24 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control/EGF/HRG, b= % migrated by 
TKI only/ TKI+EGF /TKI+HRG. 
4.4.2 mAb influence on migration in growth factor modulated cells 
To assess the anti-migratory activity of the mAbs in the presence of 1 ng/mL of EGF 
or HRG, the scratch assay was carried out in the presence of 50 µg/mL of pertuzumab, 
trastuzumab or 25 µg/mL + 25 µg/mL mAb combination. The assay was done over 24 
h, and migration was assessed in relation to the 0 h scratch. 
In the PEA1 cell line, the addition of EGF increased the anti-migratory effect of 
pertuzumab, trastuzumab and the combination of mAbs in contrast to the control 
without growth factors (Figure 4.19, Table 4.3). The addition of HRG enhanced the 
anti-migratory effect in pertuzumab and the combination of mAbs with respect to the 
control. On the other hand, in PEA2 cell line, the addition of EGF or HRG decreased 
the anti-migratory capabilities of trastuzumab and the combination of mAbs, whereas 

















Figure 4.19: Anti-migratory effect of mAbs on EGF- and HRG- stimulated cell lines 
(a) pertuzumab 50 µg/mL on PEA1 cell line, (b) pertuzumab 50 µg/mL on PEA2 cell line, (c) 
trastuzumab 50 µg/mL on PEA1 cell line, (d) trastuzumab 50 µg/mL on PEA2 cell line, (e) 
combination 25 + 25 µg/mL on PEA1 cell line, and (f) combination 25 + 25 µg/mL on PEA2 
cell line. Results are presented as mean ± SEM of 4 technical replicates and 3 biological 
replicates. Each time point is normalised to 0 h.  Statistical analysis was performed by two-






 PEA1 PEA2 
 mAb only + EGF + HRG mAb only + EGF + HRG 
Pertuzumab  
(50 µg/mL) 5% 25% 27% 26% 23% 25% 
Trastuzumab  
(50 µg/mL) 6% 23% 3% 47% 30% 41% 
Combination  
(25 + 25 µg/mL) 10% 24% 18% 58% 24% 45% 
Table 4.3: Percentage relative inhibition on migration compared to each condition’s 
respective control at 24 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control/EGF/HRG, b= % migrated by 
mAb only/ mAb+EGF /mAb+HRG. 
4.5 Effect of EGF and HRG modulation on invasion 
The effects of EGF and HRG in the presence or absence of neratinib in a 3D model of 
invasion were next investigated. This was done by positioning a spheroid per well in 
a 24-well plate within collagen gel, and adding 1 ng/mL EGF or HRG with or without 
0.1 µM neratinib. These spheroids were allowed to invade over a period of 96 h, and 
the area at each time point was normalised to the area at 0 h.  
4.5.1 Neratinib influence on modulated cell-spheroids 
The cell line spheroids invaded more in the presence of EGF compared to the untreated 
control in all cell lines (Figure 4.20). Similarly, HRG increased invasion in PEO1, 
PEO14 and PEO23 though generally to a lesser degree than with EGF, but reduced 
invasion in PEA2 and PEO4 cells. Neratinib was effective at reducing invasion in all 
instances, irrespective of the presence of EGF and HRG. However, in the presence of 
EGF, neratinib was able to inhibit migration more than the control, especially in PEO1 
and PEO4 cell lines, with inhibitions of 83% versus 65% in EGF-induced and controls 
respectively in PEO1, while in PEO4, the inhibition in EGF-induced versus control 
















Figure 4.20: Anti-invasive effect of 0.1 µM neratinib on EGF- and HRG- stimulated cell 
line spheroids 
(a) PEA2, (b) PEO1, (c) PEO4, (d) PEO14, and (e) PEO23. Results are presented as mean ± 
SEM of at least 3 technical replicates and 3 biological replicates. Each time point is 
normalised to 0 h.  Statistical analysis was performed by two-way ANOVA followed by Holm–
Šidák test (where ***P≤0.001 and ****P≤0.0001).  
 TKI only + EGF + HRG 
PEA2 80% 83% 64% 
PEO1 65% 83% 67% 
PEO4 56% 96% 17% 
PEO14 71% 73% 81% 
PEO23 71% 83% 79% 
Table 4.4: Percentage relative inhibition on invasion compared to each condition’s 
respective control at 96 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control/EGF/HRG, b= % migrated by 





EGF is expressed in approximately 72% of epithelial ovarian cancer tumours, and its 
expression was not associated with histological subtype or disease stage [406, 407]. 
EGF is thought to induce epithelial-mesenchymal transition in ovarian cancer, which 
plays an important role in cancer invasion and metastasis [408]. In ovarian cancer, 
approximately 90% of the tumours expressed HRG, and was found to be higher in 
serous than endometrioid subtypes. Additionally, HRG was not associated with 
disease stage or tumour grade [409]. HRG was associated with peritoneal 
dissemination through increased proliferation in vitro [410].  
4.6.1 TKIs inhibit phosphorylation by EGF and HRG modulation 
In this study, the effects of EGF and HRG on downstream signalling of the HER 
pathways were investigated. The cell lines responded differently to EGF and HRG 
stimulation. When EGF was added to the cell lines, this generally caused decreased 
expression of HER receptors, consistent with internalisation and down-regulation of 
EGFR. This internalisation and trafficking process to endosomes is widely reported 
upon ligand binding with EGFR, and has been associated with a diminished EGFR 
signal until EGFR levels on the cell surface are replaced [411]. On the other hand, 
HRG caused an overall increase in expression of the HER receptors. Generally, a 
reduction in EGFR expression and an increased expression of the other HER receptors, 
was associated with an increased phosphorylation of ERK and Akt, except in the 
PEO14 and PEO23 cell lines. In this case, where there was an increased EGFR 
expression and reduction in HER3 and HER4, an increase in phosphorylation of Akt 
and ERK was observed. The downstream signalling generally peaked after 48 h, which 
could indicate that at 24 h, many of the signalling components are being used up, and 
are being regenerated after 48 h.  
Previous studies in ovarian cancer cell lines have suggested that EGF binds to EGFR-
HER2 complexes, and also causes cross-talk between EGFR and HER3 [412]. The 
same study also found that activation of HER3 by HRG is independent of HER2 




In section 4.1, neratinib decreased HER2 expression in the cell lines expressing HER2, 
consistent with studies described by Canonici et al. and Zhang et al., which have also 
shown that neratinib reduced HER2 expression after 12 h and 24 h in HER2+ breast 
cancer cell lines, possibly through moderately increasing HER2 transcription, 
followed by internalisation and lysosomal degradation of receptor [299, 413]. 
Neratinib inhibited HER4 expression in PEA2 and PEO4 cells, consistent with 
previous studies in breast cancer, whereby neratinib inhibited trastuzumab-induced 
HER4 cytoplasmic and nuclear HER4 expression [414].  
All the TKIs were able to reduce the phosphorylation events investigated that were 
brought about by EGF and HRG stimulation. In previous studies comparing lapatinib 
and sapitinib’s inhibitory action against HRG-stimulated phosphorylation, sapitinib 
produced more potent inhibition of HER2 and HER3 receptors [286]. Similarly, in this 
study sapitinib showed the greatest inhibitory potential overall especially in PEO1 and 
PEO14 cell lines, followed by neratinib on PEA2 and PEO4 cell lines and afatinib in 
PEO1 and PEO14 cell lines. The inhibitory potential was greater in HRG-stimulated 
cells, which is consistent with the fact that apart from inhibiting EGFR and HER2, 
sapitinib acts on HER3 receptors, whilst neratinib inhibits HER4 receptors, both of 
which are stimulated by HRG. Additionally, PEO1 and PEO14 cells generally had 
higher expressions of HER3 receptors, which might have been beneficial for the 
sapitinib action, whilst PEA2 and PEO4 have increased HER4 expression, required for 
neratinib efficacy. On the other hand, canertinib did not reduce the increased p-ERK 
expression brought about by HRG stimulation, especially in the PEO1, PEO4, PEO14 
and PEO23 cell lines. This could be because these cells saw an increase in EGFR and 
a reduction in HER2 and HER4 receptors upon HRG stimulation, which could suggest 
there were insufficient HER2 and HER4 receptors for dimerisation. In previous 
ovarian cancer studies, canertinib was found to reduce p-EGFR expression but not so 
much p-HER2 [415], which was also observed in this study with the PEO23 cell line.  
When mAbs were added to the EGF or HRG stimulated cell lines, they were only able 
to reduce Akt and ERK phosphorylation brought about by HRG, but not EGF. This 
outcome has also been described in lung cancer cell lines stimulated with EGF or HRG 




mAbs, which act specifically on HER2-containing dimers. Apart from EGFR-HER2 
heterodimers, EGF can produce EGFR-based homodimerisation, which are not 
inhibited by these HER2 targeted mAbs. However, HRG causes HER2-HER3 
heterodimerisations, which are essential for the mode of action of these mAbs, 
especially pertuzumab and does not result in functional HER3 homodimers due to the 
weak kinase activity in HER3. Additionally, Nagumo et al. have shown that HRG 
drives a lower mRNA expression of HER3 [417], which is normally associated with 
increased sensitivity to pertuzumab therapy [231]. 
From the time course experiments using phospho-specific antibodies, it was noted that 
the phosphorylation signals were not consistent, and sometimes were oscillating 
(section 4.2.3). Biological oscillations are common phenomena, and occur in circadian 
rhythm, cellular division cycles, and heartbeats amongst others [418]. In vitro, this has 
been observed in breast cancer cell lines, whereby addition of EGF and HRG caused 
oscillations in the phosphorylation of ERK and Akt. These were associated with 
receptor amplification, loss of transcriptional feedback and pathway crosstalk [419].  
EGF and the combination of EGF and HRG had the strongest stimulation on the cell 
lines. Although one would hypothesise that the addition of EGF and HRG 
simultaneously to the cells would produce a greater receptor-specific phosphorylation 
effect than either growth factor alone, this was not always occurring. It might be 
because the ligands would antagonise each other at receptor level, or else, there were 
insufficient HER receptors for both ligands to bind to and produce a synergistic 
phosphorylation effect. Neratinib was generally effective at reducing the 
phosphorylation effects induced by EGF and/or HRG ligands. However, when EGF 
and HRG were added simultaneously, neratinib was sometimes not able to inhibit 
phosphorylation of the downstream signalling as effectively as with EGF or HRG 
alone. This might be because the extent of phosphorylation brought about by both 
ligands was too strong to be effectively inhibited by neratinib.  
EGF, HRG or the combination produced a transient ERK activation, in the cell lines 
except in PEO14 cells. Transient activation is often linked with EGFR homodimers or 




the PEO14 cell line had the lowest proliferation rate (section 4.3). On the other hand, 
prolonged activation of ERK as in the case of PEO14 is often associated with 
EGFR/HER2 or HER3 and HER4 activation [412]. This prolonged activation is 
thought to cause cell differentiation in breast cancer cell lines [420]. 
4.6.2 TKIs inhibit the functional effects brought about by EGF and HRG 
stimulation 
The addition of EGF to lapatinib decreased the anti-proliferative effect of lapatinib in 
all six cell lines, while EGF reduced the anti-proliferative effect of neratinib in five of 
the six cell lines. On the other hand, treatment with HRG and lapatinib had a more 
potent effect than lapatinib only in three of the six cell lines, whereas four of the six 
cell lines were more sensitive to neratinib with HRG. This slightly contradicts results 
from previous studies in breast cancer, which suggested that HRG abrogated the anti-
tumour effects of lapatinib, while it did not reverse the anti-proliferative effects of 
neratinib [421]. Another breast cancer cell line project showed that HRG-induction 
reduced the anti-proliferative effects of lapatinib and neratinib  [422]. It could be 
inferred that addition of ligands could either create stronger drives which require more 
TKI or mAb to block the stimulation, which might be the case with EGF. Alternatively, 
it might produce more cellular use and dependency on the signalling pathway, thus 
inhibiting it might have better functional effects, as in the case of HRG.  
The relative levels of expression of the HER family members may be important in 
determining the type of response obtained. Previous in vitro studies demonstrated that 
HRG in cell lines with high levels of HER2 compared to HER3 and HER4, produced 
growth inhibition. On the other hand, HRG caused stimulation in growth in cell lines 
with low levels of HER2 compared to HER3 and HER4 [423]. This was similar to the 
results encountered in this project with PEA1, PEO1, and PEO23 cells, which had a 
stimulatory effect in migration (PEA1) and invasion (PEO1 and PEO23) when HRG 
was added. These three cell lines have a low HER2 to HER3 and HER4 cell line ratio. 
Conversely, PEA2 and PEO4 cells had migration (PEA2) and invasion (PEA2, PEO4) 





In the cell lines that were not sensitive to TKIs, EGF and HRG induction increased the 
sensitivity of these cell lines towards the TKIs. For instance, EGF and HRG-modulated 
PEA1 cells responded better to TKIs and migration was decreased by an average of 
20% in comparison to cells which did not have growth factor stimulation. Similarly, 
cell lines which were least responsive to neratinib’s anti-invasive properties, e.g. 
PEO1, PEO4 and PEO23, responded more to neratinib when the cells were stimulated 
by EGF. On the other hand, the PEA2 cell line whose migration was originally 
sensitive to TKIs, did not respond better to TKIs when EGF was added to the cell line 
and responded worse when HRG was added to PEA2 cell line. One plausible 
explanation for this could be because upon the addition of EGF and HRG in PEA1 and 
EGF in PEA2 cells, these caused an increase in HER2 and HER3 receptors, while the 
addition of HRG in PEA2 caused a decrease in HER2, HER3 and HER4 receptors. 
That would lead to less receptors upon which the TKIs could act and produce their 
inhibitory effect. 
When HRG was added to the mAb treatment, the mAbs still produced anti-
proliferative and anti-migratory effects, sometimes even stronger than the controls. 
These cell lines did not express high levels of HER2 expression, which is an indication 
for sensitivity to trastuzumab in breast cancer [424]. Yet, previous studies in breast 
cancer, suggest that trastuzumab is capable of inhibiting proliferation in the presence 
of HRG, despite normal expression of HER2 [189, 425]. On the other hand, the 
addition of EGF abrogated the effects of mAbs on proliferation in all cell lines and 
migration in PEA2 cell lines. This links with the lack of inhibition by mAbs on EGF-
induced downstream signalling of the cell lines.   
In previous studies, EGF and HRG stimulation was reflected in the proliferation rates 
of ovarian cancer cell lines [409],  however, in this study this was not as pronounced. 
This difference might be because previous studies have used higher concentrations of 
EGF and HRG (1nM, i.e. 6.4 ng/mL and 7.4 ng/mL respectively). Although MAPK 
signalling was increased in the cell lines when they were incubated with EGF or HRG 
up till 48 h (Section 4.1), this stimulation might have decreased after a while and by 




These experiments shed light on the importance of HER expression level, whereby 
differential functional effects were observed when EGF or HRG were added. This 
chapter shows the importance of evaluating the expression of EGF and HRG within a 
tumour, as the inhibitors might be less effective when certain ligands are expressed at 
high levels within the tumour.  From these experiments, when EGF was highly 
expressed within a tumour, the mAbs would not produce their maximal inhibitory 
effect, but the presence of HRG does not reverse the inhibitory effects of mAbs as 
much. On the other hand, TKIs act more effectively in situations where ligands 
increase the availability of HER family expression, for example when HER2 and 





5  The impact of HER expression 
modulation on TKI sensitivity 
In Chapter 3, the results demonstrated that HER-targeted TKIs, in particular neratinib, 
produced anti-tumour activity in cell lines, irrespective of platinum sensitivity. The 
platinum-resistant cell lines generally had increased expression of HER2, HER3 or 
HER4, and a lower expression of EGFR. In Chapter 4, EGF and HRG activated 
differential HER family dimerisation, and this influenced the inhibitory effects of 
HER-targeted therapies, whereby for example, the presence of HRG had better effects 
on the inhibitory properties of neratinib, sapitinib and afatinib. Hence, this chapter 
aimed to look further into the role that levels of EGFR, HER2 and HER3 expression 
play in the HER-targeted TKI response. 
Increased EGFR expression is associated with increased malignancy of ovarian cancer 
[136]. Additionally, it’s activation by platinum therapy contributes to platinum-
resistance [184]. The HER-targeted TKIs were able to inhibit phosphorylation of 
EGFR, as seen in Chapter 4. In this chapter, the role of 0.1 µM neratinib on cellular 
proliferation and migration was investigated, by knocking down EGFR, and analysing 
the effects that reduction of EGFR had on the PEA1 and PEA2 cell line pair. This pair 
was chosen as both cell lines had high EGFR expression.  
HER2 overexpression or high expression is linked with increased sensitivity to HER-
targeted mAbs and TKIs, especially in breast cancer [426-429]. This may also be true 
in ovarian cancer [130, 430], although not supported by all reports [225, 317]. On the 
contrary, low HER3 levels have been associated with increased response to HER2-
targeted (pertuzumab) therapy [230, 231], while low HER2 expression has been 
associated with improved response to anti-HER3 (seribantumab) treatment [249]. 




HER2 and HER3 in the response to TKI therapy. This was done by generating stable 
HER2 or HER3 overexpressing cells using plasmids. In addition to the three pairs of 
HGSOC cell lines, the non-HGSOC SKOV3 cell line was also compared, as it is a 
HER2 overexpressing cell line [338]. 
5.1 The effect of EGFR knockdown on ovarian cancer cell 
lines 
Transient EGFR knockdown was carried out by SiRNA transfection, using 50 nM of 
individual EGFR target SiRNA (as described in section 2.6 in Materials and Methods). 
EGFR expression was reduced by over 70% on days 2 to 5 (Figure 5.1). This 
knockdown was best achieved by the individual oligonucleotide J-003114-13 (J13), 
hence this was used in subsequent experiments. To assess proliferation, the cells were 
transfected 48 h after seeding and fixed 96 h after transfection. To assess migration, 
the cells were transfected 24 h following seeding, and the scratch was done 48 h after 
transfection, to allow cellular growth to reach 100% confluence. An untreated control, 
a mock and a 50 nM non-targeting control were also investigated, and results were 
normalised to untreated control and statistical analysis was compared against the non-
targeting control. 
 
Figure 5.1: EGFR expression of EGFR-knocked down PEA1 and PEA2 cell lines 
The cell lines were transfected with 50 nM of individual oligonucleotides J-003114-12 (J12) 
and J-003114-13 (J13). Cell lysates were collected from day 2 to day 5 after transfection to 
assess the level of EGFR expression. Both cell lines had their EGFR expression reduced by 




5.1.1 EGFR knockdown effect on proliferation 
Knock-down of EGFR caused a statistically significant decrease in proliferation, 
especially in the platinum-sensitive cell line, PEA1 (Figure 5.2). When neratinib was 
added to EGFR knocked-down cells, the inhibitory effect was similar to that obtained 
when neratinib was added to non-EGFR knocked-down cells. However, neratinib 
inhibition was greater than the proliferation suppression effect occurring in EGFR 





Figure 5.2: EGFR knockdown effect on neratinib anti-proliferative activity 
(a) Effect on PEA1 cell line, (b) effect on PEA2 cell line. Concentration of neratinib used was 
0.1 µM, and EGFR J13 SiRNA concentration was 50 nM. Data are represented as average of 
3 technical replicates and at least 4 biological replicates ± SEM. The day 0 value is subtracted 
from the timed value and normalised to the untreated control. One-way ANOVA was 
performed against the non-targeting (scrambled) control, (where **P≤0.01, and 
****P<0.0001). 
5.1.2 EGFR knockdown effect on migration 
When the effects of EGFR knock-down on migration were investigated, migration was 
decreased in cells with reduced EGFR expression (Figure 5.3). When neratinib was 
added to the EGFR-deficient cells, the anti-migratory effect of neratinib was not as 










Figure 5.3: EGFR knockdown effect on neratinib anti-migratory activity 
(a) effect on PEA1 cell line, (b) effect on PEA2 cell line. Concentration of neratinib used was 
0.1 µM, and EGFR J13 SiRNA concentration was at 50 nM. Data are represented as average 
of 5 technical replicates and at least 3 biological replicates ± SEM. The data were normalised 
to 0 h. Two-way ANOVA followed by Holm–Šidák test was performed against the non-
targeting (scrambled) control, (where *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001). 
5.2 The effect of HER2 and HER3 overexpression on ovarian 
cancer cell lines 
Stable transfectants with HER2 or HER3 plasmids were produced for the three pairs 
of WT HGSOC cell lines (PEA1-PEA2, PEO1-PEO4 and PEO14-PEO23) (as 
described in section 2.7 in Materials and Methods). The transfections were carried out 
using Lipofectamine 2000 transfection agent and individually transfected cells were 
selected using G418 antibiotic to prevent WT cells from contaminating the HER2 or 
HER3 overexpressing cells. The concentration of the antibiotic used depended on the 
killing curve for each WT cell line and was established before starting the 
transfections. The cell lines were always incubated in G418 antibiotic containing 
medium, to maintain selectivity of transfected cells. 
5.2.1 Downstream pathway response to TKI therapy 
The HER2 and HER3 transfected cell lines derived from the six cell lines (PEA1-
PEA2, PEO1-PEO4 and PEO14-PEO23) were treated with the five TKIs for 24 h, and 
subsequently EGF or HRG were added for 30 min before lysate collection. This was 
done to investigate how the inhibitory activity of the HER-targeted therapy suppress 




overexpressing cells. Activation of the downstream products Akt and ERK were 
investigated to evaluate the response of these pathways to HER-targeted therapy.  
In the PEA1-HER2 cell line derivative, p-HER2 expression increased in the 
transfected cell line, and this stimulation was inhibited by the TKIs. Expression of p-
ERK and p-Akt were slightly increased in the HER2 transfected cells, and further 
stimulated upon EGF addition. The TKIs, reversed this stimulation. In PEA2-HER2 
transfected cells, the p-HER2 expression was not affected but was inhibited by the 
TKIs, except sapitinib. The expression of p-ERK did not increase upon HER2 
transfection, however EGF stimulation increased p-ERK expression which was 
reversed by lapatinib and sapitinib. 
In the PEA1-HER3 cell line derivative, p-HER2 was slightly stimulated by EGF and 
HRG, and the signal was reversed by the TKIs. HER3 expression was unaffected by 
the TKIs. Expression of p-ERK was stimulated in the cell line when EGF was added, 
which was reversed by all TKIs, whereas addition of HRG caused stimulation of p-
Akt expression, which was reversed by afatinib, lapatinib, neratinib and sapitinib. In 
the HER3 transfected PEA2 cell line, p-HER2 was unchanged with the addition of 
EGF or HRG, but was inhibited by the TKIs. Addition of EGF increased p-ERK 







Figure 5.4: HER pathway and downstream signalling proteins for PEA1 HER2 or HER3 
and PEA2 HER2 or HER3 modulated cell lines when EGF/HRG with or without TKIs were 
added 
TKIs were added at clinically relevant concentrations for 24 h; 30 min before lysate collection, 
1 ng/mL EGF or HRG were added to the cells. The experiment was repeated once and the 
loading controls are a representation to the other membranes. 
The other four cell lines PEO1-PEO4 and PEO14-PEO23 were also investigated, and 
they produced similar results to PEA1-PEA2 cell line pair (see Appendix 1). 
5.2.2 Proliferation response to TKI therapy 
The effects of the five TKIs and the cytotoxic drugs (cisplatin, carboplatin and 
paclitaxel) in high HER2 and HER3 expressing cell line transfects were investigated 
to evaluate their properties on sensitivity to therapy. The cells were incubated with the 





The TKIs and cytotoxic agents inhibited the proliferation of the cell lines in a 
concentration-dependent manner (Figure 5.5). The HER2 and HER3 transfected PEA1 
cell line derivatives were, in general, more sensitive to the TKIs than the parental cell 
line (Table 5.1). On the contrary, the HER2 or HER3 transfected PEA2 cell lines were 
more resistant to the TKIs than the PEA2 WT cell line. Similar effects were noticed 
with the platinum-based chemotherapy. However, the PEA1 cell line derivatives were 
more resistant to paclitaxel than the parental PEA1 cell line, while PEA2 cell line 









































(a-h) Effects of TKIs and cytotoxic agents on PEA1 cell line and its HER2 or HER3 derivatives 
after 120 h (a) afatinib, (b) canertinib, (c) lapatinib, (d) neratinib, (e) sapitinib, (f) cisplatin, 
(g) carboplatin, and (h) paclitaxel. (i-p) Effects of TKIs and cytotoxic agents on PEA2 cell line 
and its HER2 or HER3 derivatives after 120 h (i) afatinib, (j) canertinib, (k) lapatinib, (l) 
neratinib, (m) sapitinib, (n) cisplatin, (o) carboplatin, and (p) paclitaxel. The results show the 
mean percentage control growth ± SEM of 6 technical replicates and 3 biological replicates. 
IC50 values PEA1  PEA2 
 Control HER2 HER3  Control HER2 HER3 
Afatinib (µM) 0.35 <0.01*** 0.01**  0.32 0.54 0.55 
Canertinib (µM) 0.38 0.10 0.10  0.28 1.23**** 1.53**** 
Lapatinib (µM) 1.65 1.17 0.27****  0.45 2.30**** 1.67**** 
Neratinib (µM) 0.02 0.01 0.01  0.02 0.05*** 0.04*** 
Sapitinib (µM) 0.23 0.02**** 0.02****  0.02 0.87**** 0.83**** 
Cisplatin (µM) 7.18 1.93**** 8.05  14.65 19.70*** 17.98**** 
Carboplatin (µM) 4.13 1.65**** 2.90****  4.89 6.18* 5.38 
Paclitaxel (nM) 1.49 2.51** 3.36****  3.40 2.77* 2.15*** 
Table 5.1: IC50 values of HER2 or HER3 modulated PEA1 and PEA2 cell line pair 
Concentrations of the TKIs tested ranged between 0.003-6 µM, cisplatin tested varied between 
0.05-12 µM, carboplatin tested ranged between 0.1-24 µM, and paclitaxel ranged between 
0.01-100 nM incubated for 120 h. Data are represented as IC50 values calculated in GraphPad 
Prism, based on an average of 6 technical replicates and at least 3 biological replicates. The 
day 0 value is subtracted from the timed value and normalised to the vehicle control. Statistical 
analysis was performed by two-way ANOVA followed by Tukey’s multiple comparisons test 
(where *P≤0.05, **P≤0.01, ***P≤0.001, and ****P≤0.0001). The green boxes signify 
increased sensitivity, red boxes represent decreased sensitivity as opposed to the respective 
WT cell line. 
The PEO1 HER3-transfected cells were more sensitive to TKI and cytotoxic therapy 
than the PEO1 parental cell line (Table 5.2). Similarly, the HER2-overexpressing 
PEO1 cell line was more sensitive to the TKI and cytotoxic therapy than the parental 
cell line, except with canertinib, cisplatin and carboplatin therapy. On the contrary, the 
HER2 and HER3 transfected PEO4 cell lines were more resistant to the TKIs and 
cytotoxic agents than the PEO4 parental cell line, except for carboplatin which was 







IC50 values PEO1  PEO4 
 Control HER2 HER3  Control HER2 HER3 
Afatinib (µM) 0.39 0.18**** <0.10**  0.68 0.92* 0.69 
Canertinib (µM) 0.60 0.73 <0.10****  0.96 1.63**** 1.61**** 
Lapatinib (µM) 1.95 1.12**** 0.22****  1.64 3.27**** 2.80**** 
Neratinib (µM) 0.03 0.02*** 0.01****  0.04 0.08* 0.04 
Sapitinib (µM) 0.40 0.26** 0.02****  0.34 1.37** 1.68*** 
Cisplatin (µM) 3.89 8.13**** 3.46*  13.33 18.3**** 16.6**** 
Carboplatin (µM) 1.68 3.71**** 1.55***  5.20 4.07*** 5.14 
Paclitaxel (nM) 2.58 2.34 1.81*  2.41 3.50*** 2.49 
Table 5.2: IC50 values of HER2 or HER3 modulated PEO1 and PEO4 cell line pair  
Concentrations of the TKIs tested ranged between 0.003-6 µM, cisplatin tested varied between 
0.05-12 µM, carboplatin tested ranged between 0.1-24 µM, and paclitaxel ranged between 
0.01-100 nM incubated for 120 h. Data are represented as IC50 values calculated in GraphPad 
Prism, based on an average of 6 technical replicates and at least 3 biological replicates. The 
day 0 value is subtracted from the timed value and normalised to the vehicle control. Statistical 
analysis was performed by two-way ANOVA followed by Tukey’s multiple comparisons test 
(where *P≤0.05, **P≤0.01, ***P≤0.001, and ****P≤0.0001). The green boxes signify 
increased sensitivity, red boxes represent decreased sensitivity, and orange boxes represent 
equal sensitivity as opposed to the respective WT cell line. 
The PEO14 HER2 and HER3 cell line derivatives were more sensitive to the TKIs 
than their parental cell line, with the HER3 derivatives being more sensitive than the 
HER2 derivatives (Table 5.3). Both derivatives were more resistant to cisplatin therapy 
while only HER3 derivative was more resistant to carboplatin therapy. On the other 
hand, the PEO23 cell line HER2 or HER3 derivatives were more resistant to the TKIs 
and cytotoxic therapy. The exceptions were sapitinib and paclitaxel, where the HER2 
derivative was more sensitive to these inhibitors than the parental cell line. 
IC50 values PEO14  PEO23 
 Control HER2 HER3  Control HER2 HER3 
Afatinib (µM) 1.68 1.21*** 0.64****  0.47 0.67 0.78** 
Canertinib (µM) 2.44 1.80**** 1.58***  0.84 1.91**** 2.07**** 
Lapatinib (µM) 6.09 4.32**** 2.56****  2.21 3.24**** 2.87** 
Neratinib (µM) 1.05 0.42**** 0.03****  0.02 0.09*** 0.06* 
Sapitinib (µM) 7.11 4.03**** 1.20****  1.97 1.55 1.92 
Cisplatin (µM) 4.93 5.74** 15.1****  13.98 21.1**** 19.3*** 
Carboplatin (µM) 3.76 2.60**** 4.19*  5.19 7.02**** 5.29* 
Paclitaxel (nM) 2.15 1.17* 1.97  2.42 2.05 2.84 
Table 5.3: IC50 values of HER2 or HER3 modulated PEO14 and PEO23 cell line pair 
Concentrations of the TKIs tested ranged between 0.003-6 µM, cisplatin tested varied between 




0.01-100 nM incubated for 120 h. Data are represented as IC50 values calculated in GraphPad 
Prism, based on an average of 6 technical replicates and at least 3 biological replicates. The 
day 0 value is subtracted from the timed value and normalised to the vehicle control. Statistical 
analysis was performed by two-way ANOVA followed by Tukey’s multiple comparisons test 
(where *P≤0.05, **P≤0.01, ***P≤0.001, and ****P≤0.0001). The green boxes signify 
increased sensitivity, red boxes represent decreased sensitivity, and orange boxes represent 
equal sensitivity as opposed to the respective WT cell line. 
The effects of TKIs on the HER2-overexpressing SKOV3 non-HGSOC cell line were 
also investigated to compare with the HER2-overexpressing HGSOC cell lines (Figure 
5.6a). The TKIs inhibited the SKOV3 cell line in a concentration-dependent manner. 
The IC50 values were higher compared to the transfected HER2 overexpressing 
HGSOC cell lines (Figure 5.6b, Table 5.4). SKOV3 was resistant to lapatinib, with 






Figure 5.6: SKOV3 cell line characteristics and anti-proliferative effects of TKIs  
(a) Protein expression of the 4 HER receptors in SKOV3 cell line was detected by western 
blot. (b) Concentration-response curves of the TKIs on SKOV3 cell line after 120 h. The results 
show the mean percentage control growth ± SEM of 6 technical replicates and 3 biological 
replicates. 
IC50 values SKOV3 
Afatinib (µM) 1.84 
Canertinib (µM) 3.09 
Lapatinib (µM) >6.00 
Neratinib (µM) 0.23 
Sapitinib (µM) 3.80 
Table 5.4: IC50 values of TKIs in SKOV3 cell line 
Concentrations of the TKIs tested ranged between 0.003-6 µM. Data are represented as IC50 
values calculated in GraphPad Prism, based on an average of 6 technical replicates and 3 
biological replicates. The day 0 value is subtracted from the timed value and normalised to 




5.2.3 Migratory response to TKI therapy 
The anti-migratory abilities of TKIs in cell lines expressing increased levels of HER2 
or HER3 were investigated. In the PEO1 cell line, enhanced expression of HER2 or 
HER3 increased the migratory ability of the cells, especially with HER2 (Figure 5.7a). 
The TKIs reduced migration in both HER2 and HER3 transfected cell lines. The anti-
migratory effect of TKIs was stronger in the HER3 transfected cells, with canertinib, 








Figure 5.7: Effects of TKIs on PEO1 HER2 or HER3 cell line derivatives 
The graphs show the migratory properties of PEO1 cell line transfects in a 24 h period. (a) 
PEO1 cell line transfects migration properties, (b)TKIs on PEO1-HER2 cell line, (c) TKIs on 
PEO1-HER3 cell line. Data are represented as average of 6 technical replicates and at least 
4 biological replicates ± SEM. The data are normalised to 0 h. Statistical analysis was 






 PEO1-HER2 PEO1-HER3 
Afatinib (0.08 µM) 13.6% 12.3% 
Canertinib (1 µM) 3.8% 37.6% 
Lapatinib (1.5 µM) 0.2% 33.1% 
Neratinib (0.1 µM) 7.6% 30.4% 
Sapitinib (1 µM) 13.2% 24.6% 
Table 5.5: Percentage relative inhibition of migration in PEO1 cell line derivatives 
compared to control at 24 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control, b= % migrated by TKI, as 
explained in section 2.2.2. 
The anti-migratory effects of TKIs on the SKOV3 cell line were investigated to 
compare their effects on non-HGSOC versus HGSOC HER2 high expressing cell 
lines. All TKIs inhibited migration of the SKOV3 cell line, with sapitinib and afatinib 
having the strongest anti-migratory effects (Figure 5.8, Table 5.6). 
 
 
Figure 5.8: Effects of TKIs on SKOV3 cell line migration 
The graph shows the migratory properties of SKOV3 cell line in a 24 h period in response to 
TKIs. Data are represented as average of 6 technical replicates and 3 biological replicates ± 
SEM. Statistical analysis was performed by two-way ANOVA. The data are normalised to 0 h. 
 SKOV3 
Afatinib (0.08 µM) 51% 
Canertinib (1 µM) 42% 
Lapatinib (1.5 µM) 36% 
Neratinib (0.1 µM) 32% 
Sapitinib (1 µM) 64% 
Table 5.6: Percentage relative inhibition on migration in SKOV3 cell line compared to 
control at 24 h 
Calculation: ((a-b)/a)*100; where a=% migrated by control, b= % migrated by TKI, as 





Multiple studies have shown the importance and potential biomarker use of HER 
expression in the HER-targeted TKI response [305, 431-435]. In the case of HER2, 
there are contradicting studies as to the level of expression needed for optimum HER-
targeted antibody therapy response in ovarian cancer cells. Some studies using 
xenograft experimental models suggest that high HER2 (amplified) expression is 
necessary at least in a non-HGSOC setting for trastuzumab/pertuzumab anti-tumour 
activity [232], while others suggest that therapy can work even at low HER2 
expression levels for trastuzumab [316, 317] and also for the anti-HER3 antibody 
seribantumab [249]. Low HER3 expression has been associated with response to anti-
HER2 pertuzumab [230, 231], while for EGFR, mutational status may be important as 
suggested by the isolated response to gefitinib in a phase II ovarian clinical trial [267]. 
This chapter aimed to further investigate the role of EGFR, HER2 and HER3 
expression levels in response to TKI treatment. 
5.3.1 Impact of EGFR expression on proliferation and migration 
Activation of EGFR is associated with increased proliferation and migration, in 
experimental models of ovarian cancer [436-438]. In the present study, when EGFR 
was knocked down, it produced a more significant decrease in proliferation in PEA1 
cells than in PEA2 cells. EGFR knock-down also resulted in decreased migration of 
both cell lines. The anti-proliferative and anti-migratory response of neratinib in EGFR 
knocked-down cells was assessed to help evaluate the importance of EGFR expression 
level in this regard. Neratinib reduced the proliferation of PEA1 and PEA2 cell lines 
further than the proliferation of EGFR-depleted cells. This suggests that while EGFR 
is playing an important role in cellular proliferation, neratinib depends not only on 
EGFR to elicit its anti-proliferative effects, and is therefore likely inhibiting other HER 
receptors, consistent with its broad spectrum activity. Previous studies have also 
shown that the anti-proliferative effects of neratinib correlate with HER2 baseline 
expression but not EGFR expression in breast cancer cell lines [299]. This EGFR-
independent anti-proliferative effect was also noticed when lapatinib was used in 
EGFR depleted, HER2+ breast cancer cell lines, where EGFR knockdown did not 




was added to HER2 overexpressing, EGFR deficient lung cancer cells [441]. On the 
contrary, although EGFR knockdown decreased the migratory ability of PEA1 and 
PEA2 cell lines, neratinib did not decrease this migration further. This is consistent 
with neratinib requiring EGFR for its anti-migratory effects. 
5.3.2 Impact of HER2 and HER3 overexpression on proliferation  
and migration 
The TKIs decreased the p-HER2 expression that was stimulated by EGF or HRG in 
the HER2-overexpressing PEA1 cell line. Lapatinib and sapitinib inhibited the p-ERK 
expression increase brought about by EGF, while all TKIs reversed HRG-stimulated 
p-ERK. Stimulation of p-ERK with EGF or HRG in the HER3-overexpressing cell line 
was reversed by all TKIs.  
In the platinum-sensitive cell lines, increased expression of HER2 or HER3 led to 
increased sensitivity to the TKIs. On the contrary, higher HER2 or HER3 expression 
in the platinum-resistant cell lines led to more resistance to the TKIs. HER2 
overexpression has been linked with increased response to paclitaxel in breast cancer 
[429], however this was not always observed in the HGSOC HER2 overexpressing 
cell lines investigated in this chapter. These results suggest that although more HER 
expression increases sensitivity to inhibitors, there is a limit to the receptor occupancy. 
Overly high expression levels might not be as favourable for optimum response to 
therapy in HGSOC, as the maximum occupancy level of the receptors would be 
reached. Other studies also suggested that the ratio of HER2 to HER3 (and not 
HER2:HER4) plays an important role for proliferation control [423] and HER-targeted 
therapy response. Additionally, another study has found that inhibition of HER3 
provides better therapeutic potential than inhibition of EGFR in HER2 positive breast 
cancer [440]. That study also found that knocking down HER3 decreases the 
proliferation to the same extent as HER2 knockdown. Moreover, p-HER3 was often 
detected when HER2 was overexpressed [440], which sheds light about the importance 
of HER2-HER3 complex as an oncogene [442]. In breast cancer, the levels of ligands 
such as HRG, are also important for the proliferation control, as HRG mediates HER2-




In breast cancer and lung cancer clinical trials, HER2+ patients respond better to 
afatinib, lapatinib, neratinib [287, 299, 435, 444, 445]. However, in the case of the 
SKOV3 cell line, increased HER2 expression did not correlate well with better anti-
proliferative response to TKIs, especially with lapatinib. The IC50 values achieved are 
all higher than the concentrations achieved in human serum after appropriate dosing. 
On the other hand, the anti-migratory response of the TKIs on the SKOV3 cell line 
was approximately 4-fold better in comparison to other HER2 positive cell lines and 
the HER2-overexpressing PEO1 cell line. These seemingly contradictory results of the 
SKOV3 cell line compared against HER2 overexpressing HGSOC cell lines suggest 
that non-HGSOC cells respond differently to TKIs, and necessitate separate 
evaluation. 
This chapter demonstrated that HER expression levels can play an important role in 
the response to HER-targeted therapy. The HER2 and HER3 expression appear to be 
important for HGSOC response to therapy, whereas EGFR expression is less important 
for response to therapy. Additionally, non-HGSOC tumours cannot be directly 












6  Gene expression response to 
HER-targeted therapy and 
growth factors 
In the previous chapters, neratinib was shown to demonstrate anti-proliferative, anti-
migratory and anti-invasive properties across the panel of platinum-sensitive and 
platinum-resistant HGSOC cell lines, even when cell lines were stimulated by EGF or 
HRG. In the first part of this chapter, experiments are described where the aim was to 
analyse the genes that are differentially expressed between the platinum-sensitive 
(PEA1) and platinum-resistant (PEA2) ovarian cancer cell lines, to evaluate the genes 
induced by HRG stimulation and which pathways are affected by ligand stimulation, 
and to identify differences between the non-treated or HRG-treated and neratinib 
treated cells to compare which pathways are affected by neratinib and other HER-
targeted inhibitors. In the second part of the chapter, genes of interest that were 
differently expressed upon neratinib treatment were identified and their proteins were 
assessed in previously constructed TMAs that contained SKOV3 tumour xenografts 
treated with the HER-targeted mAbs. The experiments had been carried out in vivo, 
and the mice had been treated with pertuzumab (20 mg/kg), trastuzumab (20 mg/kg) 
or the combination (20 mg/kg each) and samples were collected on days 1, 2, 4, 7, and 
14 [232, 233].  
RNAseq gene expression analysis was used to study the transcriptomes of PEA1 and 
PEA2 cells in the presence of HRG and/or neratinib (quality control data for the 
samples can be found in Appendix 2). Four treatment groups were compared, and three 
replicates for each group were prepared (Figure 6.1). HRG was chosen over EGF as a 
previous study investigating the role of EGF or HRG stimulation in breast cancer cell 




expressed genes, however, HRG resulted in more differently expressed genes than 
EGF [405]. 
 
Figure 6.1: Overview of gene expression analysis treatment groups 
There were 4 different groups for each cell line, which included the untreated controls, 
neratinib-treated (treated for 6 h with 0.1 µM neratinib), HRG-stimulated (0.1% serum, 
deprived for 6 h, and 10 ng/mL HRG added for 90 min), neratinib + HRG-treated (treated for 
6 h with neratinib, and 10 ng/mL HRG added for 90 min). 
6.1 Differential gene expression: platinum-sensitive versus 
platinum-resistant cell lines 
The gene expression differences between the platinum-sensitive PEA1 cell line and 
the platinum-resistant cell line PEA2 gathered from the RNAseq data were analysed 
using the Rank Product function within TMeV, with the false discovery rate (FDR) 
being set at 5%. This was done to evaluate the main differences between platinum-
sensitive and platinum-resistant HGSOC and investigate the correlation between gene 
expression and what was observed in vitro. 
RNAseq yielded 16,352 gene expressions values. There were 1,387 (about 8% of the 
gene yield) more highly expressed genes and 1,368 (about 8% of the gene output) more 
lowly expressed genes in the PEA2 cell line versus the PEA1 cell line. The DAVID 
online resource5 revealed the pathways that were more highly expressed in the PEA1 
cell line included the ECM-related, focal adhesion and PI3K-Akt pathways (Figure 
                                               




6.2a). The pathways that were more highly expressed in the PEA2 than in the PEA1 
cell line included the Wnt signalling and MAPK pathways. 
Clustering the highlighted biological processes between the cell lines (Figure 6.2b) 
demonstrated that genes most highly expressed in the PEA1 cell line included genes 
associated with cell cycle (example CDKN2A and MYC) and cell migration processes 
(such as MET and ENG). Genes that were more highly expressed in the PEA2 cell line 
than in PEA1 cells included genes associated with cell adhesion, tyrosine kinase 
activity (including HER2, HER3 and HER4) and Wnt (wingless) activity.  
 
Figure 6.2: Analysis of differently expressed genes between the PEA1 and PEA2 cell line 
pair 
(a) Pathways related to the differently expressed genes and the –log10 p-value of each 
pathway analysed using DAVID online resource. The blue bars represent the pathways that 
are lower expressed in PEA1 cell line with respect to PEA2 cell line, while the red bars 
represent the pathways that are more highly expressed in PEA1 cell lines versus PEA2 cell 
line. (b) Log2 mean centred heatmap on the differently expressed genes between PEA1 and 
PEA2 cell line pair. Red represents higher relative expression and blue lower relative 
expression. The genes were clustered and average linkage was applied in Cluster 3.0, and the 
heatmap was drawn in Treeview. The genes in each cluster were analysed for their biological 




6.2 Differential gene expression: untreated or HRG treated 
versus neratinib-treated 
The gene expression differences upon HRG treatment were sought to assess cellular 
response to this growth factor and investigate any differences between how HRG 
affects platinum-sensitive and platinum-resistant cell lines. HRG had different cellular 
functionality effects in PEA1 and PEA2 cells, hence the processes relating to the 
differential gene expression between the untreated controls and the HRG-activated 
cells in both cell lines were investigated. Neratinib inhibited proliferation, migration 
and invasion of the cell lines hence the pathways and biological processes affected by 
neratinib treatment were investigated in the absence or presence of HRG.  
Differences between treatment groups were evaluated using the Rank Products method 
within TMeV, with FDR set at 5%, and these are depicted in Figure 6.3. In PEA1 cells, 
there were: 
• 394 (2.4%) differently expressed genes in untreated control versus HRG-
treated cells 
• 439 (2.6%) differently expressed genes in untreated control versus neratinib-
treated cells  
• 434 (2.7%) differently expressed genes between the HRG-treated and HRG + 
neratinib-treated cells 
Of these genes, there were 19 genes which were co-expressed in all three treatment 
groups. The overlapping genes were mostly relating to the MAPK pathway, featuring 
genes such as RASGRP1, CACNG6, DUSP6, MAPK8IP1 and TGFB3. Other genes 
were related to TK signalling (genes including HER3, IL7, GJC2, NGF, NTF3 and 
SEMA3B), and transcription (genes including many zinc finger proteins and YBX2). 
Neratinib induced proliferation-associated genes (through WISP2, IGFBP1, SGK1 and 
TMC8) as well as genes associated with the MAPK pathway (through C1QTNF2, 
CHRNA7, FGF1 and LRRK2). Neratinib treatment on HRG stimulated cells, also 




FPR1), transcription (zinc finger proteins and TRIB3) as well as cell-cell signalling 
genes (EFNB2, GJA3, IL11, NOV and TRHDE). 
 
Figure 6.3: Differently expressed genes in PEA1 cells across different treatment groups 
(a) number of differently expressed overlapping genes, (b) heatmap of the differently expressed 
genes in the different treatment groups and key genes associated within each group. The 
analysis was carried out using Rank Products with 5% FDR. The significant differently 
expressed genes within each group were defined in accordance with the DAVID online 
resource. HRG/Ner/HRG+Ner represents genes that were co-expressed between the 3 
treatment groups, HRG/Ner represents genes that were co-expressed between HRG and 
neratinib treatment groups, HRG/HRG+Ner represents co-expressed genes in HRG treated 
and HRG+neratinib treated, Ner/HRG+Ner represents the overlapping genes in neratinib and 
HRG+neratinib treatments, while HRG represents genes that were only differently expressed 




inhibition and HRG+Ner represents the genes that are differently expressed upon HRG and 
neratinib treatment. 
Figure 6.4 depicts the differently expressed genes in PEA2 cells, and there were: 
• 410 (2.5%) differently expressed genes in untreated control versus HRG-
treated cells 
• 458 (2.8%) differently expressed genes in untreated control versus neratinib-
treated cells  
• 434 (3.1%) differently expressed genes between the HRG-treated and HRG + 
neratinib-treated cells 
In PEA2 cells, the co-expressed differently expressed genes were mostly related to the FoxO 
pathway (TNFSF10, CCND1, SGK2, MAPK12, PCK2, and PIK3R3), and MAPK as well as 
PI3K-Akt pathway (ATF4, NR4A1, MYC, EPHA2, GHR, DUSP5, TNF, and DUSP6). 
Stimulation with HRG modulated expression of transcription genes (such as INHBA, LHX2 
and zinc finger proteins). Neratinib inhibition affected genes of the PI3K-Akt pathway 
(CDKN1A, EPOR, IRS1, and IL6).  On the other hand, neratinib treatment and HRG 
stimulation mainly affected transcription (MMP9, HMGA2, DDIT3), PI3K-Akt and MAPK 
pathway (LAMC3, KITLG, JAK3, NGF, ITGA2B, DUSP2, HSPA2) as well as the p53 pathway 





Figure 6.4: Differently expressed genes in PEA2 cells across different treatment groups 
(a) number of differently expressed overlapping genes, (b) heatmap of the differently expressed 
genes in the different treatment groups and the key genes associated within each group. The 
analysis was carried out using Rank Products with 5% FDR. The significant differently 
expressed genes within each group were defined in accordance with the DAVID online 
resource. HRG/Ner/HRG+Ner represents genes that were co-expressed between the 3 
treatment groups, HRG/Ner represents genes that were co-expressed between HRG and 
neratinib treatment groups, HRG/HRG+Ner represents co-expressed genes in HRG treated 
and HRG+neratinib treated, Ner/HRG+Ner represents overlapping genes in neratinib and 
HRG+neratinib treatments, while HRG represents genes that were only differently expressed 
upon HRG stimulation, Ner represents the genes differently expressed only upon neratinib 





To support the analysis of genes that change upon HER-targeted therapy, the publicly 
available Monks et al. dataset [446], featuring HGSOC cell lines (OVCAR3, 
OVCAR4, OVCAR5 and OVCAR8), treated with lapatinib for 6 h, was chosen. The 
differently expressed genes upon treatment were evaluated using TMeV, at 1% FDR. 
At such stringent criteria, there were over 120 differently expressed genes that were 
co-expressed between at least one neratinib-treated cell line and one lapatinib-treated 
cell line (Figure 6.5). The most significant pathways that these overlapping genes 
represented included the TNF, FoxO and mTOR pathway. 
 
Figure 6.5: Differently expressed genes in lapatinib-treated HGSOC cell lines 
(a) Venn diagram of differently expressed genes between lapatinib-treated HGSOC cell lines 




differently expressed genes in lapatinib and neratinib treated HGSOC cell lines. The 
differently expressed genes in dataset GSE116436 [446] were evaluated using FDR of 1%. 
The untreated control data were compared against 1 µM lapatinib treatment for 6 h. The genes 
taken into consideration for pathway evaluation were the genes which had at least one 
lapatinib-treated and one neratinib-treated cell line involvement. The pathways were analysed 
using DAVID online resource and the most significant ones are shown. 
6.3 HER-targeted therapy-induced biomarkers 
To identify predictive biomarkers which might be used to assess response to HER-
targeted treatment, previous gene expression data containing information about the 
effect of trastuzumab, pertuzumab or their combination on SKOV3 ovarian cancer 
xenografts was mined [232]. The gene expression data for combined pertuzumab and 
trastuzumab therapy after four days of treatment were compared against the untreated 
control to explore the differently expressed genes using the Rank Product method in 
TMeV. This treatment group was considered as it produced the best growth-inhibitory 
effects against the ovarian cancer xenografts tested [232, 233]. The differently 
expressed genes were compared with the differently expressed genes that resulted 
upon neratinib treatment in the PEA1 and PEA2 cell line pair discussed in section 6.2, 
and the co-expressed genes were taken into consideration (Figure 6.6).  
There were 13 genes that were down-regulated and co-expressed between mAb-treated 
xenografts and at least two neratinib-treated groups (Figure 6.6a). On the other hand, 
there were 24 genes that were up-regulated and co-expressed in at least two neratinib-
treated groups and mAb-treated xenografts (Figure 6.6b). Literature searching was 
used to help determine which of these genes were of greatest interest that could be 
explored at the protein level using TMAs. The criteria for the gene choice included the 
novelty of the genes in the ovarian cancer setting yet with enough being known about 
the genes, as well as the availability of antibodies to the proteins for the genes of 
interest. The TMAs constructed consisted of SKOV3 ovarian cancer tumour cores that 
were treated with trastuzumab, pertuzumab or the combination sampled over a period 
of days from the study by Sims et al. [232]. The proteins that were investigated further 
were: CEBPG (CCAAT Enhancer Binding Protein Gamma), DDIT4L (DNA Damage 
Inducible Transcript 4 Like), RALGDS (Ral guanine nucleotide dissociation 






Figure 6.6: Venn diagram with co-expressed genes between neratinib-treated cell lines and 
mAb-treated xenografts 
(a) Down-regulated overlapping genes between PEA1 cell line neratinib control, PEA1 cell 
line HRG-neratinib treated, PEA2 cell line neratinib control, PEA2 cell line HRG-neratinib 
treated, and ovarian cancer xenografts treated with combination of pertuzumab + 
trastuzumab. (b) Up-regulated overlapping genes between PEA1 cell line neratinib control, 
PEA1 cell line HRG-neratinib treated, PEA2 cell line neratinib control, PEA2 cell line HRG-
neratinib treated, and ovarian cancer xenografts treated with combination of pertuzumab + 
trastuzumab, (c-f) gene expression of the 4 HER-therapy induced candidates in PEA1 and 
PEA2 untreated and neratinib-treated and in the xenograft model in the controls and 
combination-treated, where (c) DDIT4L, (d) SPRY2, (e) CEBPG, and (f) RALGDS. The gene 
expression data for mAb xenografts were taken from Sims et al. [232]. 
6.3.1 Expression of the therapy-induced biomarkers in platinum-
sensitive vs platinum-resistant tumours 
The TCGA gene expression dataset for HGSOC [447] was analysed to investigate 
differences in the therapy-induced biomarker expression in platinum-sensitive versus 




dataset were based on the disease-free status versus progression within six months 
after completing platinum-based therapy for the platinum-sensitive and platinum-
resistant classification respectively [447]. The gene expression levels of CEBPG, 
RALGDS, SPRY2 and DDIT4L were exported from the dataset across platinum-
sensitive and platinum-resistant tumour expression. CEBPG and DDIT4L were more 
highly expressed in the platinum-resistant samples. On the other hand, RALGDS and 
SPRY2 had higher expressions in the platinum-sensitive samples.   
 
Figure 6.7: Therapy-induced biomarkers in platinum-sensitive and platinum-resistant 
tumours 
The TCGA data [447], were accessed and CEBPG, DDIT4L, RALGDS and SPRY2 expression 
information of platinum-sensitive and platinum-resistant tumours was extracted. The 
differences in expression were not statistically significant. “Sen” means sensitive and “Res” 
means resistant. 
6.3.2 Patient survival analysis of therapy-induced biomarkers 
The impact of CEBPG, DDIT4L, RALGDS and SPRY2 gene expression on PFS and 
OS of serous ovarian cancer patients was investigated using KMplot6 [448]. Kaplan-
Meier plots show that high expression of CEBPG and DDIT4L are linked with 
significantly worse PFS and OS, while low expression of RALGDS and SPRY2 are 
associated with worse PFS and OS (Figure 6.8). 
                                               





Figure 6.8: Kaplan-Meier plots for progression free survival and overall survival for 
CEBPG, DDIT4L, RALGDS and SPRY2 
The online resource KMplot [448] was used to perform survival analysis for CEBPG, 
DDIT4L, RALGDS and SPRY2 expression in serous ovarian cancer samples across all cancer 
grades over 240 months. Samples were placed into high (red line) and low (black line) 
expression groups based on the optimum cut-point in each individual analysis. Each plot 




6.3.3 Treatment-induced expression of biomarkers 
The selected treatment-induced biomarkers identified from the co-expression between 
differently expressed genes upon neratinib treatment and differently expressed genes 
upon mAb treatment were assessed in TMAs containing xenograft tumours treated 
with pertuzumab, trastuzumab or the combination, over a 14-day period. Each 
treatment group consisted of three tumour replicates and there were four technical 
replicates. The expression levels of CEBPG, DDIT4L and RALGDS proteins were 
highest in tumours containing combination treatment of mAbs, followed by 
pertuzumab-treated samples and trastuzumab-treated samples. The untreated controls 
had the lowest protein expression. On the contrary, SPRY2 protein expression was 
lowest in the mAb combination-treated and pertuzumab-treated samples, and highest 
in the untreated control. The protein expression usually peaked around day 2-4 of 
















Figure 6.9: Expression of biomarkers upon mAb treatment in TMAs containing xenograft 
tumour samples 
(a) expression of CEBPG protein, (b) expression of DDIT4L protein, (c) expression of 
RALGDS protein, (d) expression of SPRY2 protein, and (e) low and high staining with CEBPG 
and RALGDS antibodies. Histoscores were measured by multiplying the % of stained cells by 
the intensity of staining. Results represent average from 3 technical replicates from 4 TMAs 
and error bars signify SEM. Statistical analysis was performed against the untreated controls 






In previous chapters, the results obtained showed differences between the platinum-
sensitive and platinum-resistant cell lines in their response to therapy. The purpose of 
this chapter was to investigate gene and protein expression differences using a data-
driven molecular approach between phenotypes and upon treatment and how these link 
to in vitro data.  
Gene expression analysis revealed that in the platinum-resistant cell line PEA2, 
expression of the ECM-receptor interaction, focal adhesion and PI3K-Akt signalling 
pathways were down-regulated pathways represented by the differently expressed 
genes over PEA1 cell line. These pathways are associated with the cell cycle and cell 
migration biological processes. Genes identified that were decreased and related to cell 
cycle included CDKN2A (cyclin-dependent kinase Inhibitor 2A), which acts as a 
tumour suppressor [449], FOXL2 (Forkhead Box L2) which is involved in ovarian 
development [450] and MYC (MYC proto-oncogene), a proto-oncogene which is 
associated with cell progression and transformation [451]. On the other hand, genes 
related to cell migration included MET (MET proto-oncogene), which plays a role in 
cell survival and invasion [452], and ENG (endoglin), which has a critical role in 
angiogenesis [453]. In breast cancer, increased MET expression has been associated 
with anthracycline-based chemotherapy resistance [452]. The expression of these 
biological processes ties in with the in vitro results, whereby the PEA1 cell line had 
faster migration rate than the PEA2 cell line. 
On the other hand, the differentially expressed genes in the platinum-resistant cell line 
were linked with the Wnt signalling and the MAPK pathways. The Wnt signalling 
pathway is involved in cellular events, such as proliferation, survival, migration and 
polarity. Previous studies have also suggested that Wnt activity plays an important role 
in the emergence of chemo-resistant ovarian cancer, with the aid of endothelin-1, 
endothelin A receptor which regulates EMT [454, 455]. Wnt5a has also been identified 
in previous studies to be associated with decreased chemosensitivity [456], which fits 
well with the findings in this project, as PEA2 cells had higher Wnt5a expression, and 




in ovarian cancer correlate with improved patient outcomes, and Wnt5a activity 
generally has negative effects on CTNNB1 [457]. Apart from Wnt signalling, cell 
adhesion is also a biological process which was differently expressed in the PEA2 
compared to the PEA1 cell line. In fact, the PEA2 cell line adhered more than PEA1 
cell line to the ECM proteins as seen in Chapter 3. Additionally, HER2, HER3 and 
HER4 genes were more highly expressed in the PEA2 cell line, a result which was 
consistent with the protein expression levels using western blot analysis. Interestingly, 
a previous study by Koti et al. identified how amongst others, the MAPK pathway was 
over-represented in the platinum-resistant HGSOC, in addition to increased IGF1 and 
NF-κB expression [458].  
Stimulation with HRG caused an up-regulation in genes linked to transcription mis-
regulation in both PEA1 and PEA2 cell lines. Mutations in the regulatory regions and 
transcription factors, are main contributors of cancer. In fact, the transcription factor 
MYC, which was differently expressed in most instances in PEA1 and PEA2 cell lines, 
is frequently amplified, and is associated with tumour aggression and poor clinical 
outcome [459].  Previous studies suggest that HRG-mediated MAPK can stimulate 
transcription of the cyclin D1 gene [460], which is required for the cell cycle 
progression through G1 phase [461]. It is important to note that gene expression levels 
do not always correlate well with protein levels as multiple factors influence levels of 
expression of both mRNA and proteins, including regulation of transcription to 
translation, mRNA half-life as well as post-transcriptional modification of proteins 
[462]. 
Addition of neratinib modulated expression of FoxO signalling pathway genes. This 
family of transcription factors regulate expression of genes associated with cellular 
physiology, including apoptosis, glucose metabolism and oxidative stress resistance 
[463]. In gastric cancer, FoxO1 is an important link between HER2 and MET 
signalling pathways through negative crosstalk, and was found to be an important 
component in acquired lapatinib resistance in HER2 positive gastric cancer cells [464]. 
This finding links well with this data considering that MET was upregulated in the 
TKI-resistant cell line PEA1, and differential gene expression identified that FoxO 




Generally, neratinib caused down-regulation of components of the MAPK and PI3K 
pathways, which are downstream of the HER receptors, even in the presence of HRG. 
The inhibition of elements of the MAPK and PI3K pathway was in line with the protein 
expression analysis carried out by western blot in Chapter 4, where neratinib was able 
to decrease the phosphorylation of ERK and Akt, which are products of the MAPK 
and PI3K pathways respectively. Some of the most influential genes in the MAPK 
pathway inhibition would be the DUSP family, as they are usually negative feedback 
regulators of ERK [465]. 
Prior studies by O’Neill et al. have shown that expression of the CCND1 gene is 
usually down-regulated in response to lapatinib, neratinib and afatinib treatment [466]. 
This was also observed in this dataset, whereby CCND1 was down-regulated in both 
cell lines, even in HRG-modulated cells. The study by O’Neil et al. also identified 
increased expression of RB1CC1 (RB1 Inducible Coiled-Coil 1), HER3, FoxO3a and 
NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1) upon treatment with 
lapatinib, neratinib and afatinib in breast cancer cell lines [466]. These genes are 
usually indicative of a HER2 pathway connection, which was consistent with gene 
expression changes using gefitinib (EGFR-specific TKI), which did not cause 
differential gene expression in these genes [466]. In this data set, HER3 expression 
was increased in only the PEA1 neratinib control, while RB1CC1, FoxO3a and NR3C1 
were not found to be differentially expressed upon neratinib treatment. 
6.4.1 Potential biomarkers of anti-HER family treatment 
Biomarkers can include genes or proteins which are used to identify pathological or 
physiological processes or diseases [467]. A biomarker may be prognostic or 
predictive. Prognostic biomarkers deliver information about the patient’s outcome to 
cancer, whilst predictive biomarkers provide information about the patient’s response 
to therapeutic interventions, and can also be a target for targeted therapy [468]. 
Previous studies by Sims et al. using the SKOV3 ovarian cancer xenograft model 
revealed that the combination of mAbs was associated with increased apoptosis, as 




observed that pertuzumab was capable of reducing p-Akt, while both monoclonal 
antibodies singly and their combination reduced p-ERK expression after 4 days [232]. 
The protein expression changes in the TMAs complemented the gene expression 
changes observed upon mAb therapy, whereby the CEBPG and RALGDS genes or 
proteins increased upon treatment, whilst SPRY2 genes or proteins decreased upon 
treatment. However, DDIT4L protein expression increased upon treatment in the 
TMAs, while the gene expression level (at Day 4) decreased upon treatment. These 
discrepancies could be due to gene transcription changes at Day 4 not reflecting the 
overall dynamic change in protein expression. The expression of the biomarkers is 
associated with better survival in the platinum-sensitive disease. CEBPG and DDIT4L 
were less expressed in the platinum-sensitive cells than the platinum-resistant cells, 
which was associated with better PFS and OS. Conversely, RALGDS and SPRY2 were 
more highly expressed in the platinum-sensitive cells, which was similarly associated 
with better PFS and OS over low expression of biomarkers. 
The CEBPG protein mediates cellular transcription involved in the metabolism and 
differentiation of cells [469]. This protein is also thought to positively regulate wound 
repair through its effects on the HER pathway [470]. In NSCLC, CEBPG expression 
has been associated with radio-sensitivity [471], while in ovarian cancer, it is 
modulated in response to paclitaxel treatment [472]. There are other members of the 
CEBP family, including CEBPB, which has two isoforms: CEBPB LIP and CEBPB 
LAP, whose ratio correlates to chemotherapy response. It was found that degradation 
of LIP causes endoplasmic reticulum stress and chemotherapy-induced cell death 
[473]. Another member, CEBPD is associated with the amplification of IL-6 and HIF-
1 signalling, which in turn link to inflammation and hypoxia [474]. 
DDIT4L (also referred to as REDD2) is a paralog of DDIT4 [475], and is upregulated 
under cellular stress, such as hypoxia, endoplasmic reticulum stress and starvation 
[476-478]. DDIT4L and DDIT4 are hypoxia-inducible factor (HIF)-1 inducible genes 
and their presence inhibits mTOR [478-480]. In ovarian cancer studies, DDIT4L gene 
upregulation caused a decrease in size of cells [481]. In this study, the Kaplan-Meier 




The Ras pathway which was up-regulated by neratinib treatment, has downstream 
effectors including PI3K, Raf and Ral-GEF [482]. The latter includes proteins that are 
regulated by the RALGDS gene. RALGDS is normally involved with golgi trafficking 
vesicle formation [482]. RALGDS and Akt contribute to the inhibition of FoxO family 
[483]. In vitro studies investigating the effects of lapatinib in HER2+ cancer cells over 
a short period time, showed that after 12 h, phospho Raf was activated with lapatinib 
treatment [484]. It is feasible therefore that there might be a lapatinib-mediated FoxO-
dependent feedback loop, activating the Raf pathway [484]. High levels of RALGDS 
were associated with better PFS and OS in the Kaplan-Meier plots. 
The sprouty family consist of four homologs, thought to be negative pathway 
regulators of the Ras/ERK pathway [485, 486]. SPRY2 can inhibit MAPK pathway 
signalling by sequestering CBL (Cas-BR-M murine ectopic retroviral transforming 
sequence homolog), which causes EGFR degradation [485, 487]. Expression of 
SPRY1 correlated with SPRY2 expression and were associated with survival in 
ovarian cancer patients [488]. Additionally, SPRY2 expression is correlated with 
tumour suppressor properties in cancer, such as proliferative, migratory, invasive and 
survival assets [486, 489-491]. In breast cancer, low expression of SPRY2 was linked 
with poor outcomes in trastuzumab-treated patients [492], which suggest that SPRY2 
might be a useful biomarker to stratify patients for mAb therapy. Gene expression 
studies upon neratinib and mAb treatment showed that SPRY2 was down-regulated, 
which suggests that the activity of neratinib and mAbs might involve the tumour 
suppressor effect of SPRY2. 
In summary, this chapter sought to investigate the pathways and processes that 
neratinib influences upon treatment using a molecular data-driven approach. The role 
of neratinib was also compared in the absence and presence of HRG. The findings 
corroborate the results in Chapter 3 and 4, whereby neratinib inhibited proliferation, 
migration and invasion even in the presence of HRG. Furthermore, the MAPK and 
PI3K pathways were also inhibited which was shown in Chapter 4 through inhibition 
of p-ERK and p-Akt in western blots. Additionally, this chapter has also brought 
together gene expression changes upon neratinib treatment with HER-targeted mAb 




pertuzumab and trastuzumab produced greatest changes in expression, followed by 
pertuzumab. This profile was observed in the proliferation and migration studies from 
Chapter 3, whereby collectively, the combination of antibodies and pertuzumab had 





7  Conclusion 
The central aim of this project was to assess the therapeutic effects of HER-targeted 
inhibitors in platinum-sensitive compared to platinum-resistant HGSOC cell lines, and 
to evaluate the role of HER family receptor expression (and presence of activating 
ligand) in the efficacy of these drugs. In this project, the effects of TKIs were compared 
with the inhibitory effects of HER-targeting mAbs, as monotherapy as well as their 
potential in combination approaches. Additionally, this undertaking sought to identify 
potential HER-targeted therapy-induced biomarkers, whose expression changed upon 
neratinib-treatment and assessment of these proteins in tissue microarrays consisting 
of ovarian cancer xenografts treated with mAbs was carried out. To our knowledge, 
this is the first study to assess the role of pan HER-targeted TKIs in clinically derived 
platinum-sensitive and platinum-resistant pairs of HGOSC cell lines. One of the pairs 
of cell lines represented a relapsed platinum-sensitive ovarian cancer case, while the 
other two pairs represented platinum-naïve ovarian cancer instances. Inhibitor effects 
on proliferation, migration, invasion, adhesion and cell signalling using both 2D and 
3D cancer cell models in the presence or absence of EGF and HRG ligands were 
investigated.  
Initial results comparing the platinum-sensitive and platinum-resistant cell lines 
showed that the platinum-sensitive counterparts, particularly in the case of PEA1- 
PEA2 cell line pair, had increased EGFR and HER3 expression, and greater 
proliferation and migration abilities than their platinum-resistant counterparts. On the 
other hand, the platinum-resistant counterpart had greater HER2 and HER4 
expression, enhanced adherence potential and was more invasive, which was generally 
similar in the other two cell line pairs. These findings were consistent with the gene 




PEA1 cell line had higher gene expression levels of components of the cell cycle and 
migration processes, whilst the PEA2 cell line had increased gene expression levels of 
molecules linked to adhesion and HER2 and HER4 expressions. 
7.1.1 TKIs in combination with cytotoxic or mAb agents augment 
inhibitory responses 
Previous studies have suggested that platinum-resistant cells have increased sensitivity 
to pertuzumab in ovarian cancer patients, especially in the presence of low HER3 
levels [230, 231]. In the current study, the TKIs were effective in their anti-
proliferative, anti-migratory, anti-invasive and anti-adhesive effects in all HGSOC cell 
lines. The most potent TKI was neratinib followed by sapitinib and afatinib. These 
three TKIs potently target three of the HER family receptors. Neratinib and afatinib 
target EGFR, HER2 and HER4, whilst sapitinib has greatest affinity for EGFR, HER2 
and HER3 [147]. The mAbs produced limited inhibitory effects in comparison to the 
TKIs investigated, but similarly were more effective in the platinum-resistant 
counterpart. Pertuzumab produced the best anti-proliferative effects, whilst 
trastuzumab plus pertuzumab had the best anti-migratory effects. 
Combination experiments assessing neratinib versus lapatinib in combination with 
cytotoxic agents and mAbs revealed that although generally neratinib had better 
additive and synergistic effects, combining lapatinib with another agent sensitised the 
cells to lapatinib treatment. Pre-treating cell lines with neratinib and adding cisplatin 
showed good synergistic effects, while the simultaneous addition of neratinib and 
pertuzumab had favourable results. Paclitaxel sensitised lapatinib’s effect in the 
platinum-sensitive cell line PEA1 and produced synergistic effects in both scheduling 
treatments. Generally, simultaneous addition of TKIs and other agents produced better 
combinatorial effects. 
7.1.2 TKIs inhibit stimulation by EGF and HRG  
Additional experiments were undertaken to assess the activity of the TKIs in the 
presence of the natural ligands EGF and HRG, whereby the former binds to EGFR 




dimerisation. Using western blot analysis, EGF caused more phosphorylation than 
HRG or the combination of EGF and HRG in the short-term (within 60 min). In longer-
term incubations (over 48 h), HRG caused more stimulation of the MAPK pathway, 
than the PI3K pathway. The results showed that the TKIs were able to inhibit the 
activity induced by these ligands on the MAPK and PI3K pathways, at concentrations 
which are safely achievable in patients. Additionally, neratinib decreased the 
expression of HER2 and HER4 receptors, especially in the PEA2 and PEO4 cell lines. 
EGF stimulated the migration and invasion rates of cell lines relative to the control 
(Figure 7.1), which was also observed in previous in vitro ovarian cancer studies, 
which showed that hyperactivity of EGFR is associated with enhanced motility, 
migration and invasion [493]. On the other hand, HRG decreased the invasion and 
migration capabilities of the cell lines. The presence of EGF decreased the sensitivity 
of the cells to neratinib and lapatinib in the anti-proliferative experiments. This 
decrease in anti-proliferative action of neratinib and lapatinib in the presence of EGF 
suggests that EGF activates EGFR-based dimerisations, and the TKIs are not fully 
capable of inhibiting the increased downstream effects. Alternatively, it may be that 
the TKIs do not rely on the EGFR solely for their anti-proliferative effects. On the 
other hand, the TKIs were still capable of inhibiting migration in the presence of EGF, 
to the same extent as to when ligands were not present. In certain cases, the presence 
of HRG decreased migration and invasion, especially in the PEA2 and PEO4 cell lines. 
These cell lines had a higher HER2 versus HER3/HER4 ratio, and this has been 
associated with inhibitory effects by the HRG ligand in previous studies [423]. 
Additionally, these two cell lines had increased expression of HER4 receptor in 
comparison to the other cell lines in this study. Hence, this could also suggest that the 
activation of HER3 and HER4 have inhibitory effects on migration and invasion.  
A previous in silico model study to predict canertinib’s sensitivity in epithelial ovarian 
tumours revealed that the best predictable model contained EGFR, HRG and at least 
another ligand, whereas HER2 decreased the accuracy of the model [285]. In the 
present study, the presence of HRG was generally associated with the cell lines being 
more sensitive to the anti-proliferative effects of TKI therapy, while EGF and EGFR 




inhibit increased p-ERK and p-Akt expression that was brought about by the 
combination of EGF and HRG.  
 
Figure 7.1: Summary of the effects of EGF or HRG on the platinum-sensitive and platinum-
resistant HGSOC cell lines 
This flow chart summarises relevant results upon the addition of the ligands - EGF or HRG - 
and presence of TKIs. The green boxes represent the favourable scenarios, whilst the red boxes 





7.1.3 EGFR, HER2 and HER3 expression levels are important for TKI 
response 
This project has also shown that the expression levels of the HER family members 
plays a crucial role in the sensitivity of cells towards the TKIs. HER2 and HER3 
overexpression in these cell lines showed shifts in sensitivity to HER-targeted therapy 
in the sensitive versus the resistant cell lines. Increased HER2 and HER3 expression 
in the platinum-sensitive cell lines resulted in increased sensitivity to the HER-targeted 
TKIs than the WT cell lines. Conversely, higher HER2 and HER3 expression in the 
platinum-resistant cell lines caused decreased sensitivity to the HER-targeted TKIs 
than the WT cell lines. These results could suggest that increasing HER2 and HER3 
expression in the platinum-sensitive cell lines creates the maximum level of receptors 
needed for the full action by the TKIs. Contrarily, too high a level of HER2 and HER3 
expression in the platinum-resistant cell lines result in the TKIs being unable to bind 
to all receptors due to receptor over-saturation. There was no direct correlation 
between the HER2 and HER3 expression in these cell lines, and the sensitivity of TKIs. 
In platinum-resistant/refractory ovarian cancer patients, there was no association 
between baseline HER2 and HER3 expression and canertinib potency in the patients 
studied [284]. Previous studies suggest that overexpression of HER3, causes sustained 
PI3K/Akt signalling, which is an important mechanism of HER-targeted therapy 
resistance [494, 495]. Additionally, HER3 overexpression has been associated with 
acquired trastuzumab resistance in ovarian epithelial adenocarcinomas [496]. 
The expression level of HER2 and HER3 might not be a straightforward way of 
predicting sensitivity to therapy in HGSOC cell lines, however, it might offer some 
predictability if platinum-sensitive and platinum-resistant cases were considered as 
distinct stages of the disease. Additionally, it supports the possibility that the ratios of 
HER receptors are crucial for the optimum therapeutic potential of HER-targeted 
therapy [423]. 
For EGFR expression, neratinib inhibition of growth was not affected by the decreased 
expression of EGFR. In fact, the anti-proliferative effects of neratinib remained very 




EGFR levels reduced the efficacy of neratinib in its anti-migratory effects. This 
suggests that for neratinib’s mode of action, the presence of EGFR is more important 
for the anti-migratory rather than anti-proliferative effects. Similarly to the study by 
Nagumo et al., the presence of EGF did not produce a more favourable environment 
for the anti-proliferative effects of pertuzumab in inhibiting the proliferation of ovarian 
cancer cell lines [417]. However, HRG presence increased the sensitivity of the cell 
lines towards pertuzumab. The enhanced sensitising effect HRG produces in the 
presence of pertuzumab was also noticed in this study, whereby the anti-proliferative 
effects were generally greater in the presence of this ligand, and all the mAbs were 
able to inhibit the phosphorylation produced by HRG stimulation but not EGF 
stimulation. This further supports the hypothesis that the HER3 to HER2 ratio is 
important for the sensitivity of HER-targeted therapy.  
Platinum-resistance in ovarian cancer has been attributed to activated MAPK and PI3K 
pathways [497]. In fact, in previous studies whereby HER-targeted or MAPK 
inhibitors were used in combination with platinum agents, these combinations showed 
increased sensitivity towards platinum agents [357, 498, 499]. In this study, it was also 
evident that the HER pathway was frequently more activated in the platinum-resistant 
counterpart, providing at least one mechanism as to why these TKIs were more 






Figure 7.2: Summary of the effects of HER family modulation on the platinum-sensitive 
and platinum-resistant HGSOC cell lines 
This flow chart summarises relevant results upon the decrease in EGFR expression, and the 
overexpression of HER2 and HER3, and presence of TKIs. The green boxes represent the 
favourable scenarios, the orange represent the neutral circumstances whilst the red boxes 





7.1.4 Gene expression analysis identifies potential biomarkers for 
HER-targeted therapy 
In concordance with western blot analysis, the gene expression analysis confirmed that 
HRG and neratinib modulated the PI3K and MAPK pathways in both PEA1 and PEA2 
cell lines. Additionally, they also affected cell cycle processes. This finding was also 
supported by the Monks et al. dataset [446], whereby the addition of lapatinib to 
HGSOC cell lines modulated the PI3K and MAPK pathways.  
This study then evaluated four HER-targeted therapy-modulated biomarkers, CEBPG, 
DDIT4L, RALGDS and SPRY2, which were co-expressed between the neratinib-
treated cell lines and the trastuzumab-pertuzumab treated SKOV3 xenografts [232]. 
CEBPG and RALGDS gene and protein expressions were up-regulated upon HER-
targeted treatment, while SPRY2 gene and protein expressions were down-regulated 
upon treatment. DDIT4L gene was down-regulated upon neratinib treatment, while the 
protein expression was up-regulated in the mAb-treated xenografts. Low levels of 
CEBPG and DDIT4L are often found in platinum-sensitive carcinoma, and associated 
with better PFS and OS, whilst higher expression of RALGDS and SPRY2 are found 
in platinum-sensitive disease and linked with favourable PFS and OS.  
7.2 Future work 
The cell line panel used in this study provided a clinically relevant model to study the 
effects of HER-targeted therapy and combination therapy, as the sensitivity and 
resistance to platinum-therapy originated naturally within patients. Such a series of 
paired cell lines provided a good opportunity to investigate the response to treatment 
on cell lines which underwent the processes of natural evolution, which would not 
have been possible from single-sample cell lines. These experiments were mostly done 
in 2D cell culture, as the approach is cost-effective, simple to set up and reproducible 
as it is commonly used. This is a clear limitation as this model does not reflect fully 
the cell-cell interactions, cell populations and structures and cell-extracellular matrix 
interactions that occur in patient tumours. Previous studies in breast cancer and 
colorectal cancer cell lines have found that the downstream activation of HER family 




not phosphorylated in tandem in both models [500, 501]. Additionally, the response 
of 3D cells to trastuzumab was better than in 2D models, which further indicates that 
the extracellular matrix plays an important role in inhibitor response [500]. Thus, 
future investigations could utilize more 3D spheroids, tumour explants (ex vivo) or in 
vivo models. More recently, ex vivo explants in ovarian cancer have been successfully 
used as a model to study the chemosensitivity of carboplatin in a number of ovarian 
cancer tissues [502]. They offer cost-effective, rapid assays, which are easily 
reproducible and allow for more than one drug to be observed at the same time [502]. 
The promising results acquired from the platinum-resistant HGSOC in response to 
HER-targeted treatment create opportunities for further research. Further exploration 
is required to assess the sensitivity of other epithelial ovarian cancer types which are 
resistant to platinum-based chemotherapy from the outset, such as clear cell, mucinous 
and low-grade serous ovarian cancer subtypes. Areas to be explored might include 
growth, migration, and invasion, cell cycle flow cytometric analysis, as well as 
downstream effects potentiated by the inhibitors. The efficacy of the TKIs could be 
correlated with HER expression and compared with the potency in platinum-resistant 
cell lines. Biochemical techniques such as immunoprecipitation or proximity ligation 
assay could be used to assess receptor dimerization.  
Previous studies have shown that treatment with gemcitabine followed by gefitinib 
produced more cytotoxic effects than the reverse sequence [503]. A limitation to this 
study was that it only assessed the effect of TKIs followed by cytotoxic agents. Hence, 
future studies could also investigate the role of an inverse sequencing of drugs and 
compare the difference in activities.  
Resistant cell lines to TKIs could be derived from TKI-sensitive ovarian cancer cell 
lines. Investigations on these cell lines could include the response of these cells to 
cytotoxic agents and mAbs on various cellular functionalities. Furthermore, gene 
expression analysis could be performed upon TKI treatment to look at the differential 
gene expression between the two sets, and possibly, screen for probable biomarkers of 




The TKIs under investigation produced inhibitory effects even in the presence of EGF 
and HRG. Previous studies showed that the combination of trastuzumab and cisplatin 
in the presence of HRG-activated HER2 cells had an enhanced receptor chemo-
sensitivity effect, even though HER2 was not over expressed [425]. Thus the 
combination of TKIs with mAbs or cytotoxic agents should be investigated in the 
presence of EGF or HRG, as EGF and HRG might modulate the sensitivity of cells to 
the combination agents. Further to this, the ability of TKIs to inhibit EGF- and HRG- 
modulated HER2 or HER3 transfected cell lines could also be investigated.   
One of the points highlighted in Chapter 5 was that the expression level of HERs play 
an important role, even though this notion has not extrapolated to include mAbs. 
Future research could transfect cells with known amounts of the HERs, and use various 
different ratios of HER expression. The resultant cell lines could be investigated for 
their response to HER-targeted therapy, including mAbs and cytotoxic agents, to give 
a better understanding of the role of HERs as a biomarker for treatment sensitivity. 
Furthermore, the EGFR knockdown of the other cell lines could also form part of 
further research and the effects of the other four TKIs could also be assessed in addition 
to neratinib.  
Gene expression analysis was only performed on two cell lines, using only neratinib 
at a single time point. Neratinib was used for its novelty, but there are no patient gene 
expression data upon neratinib treatment available as far as we are aware that could be 
compared.  Thus, potential further studies could look at more HGSOC platinum-
sensitive and platinum-resistant cell lines to validate the results, and also other ovarian 
cancer cell line subtypes to compare and contrast findings in the absence of patient 
data. The therapy-induced biomarkers could also be validated using cell-line samples 
treated with other HER-targeted therapy on western blots or techniques such as reverse 
phase protein arrays. Additionally, other TKIs could be evaluated to compare the genes 
and pathways that are mostly affected upon TKI treatment and get a better 





7.3 In summary 
These results show that the broad-spectrum TKIs may be useful in HGSOC patients, 
irrespective of whether they are sensitive or resistant to platinum therapy as they 
possessed anti-tumour activity across multiple types of cellular functionality, 
including proliferation, migration and invasion. The presence of EGF and HRG did 
not diminish the inhibitory effects of the TKIs on these cell lines. Additionally, the 
importance of the expression levels of the HER family of receptors has been 
highlighted, and a main inference was the significance of the ratio of HER2 and HER3 
expression for optimal response to TKIs. This study has also identified four potential 
HER-targeted therapy-induced biomarkers (CEBPG, DDIT4L, RALGDS and 
SPRY2), whose expression changed upon neratinib treatment. The expression of these 
proteins has been assessed in xenografts treated with mAbs, and the results generally 
reflected the gene expression changes. 
In conclusion, this present study contributes to our understanding of the involvement 
of the HER family towards the activity of HER-targeted TKIs in HGOSC. The 
expression of the HER family could be important as a biomarker for response to 
therapy. Broad spectrum TKIs have shown great potential, even in platinum-resistant 
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Appendix 1: Supplementary Figures to Chapter 5 
In PEO1 and PEO4 cell line transfects, HRG produced the highest stimulation in p-
HER2, whilst EGF produced the highest stimulation on p-ERK. All TKIs were able to 
inhibit the stimulation, especially sapitinib and lapatinib. 
 
Figure 7.3: HER pathway and downstream signalling proteins for PEO1 HER2 or HER3 
and PEO4 HER2 or HER3 modulated cell lines when EGF/HRG with or without TKIs 
were added 
TKIs were added at clinically relevant concentrations for 24 h; 30 min before lysate collection, 
1 ng/mL EGF or HRG were added to the cells. The experiment was repeated once and the 




In PEO23 cell line transfects, HRG produced the highest stimulation in p-HER2, whilst 
EGF produced the highest stimulation on p-ERK in both PEO14 and PEO23 cell line 
transfects. All TKIs were able to inhibit the stimulation, especially sapitinib and 
lapatinib. 
 
Figure 7.4: HER pathway and downstream signalling proteins for PEO14 HER2 or HER3 
and PEO23 HER2 or HER3 modulated cell lines when EGF/HRG with or without TKIs 
were added 
TKIs were added at clinically relevant concentrations for 24 h; 30 min before lysate collection, 
1 ng/mL EGF or HRG were added to the cells. The experiment was repeated once and the 





Appendix 2: Quality Control of RNAseq samples 
 
Figure 7.5: Quality control data of the RNAseq samples 
The Agilent QC report was issued by Edinburgh Clinical Research Facility, University of 
Edinburgh. Where C = control, N = neratinib, H= heregulin, RIN = RNA integrity number, Q 








Appendix 3: Gene Lists to Chapter 6 










Genes related to Section 6.2 
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